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THE ROLE OF SEMAPHORIN 5A IN PANCREATIC CANCER PROGRESSION 
AND METASTASIS 
Sugandha Saxena, Ph.D. 
University of Nebraska Medical Center 
Supervisor: Rakesh Singh, Ph.D. 
This dissertation investigates the pathological significance and functional 
role of Semaphorin 5A (SEMA5A), an axon guidance molecule, during Pancreatic 
Cancer (PC) progression and metastasis. We analyzed the expression of SEMA5A 
in human PC tissue and metastatic sites as well as in different PC progression 
models of Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic 
Neuroendocrine Tumors (PanNET). This study has identified upregulation of 
SEMA5A in primary pancreatic tumors and metastases in comparison with the 
normal pancreas. Furthermore, we examined the functional role of SEMA5A and 
demonstrated that the upregulated secretory form of SEMA5A increases PC cell 
migration, as well as enhances metastasis by acting as a ligand for the Plexin B3 
receptor. We have also shown that SEMA5A enhances PC cell migration by 
activating Met tyrosine kinase receptor. In addition, we made an attempt to 
understand the function of endogenous SEMA5A expression in a PC cell by 
generating knockdown of SEMA5A in different PC cell lines. Interestingly, we 
observed that loss of SEMA5A increases cellular migration and enhances 
metastasis by inducing Epithelial to Mesenchymal Transition (EMT). Furthermore, 
iii 
 
 
we demonstrate that upregulation of TGF2 secretion and non-canonical 
activation of PI3K-AKT signaling may mediate this transition. Similar to loss of 
SEMA5A, knockdown of Plexin B3 also induces a mesenchymal phenotype and 
enhances metastasis, though not by inducing EMT. Together, these data 
demonstrate that SEMA5A-Plexin B3 axis may play an important role in 
maintaining an epithelial state of PC cells that limits the invasive capabilities of the 
PC cell. Overall, the results presented in this dissertation reveal that SEMA5A 
signaling can mediate both tumor-promoting roles by enhancing cellular migration 
and angiogenesis and tumor inhibitory effects by maintaining the epithelial 
phenotype and keeping invasion under check. 
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Chapter 1 
Introduction 
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I. The Significance of the Study: 
 Pancreatic cancer (PC) is a highly aggressive disease with poor survival. 
The high mortality in PC patients is largely attributable to the late detection and 
metastatic dissemination at the time of diagnosis. In the pursuit to improve the 
clinical outcome of this disease, research focusing on targeting metastatic 
dissemination is highly warranted. Several studies have established that axonal 
guidance molecules, such as semaphorins (human: SEMA; mouse: Sema), are 
mediators of angiogenesis, cellular migration, and metastasis in various cancers. 
SEMA5A is a novel member of this family of proteins and has differential 
expression in PC. However, the precise functional significance of SEMA5A and its 
putative receptor Plexin B3 in PC metastasis remains unidentified. In this project, 
we determined the significance of SEMA5A and its putative receptor Plexin B3 in 
PC progression and metastasis by defining their pathological relevance and 
mechanism of action. The results generated in this study will increase our 
molecular understanding of new possible targets, which will ultimately aid in 
overcoming the problem of PC metastasis in the future. 
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II. Overview of the Normal Pancreas: 
Anatomy: 
 The word “pancreas” means all flesh. The position of the human pancreas 
is in the upper abdomen behind the stomach, and the pancreas has with a length 
of 15-20 cm and weight around 100 grams (Longnecker, 2014). It is an elongated 
gland with anatomical division into a head, body, and tail. The head of the pancreas 
lies in the loop of the duodenum, the body of the pancreas crosses the midline of 
the human body, and the tail lies near the hilum of the spleen. The designated 
neck of the pancreas is the region that lies anterior to the superior mesenteric aorta 
and is relatively thinner than the adjacent portions of the head and the body. The 
neck is also in proximity to major blood vessels, including the superior mesenteric- 
artery, –portal vein, inferior vena cava, and abdominal aorta, which limits the option 
of surgical margin during pancreatectomy. The common bile duct from the liver 
and gallbladder passes through the head of the pancreas to join the main duct of 
the pancreas (duct of Wirsung) near the duodenum. At the union of the pancreatic 
duct and the common bile duct is present the ampulla of Vater, also known as the 
hepatopancreatic duct, which is surrounded by the sphincter of Oddi. The valve of 
the sphincter of Oddi regulates the flow of bile and pancreatic juice into the 
duodenum and also prevents the reflux of intestinal contents into the pancreatic 
duct.  
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Histology: 
 The pancreas has a thin layer of moderately dense connective tissue that 
forms the capsule around the glands. From this capsule, septa extend into the 
gland, dividing it into ill-defined lobules. There are two components of these 
pancreatic lobules: the exocrine part with acinar glands and ducts, which 
represents the bulk of the pancreas, and the endocrine part consisting of the Islets 
of Langerhans embedded within this exocrine tissue. Exocrine pancreatic acini and 
ducts form a complex tubular network. Endocrine Islets of Langerhans comprise 
1-2% of the pancreas and are either spherical or ellipsoid in structure. The Islets 
of Langerhans contains 20 % alpha () cells, around 70% beta (cells, 10% delta 
(cells, less than 5% gamma () or pancreatic polypeptide (PP) cells, and less 
than 1% epsilon () cells (Stefan et al., 1982). Near the acinar lobule are present 
smaller sized Islets, while bigger sized islets are present along the main and 
interlobular ducts of the pancreas. 
Function: 
 The pancreas is an organ associated with the gastrointestinal system and 
has a dual function. The exocrine portion of the pancreas produces and secretes 
essential digestive enzymes into the duodenum, and the endocrine Islets of 
Langerhans secretes hormones. The  cells produce glucagon,  cells produce 
insulin, cells produce somatostatin, PP cells produce pancreatic polypeptide 
(<5%), and cells produce ghrelin. The endocrine compartment of the pancreas is 
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sufficiently vascularized, allowing for the effective functioning of the endocrine 
organ.  
III. PC: 
Epidemiology: 
 PC is the growth of abnormal cells in the pancreas that leads to the 
formation of a tumor. In comparison with other cancers such as lung, breast, and 
prostate, the occurrence of PC is less common, yet PC remains one of the 
deadliest cancers (Siegel et al., 2017). It is the fourth leading cause of cancer-
related deaths in United States of America and is projected to become the second 
leading cause by the end of 2030 (Rahib et al., 2014). The American Cancer 
Society estimates a total of 53,670 new cases and 43,090 deaths for both sexes 
in the year 2017 (Siegel et al., 2017). The incidence of PC is more common in 
older people than young and in males more than females. For the year 2017, the 
estimated new cases for males and females are 27,970 and 25,700 respectively. 
The estimated death numbers for each sex are 22,300 for males and 20,790 for 
females. For all stages of PC combined, the one-year relative survival rate is 29%, 
and the five-year rate is 7% (Fogel et al., 2017). 
 Even though the five-year survival rates have been improving for PC, the 
disease is still considered largely incurable because of the lack of effective early 
diagnostic tools and systemic therapies. In addition, another explanation of the 
poor survival of PC patients is the fact that 53% of patients (all races) present 
themselves with distant metastasis at the time of diagnosis. Therefore, one of the 
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major challenges in the field of PC is early detection at a stage where cancer has 
not metastasized and surgical resection is possible. The recurrence of the disease 
after surgery alone is common for PC, with over 50% of patients having a local 
recurrence, and a majority of patients have a peritoneal or liver metastases (Kleeff 
et al., 2007).  
Risk Factors for PC Development:  
 Though our knowledge is still insufficient to identify the causes of PC, 
people positive for factors such as smoking, obesity, genetic disorders and 
mutations, diabetes, poor diet, and inactivity have been identified to be at higher 
risk (Ilic and Ilic, 2016). The risk of developing PC increases with age, and more 
than 50% of pancreatic adenocarcinomas occur in those over age 70. PC is more 
common in men than women, and the American Cancer Society reports a higher 
number of cases in the African-American population than in the Caucasian 
population (Siegel et al., 2017). Meta-analysis studies report an association 
between cigarette smoking and PC. Smokers are at 75 percent higher risk in 
comparison with non-smokers, and this increased risk persists for at least ten 
years after smoking cessation (Ilic and Ilic, 2016). Another meta-analysis of twenty-
three prospective studies of body mass index and PC risk reports that both general 
and abdominal obesity increases PC risk (Aune et al., 2012). Individuals with 
preexisting disease conditions like diabetes and pancreatitis, and individuals with 
inherited genetic disorders such as Peutz-Jeghers syndrome, the hereditary 
breast, ovarian cancer syndrome, and others have a higher chance of developing 
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PC. Lastly, individuals with mutations in specific genes, including K-RAS, 
CDKN2A, TP53, PRSS1, and BRCA2, have an increased risk of developing PC 
(Raimondi et al., 2009),(Ilic and Ilic, 2016). 
Types of PC: 
 Classification of PC depends on the location of cancer in the pancreas and 
the cell type of cancer initiation, as both the location and cell type affect the 
functioning of the pancreas. There are two types of PC: exocrine and endocrine. 
Two-thirds of PC begin in the head of the pancreas, while the remaining one-third 
occur in the tail. Also, the vast majority of PC are exocrine in type, and although 
uncommon, cancer can also begin in the specialized pancreatic endocrine cells 
that produce hormones. The survival time of patients diagnosed with endocrine PC 
is almost two years longer than those diagnosed with exocrine PC (Fesinmeyer et 
al., 2005). 
Tumors of the Exocrine Pancreas: 
 Exocrine PCs are mostly ductal adenocarcinomas that start in the cells 
lining the ducts of the pancreas. Also, the less common types of exocrine PC 
include cystic tumors that cause a cyst or fluid-filled sac in the pancreas, poor and 
cancer of the acinar cells, which arises in the clusters of cells that produce 
digestive enzymes. Other variants of adenocarcinoma include adenosquamous 
carcinomas, colloid carcinomas, hepatoid carcinomas, medullary carcinoma, 
signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated 
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carcinomas with osteoclast-like giant cells (Hruban and Fukushima, 2007). The 
solid pseudopapillary tumor is a rare low-grade neoplasm that mainly affects 
younger women and has a very good prognosis (Shuja and Alkimawi, 2014). 
Pancreaticoblastoma is another malignant pancreatic neoplasm that occurs 
primarily in children 15 years and under (Chung et al., 2006). 
 PDAC results in blockage of the pancreatic duct, which may be a causative 
factor for jaundice and cachexia and can serve as an apparent explanation of 
higher fatality rate of exocrine tumors (Hruban and Fukushima, 2007). PDAC are 
virulent in nature, as at the time of diagnosis, the tumor cells have already 
metastasized to distant organs. Thus, to diagnose this disease early, it becomes 
important to study the precursors of ductal adenocarcinoma, which are pancreatic 
intraepithelial neoplasias (PanINs), intraductal papillary mucinous cystic 
neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) (Hruban et al., 2007) 
 PanINs are microscopic neoplastic clusters of proliferating epithelial cells in 
pancreatic ducts that can be subdivided into PanIN grades 1-3. A study of PanINs 
suggests the possibility of a diagnosis of PC at a non-invasive stage and before 
the development of invasive cancer (Hruban and Fukushima, 2007). PanINs 
involve epithelial cells producing mucin with varying degrees of cytological and 
architectural atypia involving the small ducts of the pancreas. PanINs starts with 
normal cells with cuboidal to the low columnar epithelium. In squamous or 
transitional metaplasia, the cuboidal ductal epithelium is replaced by stratified or 
pseudostratified transitional epithelium without atypia. PanIN-1A are flat epithelial 
9 
 
 
lesions consisting of tall columnar cells with abundant mucin production. PanIN-
1B are similar to PanIN-1A with papillary architecture. PanIN-2 are mostly papillary 
with some nuclear abnormalities, followed by PanIN-3 with marked cytological 
abnormalities, true cirbriforming, budding off of epithelial cells and luminal necrosis 
(Hruban et al., 2007). PanIN-3 lesions resemble infiltrating ductal carcinoma with 
no invasion through the basement membrane. These PanIN types can progress 
from one type to the other.  
 MCNs, comprised of tall columnar epithelial cells producing mucin, do not 
involve the duct system of the pancreas and are grossly visible neoplasms. MCNs 
also progress from dysplasia to in situ carcinoma to invasive adenocarcinoma. 
MCNs are mostly prevalent in women whereas PanINs occur in both women and 
men (Matthaei et al., 2011). The location of MCN is in the body and tail of the 
pancreas. 
 IPMNs grow in larger native ducts of the pancreas as mucinous and villous 
neoplasms. Like PanINs, IPMNs have various types, and they progress from one 
type to the other – intraductal papillary mucinous adenomas, borderline IPMN and 
intraductal papillary mucinous neoplasm with carcinoma in situ. IPMN is in the 
head of the pancreas with the characteristic frequent mutation in codon 12 of the 
K-ras oncogene (Grützmann et al., 2010). 
Tumors of the Endocrine Pancreas: 
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 Endocrine tumors are rare and start in the islet cells and are called islet cell 
tumors or PanNETS (Longnecker, 2014). Nomenclature of these tumors is 
according to the hormone they overproduce. They are sub-classified into 
insulinoma, glucagonoma, somatostatinoma, or nonfunctional islet cell tumors. 
Difficulties in PC Therapy: 
 PC and liver cancer are two typically fatal malignancies. Problems faced by 
PC researchers are innumerable, making this cancer one of the most difficult to 
treat. Early diagnostic examination is not possible due to the retroperitoneal 
position of the pancreas. Diagnosis of some other cancers, like skin cancer, is 
possible through external visualization; external palpation for breast cancer, 
internal visualization during PAP smears can detect cervical cancers, screening by 
digital rectal examination or prostate-specific antigen can diagnose prostate 
cancer, and colonoscopy can find colorectal cancers (Kaur et al., 2012). Also, 
detection of the tumor is hindered by intense desmoplasia with a dense 
extracellular matrix (ECM), stellate cells, immune cells, and other cells, limiting the 
detection of factors secreted by the tumors.  
 Symptoms of PC are generic, including abdominal or back pain, weight loss, 
jaundice (yellowing of skin and eyes), loss of appetite, nausea, light stool color, 
and diabetes. Moreover, most patients do not develop symptoms until the cancer 
has metastasized. At the time of diagnosis, only 20% of the patients are surgical 
candidates with tumors localized in the pancreas. Of the remainder of the patients, 
half present themselves with the locally advanced disease with tumors spread to 
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nearby organs, and the other remainder half have rapidly progressing metastatic 
PC (Li et al., 2010). The aggressive nature of PC leads to multiple levels of therapy 
resistance, and clinical trial efforts to improve current regimens fail drastically for 
advanced stages of PC. In general, it is difficult to distinguish between a benign 
reactive gland of chronic pancreatitis and an infiltrating gland of well-differentiated 
PC. Chronic pancreatitis and PC differ significantly with outcome regarding life 
expectancy and treatment (Hruban and Fukushima, 2007).  
Clinical Management of PC: 
 A comprehensive analysis of the extent of PC reveals that most patients fall 
into one of three clinical stages: resectable, unresectable, and metastatic PC. 
Clinical stage and disease resectability are the major determinants of the treatment 
and clinical management of PC. Treatment options include surgery, 
chemotherapy, and radiation. The modality and sequence depend on the clinical 
stage of the disease (Reynolds and Folloder, 2014). Whipple operation or 
pancreaticoduodenectomy (when the location of the tumor is in the head of the 
pancreas) and distal pancreatectomy with splenectomy (when the location of the 
tumor is in the body or tail of the pancreas) are two types of surgery performed for 
PC. Gemcitabine and fluorouracil are the primary chemotherapeutic agents used 
for PC. 
 For resectable PC, it is recommended to proceed immediately with surgery 
followed by adjuvant therapy. However, some centers recommend the use of 
neoadjuvant therapy that is the use of radiation and chemotherapy before surgery 
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(Reynolds and Folloder, 2014). Borderline resectable PC is a recent new category 
of resectable tumor that is regarded as heterogeneous, and which is treated with 
combination therapy like FLOFIRINOX (a combination of fluorouracil, oxaliplatin, 
irinotecan, and leucovorin) followed by radiation (Reynolds and Folloder, 2014). 
Locally advanced tumors and metastatic PC are considered unresectable and 
therefore incurable. This stage has no option for resection and treatment usually 
consists of systemic chemotherapy or radiation. Survival of metastatic PC patients 
is less than a year with a poor response to chemotherapy. Therefore, the goal of 
treatment is to provide relief of their symptoms and improve the quality of life. 
Future Therapeutic Options: 
 Several promising therapeutic avenues for patients with locally advanced 
and metastatic PC are under development. Efforts are under way to identify targets 
that can discriminate early or late-stage cancer. Among the most promising targets 
is a peptide that is upregulated in PanIN 3 carcinomas and recognizes the 
extracellular expression of Plectin-1 (Bausch et al., 2009; Kelly et al., 2008; 
Oberstein and Olive, 2013). 
 New therapeutic avenues for patients with advanced or metastatic PC are 
being explored. A variety of approaches has been taken to target components of 
the pancreatic tumor stroma. To facilitate the delivery of drugs like gemcitabine to 
pancreatic tumors, a modified enzyme PEGPH20, which breaks down hyaluronan 
crosslinks in the extracellular matrix, is in clinical trials (Jacobetz et al., 2013; 
Oberstein and Olive, 2013; Provenzano et al., 2012). Two agents (gamma-
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secretase inhibitor RO4929097 and a potent DNA alkylator TH-302) that take 
advantage of the paucity of the vasculature in PC are also in clinical trials (Cook 
et al., 2012; Von Hoff et al., 2011). Recently, after an encouraging phase II study, 
the phase III study of gemcitabine with a nanoparticle reformulation of taxol 
(Abraxane), confirmed this therapy to be a new tool for the treatment of PC patients 
(Von Hoff et al., 2011). Finally, two novel immunotherapy approaches, anti-GM-
CSF antibodies, and a CD40 agonist in combination with gemcitabine are under 
development for PC (Bayne et al., 2012; Oberstein and Olive, 2013; Pylayeva-
Gupta et al., 2012).  
IV. Metastasis: 
Definition and Early Ideas: 
 Metastasis is the process in which cancer cells migrate from the primary 
site of origin to nearby areas or distant sites to establish secondary growth of tumor 
cells. As described earlier, metastases or the consequences of their treatment are 
significant contributors to cancer death, and more than 40% of patients present 
with metastatic PC at the time of diagnosis (Li et al., 2010). Despite improvements 
in the treatment of a resectable tumor, metastasis is the driver of mortality.  
 Metastasis produced by different cancers is predictable, and hence 
oncologists believe that it is not a random process (Comen, 2012). Mechanisms of 
the process of metastasis came through many historically accepted models. In the 
early 19th century, Campbell Greig De Morgan proposed that cancer cells linearly 
progress from the primary tumor to lymph nodes and then to distant sites. In 1889, 
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Stephen Paget further explained the principle of metastasis in his “seed and soil 
hypothesis” stating, “When a plant goes to seed, its seeds are carried in all 
directions; but they can only live on congenial soil.” Thus, there are two 
components in the establishment of metastasis: the selected metastatic cell (seed) 
and the unique organ environment (soil) (Fidler and Kripke, 2015). 
 In the mid-20th century, scientists elaborated that the spread of cancer cells 
can occur not only through lymphatic dissemination but also through 
hematogenous dissemination (Comen, 2012). Furthermore, researchers 
demonstrated a disconnect between tumor size and nodal status, showing that 
small tumors may have greater than expected lymph node involvement versus 
large tumors with no lymph node involvement. This observation reflects the 
inherent difference in the ability of a tumor cell to metastasize. 
 Larry Norton and Joan Massague (Comen et al., 2011) developed the 
theory of “self-seeding” suggesting a multi-directional nature of cancer spread that 
can seed distant sites as well as primary tumor itself.  
The Invasion-Metastatic Cascade:  
 Metastases are the result of the successful completion of multistep 
biological events known as the invasion-metastasis cascade (Valastyan and 
Weinberg, 2011; Vanharanta and Massague, 2013). The details of each step in 
this cascade are the following. First, local invasion occurs, which involves entry of 
cancer cells from a well-defined tumor boundary into the surrounding tumor 
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stroma. This entry provides abundant opportunities for invading tumor cells to 
access the systemic circulation and thereby disseminate to secondary sites. The 
second step following local invasion is intravasation, which is the entry of invasive 
cancer cells into the lumen of lymphatic or blood vessels. Hematogenous 
circulation is the major route for tumor cell dissemination (Gupta and Massague, 
2006). Tumor cells can also stimulate neovascularization (formation of new blood 
vessels). These newly generated blood vessels, characterized by weak 
interactions between adjacent cells and insufficient coverage by pericytes, 
facilitate the process of intravasation (Carmeliet and Jain, 2011b).  
 After the successful intravasation of tumor cells, their survival ability in the 
circulation is tested (Valastyan and Weinberg, 2011). These cells face a variety of 
stresses like detachment from the ECM, hemodynamic shear force, and predation 
by cells of the innate immune system. Once cells have survived this part of their 
journey, they arrest at a distant organ site. Whether this arrest is due to the layout 
and size restriction of the vasculature or homing of these cells to the specific organ 
as a result of interaction between tumor cells and the luminal walls of the 
vasculature needs further investigation. The cells must then extravasate, which 
can either involve microcolony growth (which ruptures the wall of the surrounding 
vessels), or cells cross the vessel by penetrating through the endothelial cells and 
pericytes. These extravasated cells must survive at the distant site to form 
micrometastases.  
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 For survival, cancer cells must adapt themselves to the microenvironmental 
differences found at the metastatic locus in comparison with the primary site such 
as the ECM and the availability of necessary growth factors or cytokines. 
(Valastyan and Weinberg, 2011). Recent studies indicate that cancer cells can 
address the issue of a differing microenvironment at the metastatic site via the 
establishment of a “premetastatic niche” (Liu and Cao, 2016). After successful 
survival of cancer cells in the foreign microenvironment, reinitiation of cancer cell 
proliferation is necessary for the formation of macrometastasis. Evidence suggests 
that one or more of the steps of the invasion-metastasis cascade are rarely 
completed successfully, thereby making the process of metastasis a highly 
inefficient one. Despite the inefficient nature of this process, many cancer cells can 
establish themselves as metastases thereby suggesting the importance of 
understanding the source of such cells and the sites which drive successful 
colonization of such cells (Vanharanta and Massague, 2013). A pictorial 
representation of metastatic invasion cascade is shown in Figure 1.1. 
Models of PC Metastasis: 
 There are two primary fundamental models to explain metastasis (Klein, 
2009; Rhim et al., 2012): early dissemination (parallel progression) and late 
dissemination (linear progression), as reviewed by Das and Batra (Das and Batra, 
2015). The parallel progression model proposes early dissemination of tumor cells 
at a stage even before the formation of a primary tumor. In this model, parallel 
development of the primary tumor and metastases takes place; thereby each 
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undergoes different genetic and epigenetic alterations. This model explains clinical 
observations that most patients die of the metastatic disease within 5-years post-
primary PC resection with no margins or evidence of metastasis at the time of 
pancreatic tumor surgery (Das and Batra, 2015). Another line of evidence comes 
from a study using a mathematical model to predict the existence of cells that are 
capable of establishing metastasis even when the size of the primary tumor is 
small (Haeno et al., 2012). Lastly, a study using lineage tracing in a genetically 
engineered mouse model demonstrated that the tumor cells from PanIN-2 and -3 
stages were able to cross the basement membrane of the pancreas and seed 
themselves in the liver (Rhim et al., 2012). 
 The linear progression model proposes the development of metastasis as 
an evolutionary process. The tumor cells undergo successive rounds of mutations 
and selection at the primary site before being deemed fit to be disseminated for 
metastatic colonization (Das and Batra, 2015). According to this model, the genetic 
alterations in the primary tumor and metastases are similar. Metastasis is 
considered to be a very late event in this evolutionary process, and the efficiency 
of dissemination is proportional to primary tumor size. Recent high-resolution 
genetic studies showed similar genetic alterations in metastases and their 
corresponding primary tumor suggesting that metastasis is a late event during the 
evolution of PC (Campbell et al., 2010). Another study using high-throughput 
sequencing information proposed a timescale for the initiating mutation, to the 
emergence of a non-metastatic parental clone, and the establishment of the 
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metastatic subclones. This time scale fits well with the late dissemination model of 
metastasis (Yachida et al., 2010). However, for critical evaluation of these models 
of metastatic dissemination, further basic and translational studies are needed.  
Targeting Metastasis: 
 Identification of metastasis-related druggable targets lags far behind 
regarding clinical trials and therapies for the standard of care. Most of the 
metastasis-directed therapies in preclinical experiments are cytostatic and not 
cytotoxic, thereby limiting their clinical validation (Steeg, 2016). Thus, there is an 
urgent need to develop new targets that can lower the metastasis-driven mortality 
rate. 
 Targeting a cancer cell is difficult because of the problem of genetic 
instability and heterogeneity (Fidler and Kripke, 2015). Genomic instability enables 
new variants to arise rapidly leading to therapy resistance. Moreover, primary 
tumors as well as metastases are heterogeneous in nature. Diverse properties like 
gene expression, growth rate, marker enzymes, sensitivity to different cytotoxic 
drugs, and others make the choice of target difficult. On the other hand, targeting 
the receptive organ-microenvironment represents a stable target. Also, just 
prevention of metastasis is not enough since dissemination of tumor cells may 
occur before surgical resection of the primary tumor. At best, such approaches will 
only prevent the further development of secondary metastases. Therefore, to 
address the major challenge of treating existing metastases, the simultaneous 
targeting of cancer cells along with the distant organ microenvironment is more 
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likely to produce better therapeutic results than solely targeting the metastatic cell 
or the organ microenvironment.  
 Our emerging understanding of the metastatic cascade will lead to the 
identification of new druggable targets (Steeg, 2016). The entire metastatic 
cascade represents potential therapeutic targets for patients with a localized 
tumor. However, in a malignancy like PC with limited cases of a localized tumor, 
the last step of metastatic colonization represents an attractive therapeutic target. 
Interruption of metastatic colonization could prevent the formation of additional 
metastases. Metastatic tumor cells undergo the process of mesenchymal–
epithelial transition (MET) during colonization (discussed in detail in the next 
section). Targeting cellular programs which control this transition may represent 
an attractive therapeutic opportunity in metastasis.  
V. Epithelial to Mesenchymal Transition (EMT): 
 In early 1980, Elizabeth Hay observed the changes in epithelial to 
mesenchymal phenotype in the primitive streak of chick embryos and described it 
as epithelial to mesenchymal transformation (Hay, 1995). However, to emphasize 
the transient nature, this process is now commonly known as epithelial–
mesenchymal transition (Lamouille et al., 2014). 
 Epithelial and mesenchymal cells represent two cell types in metazoans 
with differences in morphogenesis and functions (Acloque et al., 2009). Epithelial 
cells have a defined structure with apical-basal polarity and a characteristic basally 
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localized basement membrane. Epithelial cells closely attach to their neighboring 
cell by intercellular adhesion complexes (tight junctions, adherens junctions, 
desmosomes, and gap junctions). They also attach to the basement membrane by 
cell-matrix anchoring junctions. On the contrary, mesenchymal cells are 
nonpolarized in structure and lack intercellular junctions. They are spindle shape 
in structure and have characteristic leading and trailing edges. This morphology 
aids their motility and invasiveness throughout the ECM. A general pictorial 
representation of cells undergoing EMT transition is shown in Figure 1.2. 
 Whether epithelial or mesenchymal, all cells in the body ultimately derive 
themselves from a single cell, the fertilized egg. During development, these cells 
can assume various phenotypic states by undergoing the process of differentiation 
(Kalluri, 2009; Kalluri and Weinberg, 2009). A state of terminal differentiation is 
necessary to carry out specialized functions of the body. However, only during 
specific steps of embryogenesis and development do these cells appear to be 
plastic and able to move back and forth between epithelial and mesenchymal 
states by the processes of EMT and MET. However, in adults conditions like a 
tissue injury and initiation of the invasive and metastatic behavior of epithelial 
cancers challenged this idea. Under these conditions, a terminally differentiated 
epithelium changes its phenotype to mesenchymal by undergoing 
transdifferentiation through activation of an EMT program. 
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Types of EMTs: 
 The decision of the classification of EMT into three biological subtypes took 
place in the meeting on EMT in Poland (2007) followed by the meeting at Cold 
Spring Harbor Laboratories (2008) (Kalluri, 2009). Distinct biological settings and 
their functional outcomes form the basis of classification. Type 1 EMT is involved 
in processes like embryo implantation, formation, and organ development. This 
class of EMT generates diverse cell types that share common mesenchymal 
phenotypes that have the potential to undergo MET and generate secondary 
epithelia subsequently. Type II EMT occurs in processes like wound healing, tissue 
regeneration, and organ fibrosis. This EMT begins as part of a tissue repair 
process and generates fibroblasts and other related cells to reconstruct tissues. 
Type 3 EMT occurs in neoplastic cells that have previously undergone genetic and 
epigenetic changes. These cancer cells undergo a type 3 EMT to invade and 
metastasize to nearby and distant organs. These three classes of EMT represent 
distinct biological processes, and with more experimentation in the future, we will 
learn more regarding the similarities and differences among the three classes of 
EMTs. 
EMT, MET, and Metastasis: 
 During EMT, epithelial cells lose their junctions and apical–basal polarity, 
reorganize their cytoskeleton, undergo a change in the signaling programs that 
define cell shape and reprogram gene expression; this increases the motility of 
individual cells and enables the development of an invasive phenotype (Lamouille 
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et al., 2014). The gain of a more mesenchymal phenotype aids different steps of 
the metastatic cascade like local invasion, intravasation, systemic circulation, and 
extravasation (Tsai and Yang, 2013). Hence, activation of an EMT program is 
considered critical for the acquisition of malignant phenotypes by epithelial cancer 
cells.  
 Interestingly, at the histopathological level, colonies at distant sites 
resemble the primary tumor from which they arose. This observation suggests that 
before establishing themselves as secondary tumors, migratory cancer cells must 
shed their mesenchymal phenotype by undergoing the process of MET. After 
undergoing extravasation, the encounter with the microenvironment at a distant 
organ can be a reason for disseminated cancer cells to undergo MET (Tse and 
Kalluri, 2007). Thus, induction of EMT during the progression of cancer and 
subsequent MET during the colonization process represents a centrally important 
mechanism for the process of metastasis (Heerboth et al., 2015).  
Molecular Program of EMT: 
 The process of EMT requires the cooperation of a large number of 
molecular signaling pathways and regulators to undergo the complex 
morphological and cellular transition. There are three groups of EMT mediators 
classified by their function. First, EMT effectors are the molecules that execute the 
EMT program. Second, EMT core regulators are the transcription factors that 
orchestrate the EMT program, and last, EMT inducers are the extracellular cues 
that activate the EMT program. 
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 EMT effectors are proteins that distinguish between the identity of the 
epithelial or mesenchymal cell. For example, key molecular components of 
structures like junctional complexes in epithelial cells are down-regulated at the 
RNA and protein levels (Zeisberg and Neilson, 2009). Among them, E-cadherin 
(E-cad) is a hallmark of the epithelial state in various epithelial cell types. Other 
molecules include -catenin, -catenin, claudins and others. Furthermore, a switch 
from cytokeratin to vimentin occurs during EMT. The increase in vimentin levels is 
also a consistent marker for the mesenchymal phenotype. Additional EMT effector 
molecules are proteins that promote cell migration and invasion such as 
fibronectin. Some nonepithelial cadherins, such as N-cadherin (N-cad) are induced 
and thought to be critical for proper cell migration.  
 EMT core regulators involve the transcriptional alteration of many genes 
regulating cell migration, cell adhesion, mesenchymal differentiation, and invasion. 
Three core groups of transcriptional factors constitute the family of the core EMT 
regulators: the Snail zinc finger family, the distantly related Zeb zinc finger family 
and the Twist basic helix–loop–helix family (Moreno-Bueno et al., 2008). 
 EMT inducers are the extracellular signals in the tumor microenvironment 
that activate the EMT program in cancer cells. All major developmental signaling 
pathways, including TGF, Wnt, Notch, and growth factor receptor, are linked to 
activation of the EMT program (Tsai and Yang, 2013). Most notably, the TGF 
pathway appears to be a primary inducer of EMT (Katsuno et al., 2013). Also, 
many EMT-inducing signals are either cell type- or tissue type-specific and 
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probably require the cooperation between multiple pathways. Cooperation or 
crosstalk between signaling pathways in EMT is quite common and is observed in 
vivo as well as in vitro (Lamouille et al., 2014). 
VI. Semaphorins in Cancer: 
Introduction and Classification: 
 The term semaphorin derives its root from the word “semaphore”- a system 
of sending visual signals using flags (Goodman CS, 1999). Semaphorins represent 
the largest family of the guidance cue ligand molecules. Along with their cognate 
receptors, semaphorins regulate axonal and dendritic growth during embryonic 
development. Semaphorins were originally named “collapsins” for their roles in the 
collapse of neuronal growth cones (Luo et al., 1993). Various cells other than 
neurons are also positive for the expression of semaphorin receptors. Thus, 
semaphorins also regulate non-neuronal processes like cardiovascular 
development (Epstein et al., 2015), vasculogenesis (Gu and Giraudo, 2013), and 
also the functions of the immune system (Suzuki et al., 2008). Interestingly, recent 
literature suggests a role for semaphorins in pathological processes like 
angiogenesis, tumor growth and metastasis (Capparuccia and Tamagnone, 2009; 
Neufeld and Kessler, 2008; Neufeld et al., 2016).  
 Structural similarities, species of origin and the presence of class specific 
carboxy-terminal domains form the basis for the classification of semaphorins. This 
family has thirty proteins (21 vertebrate, eight invertebrate and one viral) 
distributed into eight classes (Neufeld and Kessler, 2008). A general pictorial 
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representation of Semaphorin family members is shown in Figure 1.3. Fasciclin IV 
in grasshoppers was the first identified semaphorin (Kolodkin et al., 1992). 
Semaphorins are characterized by a conserved sema domain which is necessary 
for their binding to the cognate receptors (Kolodkin et al., 1993). The sema domain 
is a seven blade beta propeller, similar to alpha integrins, with around  500 amino 
acids in the N-terminal region (Gherardi et al., 2004). Semaphorins, plexins and 
Met, and Ron receptor tyrosine kinases share the “sema” domain (Gherardi et al., 
2004). A MET-related sequence (shares homology with the Met subfamily of 
tyrosine kinase receptor) or PSI domain (found in plexins, semaphorins, and 
integrins) is a cysteine-rich domain (CRD) present next to the sema domain at its 
terminal end (Kozlov et al., 2004). Apart from common sema and PSI domains, 
each class has a unique feature. Class 2-5 and class 7 semaphorins have the CRD 
domain followed by one immunoglobulin domain, which is absent in class 6 
semaphorin proteins. Class 5 semaphorins are unique in having thrombospondin 
(TSP 1) repeats (Adams and Lawler, 1993; Adams et al., 1996). Semaphorins can 
either be secreted (class 2, 3 and 5) or membrane-bound (class 1, 4-7) in nature. 
The membrane-bound Semaphorins can either be transmembrane (class1, 4-6) or 
membrane-anchored (class 7) via glycosylphosphatidylinositol sequences 
(Tamagnone and Comoglio, 2000).  
Receptors for Semaphorins: 
 There are two specific receptors for semaphorins: plexins and neuropilins 
(NRPs). Plexins are the receptor for membrane-bound semaphorins, whereas 
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plexins along with NRPs as co-receptors are receptors for secreted semaphorins 
(Zhou et al., 2008) (Fig. 1.4).  
 Plexins: There are four subfamilies of plexins in vertebrates named A, B, C 
and D and only two plexin proteins in invertebrates (Takahashi and Strittmatter, 
2001). Subfamily A has four (A 1-4) members, subfamily B has three (B 1-3), and 
subfamily C and D have one member each. Similar to semaphorins, plexins also 
contain a sema and a CRD domain in their extracellular region. The sema domain 
has an auto-inhibitory effect on the plexin receptor and prevents the activation of 
the receptor in the absence of the ligand (Takahashi and Strittmatter, 2001). 
Plexins have three CRD domains and three immunoglobulin-like domains called 
immunoglobulin-like plexin transcription factor domains in the extracellular region. 
The intracellular region of plexins consists of two highly conserved domains with 
striking similarity to GTPase activating proteins (GAP like domains). A linker 
domain is present in between these conserved domains that interacts with GTP-
bound monomeric GTPases of the Rho family. In addition to the above domains, 
Class B plexins also have a C-terminal consensus sequence that interacts with 
PDZ domains. Plexins are either membrane bound or secretory in nature. A 
general pictorial representation of Plexin structure and family members is shown 
in Figure 1.4. They can mediate autocrine or paracrine signaling by binding to their 
respective semaphorin and can act as ligands as well as receptors for 
semaphorins. Furthermore, they can either mediate signaling alone or with their 
co-receptors, NRPs (Zhou et al., 2008). 
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 NRPs: There are two members of this family of proteins, NRP1 and NRP2. 
They are membrane bound as well as soluble molecules of 120 to 130 kDa 
molecular weight and can have multiple isoforms (Neufeld et al., 2002). NRPs 
contain a CUB a1/a2 domain which can bind to the sema domain as well as two 
coagulation factor V/VIII homology domains b1 and b2 which are known to bind to 
vascular endothelial growth factor (VEGF). Following these are a meprin domain 
(involved in protein dimerization), a transmembrane domain, and a short 
cytoplasmic domain a transmembrane domain and a short cytoplasmic domain 
(Neufeld et al., 2002; Soker et al., 1996). A general pictorial representation of NRP 
structure is shown in Figure 1.4. Like the plexin class B family, NRPs also contains 
a PDZ domain that binds to the PDZ domain of NRP-interacting proteins to initiate 
signaling. NRPs cannot signal themselves due to the absence of a kinase motif 
and a short cytoplasmic tail (Ellis, 2006). They signal by forming complexes with 
plexins or VEGF receptors depending on whether the interacting partner is 
semaphorins or VEGFs respectively. NRPs are known to have bifunctional activity, 
i.e. they inhibit angiogenesis and tumor progression by interacting with 
semaphorins or enhance them by interacting with angiogenic VEGF ligands. More 
research is required to understand the role of NRPs as binding partners of 
semaphorins.  
Diverse Signaling of Semaphorins: 
 Semaphorins, whether secreted or membrane-bound, are known to form 
dimers to fulfill their functional activity (Artigiani et al., 2004; Janssen et al., 2010; 
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Oster et al., 2003). The sema domains of semaphorin and plexin molecules 
interact with each other in a trans-manner to trigger signaling (Rizzolio and 
Tamagnone, 2007). Semaphorin dimers bind independently to two plexin 
molecules which stabilize the plexin dimerization for initiation of downstream 
signaling (Janssen et al., 2010; Zhou et al., 2008). However, secreted 
semaphorins (Class 3) interact with NRPs first to form complexes with plexins and 
initiate downstream signaling. 
 Semaphorin signaling through plexins is “forward” signaling. Semaphorins 
can initiate various signaling cascades upon binding with their cognate plexin 
receptors resulting in diverse cellular effects (Battistini and Tamagnone, 2016; 
Capparuccia and Tamagnone, 2009). The intracellular domain of Plexin molecule 
in itself lacks kinase activity. For signaling, plexins can also interact with different 
tyrosine kinases such as Met, receptor tyrosine-protein kinase erbB-2 (ERBB2), or 
Src, which may elicit different functional outcomes depending upon the type of 
cells. Plexins upon interaction with receptor, as well as cellular tyrosine kinases 
can initiate downstream signaling either by phosphorylating themselves 
(Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ Protein Kinase B (AKT) 
pathway) or by phosphorylating the tyrosine residues on the cytoplasmic GAP 
domains of plexins. Phosphorylation of the GAP domain can elicit different 
effectors like RAS or Rho that can control integrin activation and cytoskeletal 
dynamics respectively. Forward signaling eventually influences cell migration.  
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 On the other hand, transmembrane semaphorins can not only act as ligands 
but receptors as well. Initiation of a signaling cascade through a semaphorin’s own 
cytoplasmic domain is called "reverse" signaling (Battistini and Tamagnone, 2016). 
Semaphorin 1a, which controls motor axon defasciculation and target recognition 
during neuromuscular development in Drosophila, is an example of reverse 
signaling (Jeong et al., 2012). Other examples of reverse signaling are class-6 
semaphorins, the most similar vertebrate member to invertebrate semaphorin 1a, 
and class-4 semaphorins containing a cytoplasmic PDZ domain (Burkhardt et al., 
2005).  
 Lastly, semaphorins and plexins can interact not only in a transmanner but 
also in a cis manner, adding another layer of diverse possible signaling outputs 
(Battistini and Tamagnone, 2016). These various signaling abilities of 
transmembrane semaphorins are already known to play multifaceted roles in 
developmental processes. More experimentation is required to understand this 
multifaceted signaling in pathological conditions like cancer. Diverse signaling of 
semaphorins is shown in a schematic in Figure 1.5. 
The Parallel Roles of Semaphorins in the Nervous System and Cancer Biology: 
 Semaphorins affect the biology of cancer progression by playing critical 
roles in pathological angiogenesis and metastatic dissemination of cancer cells 
(Neufeld and Kessler, 2008; Neufeld et al., 2012; Rehman and Tamagnone, 2013). 
Semaphorins are bifunctional guidance cue ligands that help growing neurons 
follow the right developmental path. Similarly, the process of angiogenesis is also 
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regulated by navigational cues that guide the growth cones of endothelial tip cells 
(Carmeliet and Jain, 2011a; Eichmann et al., 2005). Recent evidence suggests 
that semaphorins can act as pro/antiangiogenic factors. Disturbance in the balance 
of these factors can disrupt the network precision resulting in pathological 
conditions (Rehman and Tamagnone, 2013). 
 The gain of migratory ability and the guidance of migrating cells to the 
secondary site are also critical events for the establishment of metastasis. 
Interaction of a cell with a guidance cue commands a cell to move. This interaction 
initiates a series of molecular events that either make the cell move forward or 
hinder it. Likewise, the movement of cells during pathological conditions like 
metastasis is also mediated by similar cytoskeletal attraction and repulsion 
changes (Adams et al., 1996; Tran et al., 2007). A growing body of evidence now 
supports the roles of various semaphorins as cues necessary for angiogenesis, 
cellular migration (Basile et al., 2006; Sadanandam et al., 2012; Tseng et al., 
2011), and organ-specific homing of cancer cells (Sadanandam et al., 2007). 
VII. Class 5 Semaphorins: 
Structure:  
 There are three members of the class 5 semaphorin family: SEMA/Sema5 
A, B, and C. SEMA5A and Semaphorin 5B are the vertebrate members whereas 
sema5c is an invertebrate member found in Drosophila (Bahri et al., 2001). The 
vertebrate members were initially identified in murine embryos as semF (SEMA5A) 
and semG (Semaphorin 5B) (Adams et al., 1996). In 1999, the semaphorin 
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nomenclature committee renamed SemF as Sema5A (mouse)/ SEMA5A under 
the unified nomenclature system (Goodman CS, 1999). SEMA5Awas found to 
span chromosome 5p15. SEMA5A is an integral membrane protein, with a 
characteristic 408 amino acid “thrombospondin repeat” domain apart from its 
conserved N-terminus sema domain in its extracellular region (Adams et al., 1996). 
Thrombospondin repeats promote attachment of various cells to ECM substrates 
and play growth-promoting roles.  
SEMA5A in Cancer: 
 Recently, many reports suggest the role of SEMA5A in the pathobiology of 
cancer. The first evidence for SEMA5A in cancer came from a study on 
leiomyomata, a benign smooth muscle neoplasm of the uterus (Tsibris et al., 
2002). Microarray data on patient samples demonstrated upregulation of SEMA5A 
in leiomyomata in comparison to the control myometrium. Later, in a Drosophila 
screening study aimed at the identification of genes essential in tumorigenicity and 
metastasis showed a functional role for sema5c (a Drosophila homolog of 
Sema5A) in the development of a cancer phenotype (Woodhouse et al., 2003). 
The role of SEMA5A in PC is described separately in the following section. 
 A study on gastric carcinoma patients reported elevated SEMA5A 
expression in primary gastric carcinoma and lymph node metastasis in comparison 
with non-neoplastic tissue (Pan et al., 2009). Also, SEMA5A knockdown in 
SGC7901 gastric carcinoma cells showed enhanced apoptosis and inhibition of in 
vitro invasiveness (Pan et al., 2010). This group further demonstrated that 
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SEMA5A activates the MEK/ERK pathway leading to the up-regulation of matrix 
metallopeptidase 9 (MMP9) (Pan et al., 2013). In contrary to the case of gastric 
carcinoma, reports demonstrate reduced expression of SEMA5A in clinical 
samples of high-grade astrocytomas compared to the normal brain (Li and Lee, 
2010). Li et al. delineated mechanistic changes inside the glioma cells suggesting 
that SEMA5A inhibits the motility of glioma cells (Li et al., 2012b). In summary, 
these findings support the role of SEMA5A as a tumor suppressor in glioma. 
Similar observations were reported for lung cancer where lower expression of 
SEMA5A was associated with poor overall survival in female, non-smoking lung 
cancer patients in Taiwan (Lu et al., 2010).  
 Together these data do not define an unequivocal role for SEMA5A in 
cancer. Rather, SEMA5A can act as a tumor suppressor or a tumor promoter, 
depending on the type of cancer. One of the reasons for these observations could 
be the interaction of SEMA5A with different receptors which can stimulate diverse 
pathways in a cell-specific manner.  
SEMA5A in PC: 
 We identified SEMA5A, a putative cell adhesion molecule, to be involved in 
organ-specific PC metastasis using an in vivo phage display library and integrated 
computational analysis (Sadanandam et al., 2007). Validation of our in silico 
results was performed using RT-PCR analysis on nine human PC cell lines, 
derived from either primary tumors or metastases (Sadanandam et al., 2010b); the 
first report to demonstrate the expression of SEMA5A in PC. SEMA5A expression 
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was found to be higher in moderately or well differentiated human pancreatic 
tissues than the normal pancreas and poorly/undifferentiated tumors. Interestingly, 
SEMA5A has higher expression in cell lines derived from metastases in 
comparison with primary tumors, suggesting its role in the metastatic progression 
of this disease. Furthermore, Plexin B3 was identified as a binding partner for 
SEMA5A, using computational analysis as well as by immunoprecipitation assay 
in various mouse tissues (Sadanandam et al., 2008).  
  In order to determine the effect of SEMA5A on PC tumorigenesis and 
metastasis, SEMA5A was overexpressed in the Panc1 cell line. The tumorigenic 
potential of SEMA5A in PC was validated by in vitro and in vivo assays. Panc1-
SEMA5A resulted in increased tumorigenesis and enhanced metastasis to distant 
organs like liver, lymph node, spleen and peritoneum when implanted 
orthotopically into nude mice (Sadanandam et al., 2010b). Furthermore, in another 
study, Panc1 cells were transfected with the extracellular domain (ECD) of 
SEMA5A to analyze its role in tumor progression and metastasis, and Panc1 
Sema5A-ECD cells showed higher metastatic potentials both in vitro and in vivo. 
These findings demonstrate the importance of SEMA5A in PC metastasis 
(Sadanandam et al., 2012). 
 Further experimentation was carried out to determine the effect of SEMA5A 
in PC. Initial evidence for the role of SEMA5A in pathological angiogenesis came 
from the defective patterning of the cranial vasculature in SEMA5A null mice (Fiore 
et al., 2005). Endothelial cells were treated with recombinant Sema5A-ECD, and 
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enhanced proliferation of endothelial cells was observed which was found to be 
mediated through Plexin B3 (Sadanandam et al., 2010a). Furthermore, endothelial 
cells treated with Sema5A-ECD secreted proangiogenic factors like VEGF and 
interleukin-8. We also observed enhanced migration of endothelial cells and 
upregulation of MMP-9, which aids in the degradation of the extracellular matrix for 
proper cellular migration. These in vitro results were supported by in vivo Matrigel 
plug assays where SEMA5A showed enhanced microvessel density. Overall, 
these data suggest that Sema5A-ECD is involved in physiological angiogenesis. 
Taken together, SEMA5A regulates angiogenesis and cellular migration in PC 
cells. 
 Diverse Signaling of SEMA5A: 
 SEMA5A is known to elicit contradicting outcomes in the case of cellular 
migration by participating in both the migration and collapse of cellular growth 
cones. On treatment with Sema5A, fibroblast cells showed disrupted focal 
adhesions and inhibition of cellular migration (Artigiani et al., 2004). In 2010, Li and 
Lee reported similar observations in the case of glioma cancer (Li and Lee, 2010). 
However, SEMA5A stimulated invasiveness in pancreatic (Sadanandam et al., 
2012) and gastric cancer (Pan et al., 2013).  
 It is interesting to observe that the interaction of the same receptor-ligand 
complex can lead to the activation of two different pathways in different cell types. 
SEMA5A can induce invasive growth via Plexin B3 receptor signaling through the 
Met receptor tyrosine kinase or the MEK/ERK pathway (Sadanandam et al., 2012). 
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On the other hand, in the case of glioma cells, SEMA5A stimulates the Plexin B3 
receptor to recruit Rho-GDIα which in turn blocks the guanine nucleotide exchange 
for Rac1 and inhibits its migratory activity (Li et al., 2012b; Li and Lee, 2010) (Fig. 
1.6). Two potential reasons for the activation of different pathways by the same 
receptor-ligand complex can be the environmental context i.e. the ECM 
components encountered by these molecules and the alternative interaction with 
either the Sema or TSP domain. This bifunctionality of SEMA5A is also known to 
exist during interaction with different proteoglycans like heparan sulfate and 
chondroitin sulfate in the nervous system (Kantor et al., 2004). 
Putative Receptors of SEMA5A: 
 A study using COS cells identified Plexin B3 as a high-affinity receptor for 
Sema5A (Artigiani et al., 2004). In the same study, Sema5A was not found to 
interact with Plexin B1 and Plexin B2. Also, both the Sema and TSP1 domains 
were shown to interact with Plexin B3, and the oligomerization of the Sema domain 
of Sema5A was found to be necessary for its functional response via plexin B3 
receptor (Artigiani et al., 2004). Recently, it was shown that Sema5A mediated 
retinal lamination is through the interaction with Plexin A1 and A3 receptors 
(Matsuoka et al., 2011). Tamagnone et. al. has demonstrated the interaction of 
Plexin A1 and A3 with NRP2 by co-precipitation experiments (Tamagnone et al., 
1999). Thus, there are many possible SEMA5A interaction partners, and it would 
be interesting to investigate the receptor for SEMA5A in PC. The literature 
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discussed in Section VI and VII is reviewed in detail by Purohit et. al (Purohit et al., 
2014). 
 Summary: PC is often considered a death sentence because the average 
survival time of PC patients is only 5-8 months. The metastatic nature of the 
disease necessitates further exploration and understanding of this process to 
decrease the mortality rate of PC. Recent genomic characterization of PDAC and 
accumulating evidence suggest that axon guidance cue molecules are important 
for regulation of motility and metastasis (Casazza et al., 2007; Neufeld and 
Kessler, 2008). In this dissertation, efforts are directed to understand the 
pathological and functional relevance of one such molecule, SEMA5A in PC 
progression and metastasis. 
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VIII. Hypothesis and Specific Aims:  
 Significance: The high mortality in PC patients is primarily attributable to the 
late detection and metastatic spread of the disease at the time of diagnosis. 
Metastasis follows a predefined pattern of spread to specific organs, depending on 
the origin of the primary tumor and interactions of cancer cells with the distant 
organ-specific microenvironment. The goal of our work is to gain a better 
understanding of the molecules and mechanisms mediating distant metastasis. 
Application of this gained knowledge will pave the way to new diagnostics and 
therapeutics for metastasis-specific treatment.  
Recent literature suggests that axonal guidance cue molecules, in 
particular, semaphorins, play a significant role in metastasis by affecting cellular 
migration, angiogenesis, and survival in cancer. Our laboratory has identified one 
semaphorin family member, SEMA5A, to be involved in organ-specific homing of 
PC metastasis using in vivo peptide phage display library. Computational biology 
strategies identified Plexin B3 as a putative binding partner of SEMA5A and 
activation of Met tyrosine kinase by Plexin B3 is a known phenomenon. Previous 
studies from our laboratory have demonstrated higher expression of SEMA5A in 
PC cells established from distant metastasis in comparison with the primary tumor. 
However, the precise role of SEMA5A in tumor growth and metastasis is not clear. 
The primary goal of my research is to delineate the underlying molecular 
mechanism of SEMA5A in PC progression with a major focus on its involvement 
in metastasis.  
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 Based on evidence from the literature, the central hypothesis of this project 
is that SEMA5A through its interaction with Plexin B3 regulates PC metastasis by 
enhancing cellular migration and aggressiveness in malignant cells. To test this 
hypothesis pursued the following two specific aims: 
 Specific Aim 1: Ascertain the pathological significance of SEMA5A in PC 
progression and metastasis. 
 Specific Aim 2: Evaluate the significance of the SEMA5A–Plexin B3 
signaling axis in PC metastasis. 
 Impact: These studies will delineate the significance and pathological 
relevance of differential expression of SEMA5A in PC progression and metastasis. 
Furthermore, characterization of its cognate receptor Plexin B3 advances its 
diverse signaling mechanisms. We expect that this study will positively influence 
the efforts of developing anti-metastatic therapies as targeting cancer cells along 
with molecules mediating various steps of the metastatic cascade are expected to 
yield better results for cancer patients. 
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Figure 1.1: The invasion-metastasis cascade. 
 A complex series of cellular processes, which are known as the invasion-
metastasis cascade, leads to the formation of clinically detectable metastases. 
In this metastatic progression, cancer cells invade the primary sites and enter 
the nearby blood vessels by undergoing the process of intravasation. Cancer 
cells translocate systemically by surviving in the circulation, followed by their 
arrest at a distant organ site and undergoing extravasation to come out of the 
blood vessels at a distant site. Cancer cells adapt themselves to survive and 
thrive in the foreign microenvironments of distant tissues, which leads to the 
formation of micrometastasis and eventually leads to metastatic colonization 
and clinically detectable metastases. [Modified with permission from “Tumor 
Metastasis: molecular insights evolving paradigms” (Valastyan and Weinberg, 
2011)] 
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Figure 1.2: Schematic representation of the process of EMT. 
 During the process of EMT, epithelial cells lose their contact with the 
neighboring cells as well as the basal lamina. They also rearrange their 
cytoskeleton and acquire spindle shape with the acquisition of mesenchymal 
characteristics so that they can invade the neighboring tissue and migrate to 
the metastatic site. 
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Figure 1.3: The classes of the Semaphorin family. 
Schematic representation of the classification of the Semaphorin family. The 
basis of classification for Semaphorin family is the similarity of domain 
architecture and the species which have the protein expression. All the classes 
of this family have a characteristic seven-blade beta propeller structure called 
the Sema domain in their N-terminus. Semaphorin members are either 
transmembrane, membrane-anchored or secreted. Abbreviations, CRD: 
Cystine rich domain, GPI: Glycophosphotidyl inositol. 
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Figure 1.4: Structure of receptors Plexins and Neuropilins of Semaphorin.  
Schematic representation of the domain architecture of Plexin and neuropilin 
family members. Plexin family also shares the characteristic sema domain in 
their N-terminus with other semaphorin family members. Plexins family 
members can also be either cleaved to become secreted or membrane bound.  
Abbreviations, CRD: Cystine rich domain, IPT: Immunoglobulin-like plexin 
transcription factor, GAP: GTPase activating protein.The Classes of Plexin 
family. 
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Figure 1.5: Different modes of signaling of Semaphorin family members. 
This schematic representation is demonstrating different modes of signaling for 
secreted and transmembrane Semaphorins. Transmembrane Semaphorins 
can interact in a cis (A) as well as a trans manner (B). In cis mode both the 
interacting partners involved in eliciting a signal are present in the same cell. In 
the trans mode, the interacting partners involved in eliciting a signal are present 
on two different neighboring cells. Interestingly, transmembrane Semaphorins 
can elicit both forward and reverse signaling. In the case of “forward” signaling, 
Semaphorins act as a ligand whereas, in the case of “reverse” signaling, 
Semaphorins act as a receptor and signal through their cytoplasmic domain.  
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Figure 1.6: SEMA5A through Plexin B3 can trigger different intracellular 
pathways. 
This schematic representation is demonstrating that SEMA5A can promote or 
inhibit the migration of cells based on the intracellular pathways triggered. By 
acting through Plexin B3, SEMA5A enhances cellular invasion via mediating 
interaction with MET receptor tyrosine kinase or by the activation of the 
MEK/ERK pathway. However, SEMA5A (again acting through Plexin B3 
receptor) inhibits cellular migration by recruitment of Rho-GDIα at its 
intracellular domains, which in turn disrupts the Rac-1 activity. 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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I. Human PC Specimens: 
 Tissue microarray (TMA) slides were obtained from two sources. TMA 
obtained from the University of Nebraska Medical Center (UNMC) Rapid Autopsy 
Program were constructed from paraffin blocks containing non-cancerous 
pancreas, tumor cores, and metastases from several sites including liver, 
diaphragm, and others. The study was approved by the Institutional Review Board 
of the UNMC. Another TMA of PDAC (Accumax Array, A207III) containing thirty-
three cases and eight unmatched normal pancreatic tissues in duplicate was a 
generous gift from Petagene (Seoul, South Korea). 
II. Mouse model of PC Disease Progression Specimens: 
 Primary tumor and metastases sections from the PDX-1-cre, LSL-KrasG12D 
(KC) and of PDX-1-cre, LSL-Kras(G12D) p53 (lox/lox) (KPC) mouse model at different 
time points/ages (10-50 weeks) were obtained from our collaborator Dr. S. Batra, 
Biochemistry and Molecular Biology, UNMC.  
III. Cell Line Cultures and Transfections: 
Human Cell Lines:  
 The PC cell line T3M-4 and CD18/HPAF cells were obtained as generous 
gifts from Dr. Hollingworth’s and Dr. Batra’s laboratory respectively. The PC cell 
lines L3.3 and L3.6pl were obtained as a generous gifts from Dr. I. J. Fidler in 
University of Texas M.D. Anderson Cancer Center. These cell lines were 
maintained in culture as an adherent monolayer in Dulbecco’s modified Eagle 
medium (DMEM) (Hyclone Laboratories, Logan, UT) supplemented with 5% fetal 
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bovine serum (Sigma-Aldrich, St. Louis, MO), 1% vitamin solution (Mediatech, 
Herdon, VA), 1% L-glutamine and 0.02% gentamycin (Invitrogen, Carlsbad, CA). 
PC cell line AsPC-1 was obtained from American Type Culture Collection 
(Manassas, VA) and was cultured using Roswell Park Memorial Institute medium 
(Sigma-Aldrich, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS) 
(Sigma-Aldrich), 1% L-glutamine (Mediatech), and 0.02% gentamycin (Invitrogen). 
Cloning of SEMA5A/Plexin B3 shRNA Oligos:  
 SEMA5A-specific (5’-GCG GAT TTC CGC AGT TAA-3’), Plexin B3-specific 
(5’- AGC AGA TGG TGG AGA GGT-3’) and scramble (control, 5’-GGC TAC GTC 
CAG GAG CGC A-3’) oligonucleotides were selected using OligoEngine software 
(OligoEngine Inc., Seattle, WA) and cloned downstream of the start codon in the 
pSuper.neo vector, as instructed by the manufacturer (OligoEngine Inc.). The 
oligonucleotide was annealed and cloned into the BglII and HindIII restriction site 
using enzyme-digested pSuper.neo vector and the sequences were verified. 
Vector pSuper.neo without insert was used as a negative control.  
Transfection of PC Cells: 
 T3M-4 and CD18/HPAF cells were transfected with pSuper.neo/scrambled, 
pSuper.neo/SEMA5A or pSuper.neo/Plexin B3 using LipofectAMINE Plus reagent 
(Invitrogen, Carlsbad, CA) according to the protocol provided by the manufacturer. 
Stably transfected cells were selected and maintained in neomycin sulfate (G418, 
Mediatech)-containing media. Transfected T3M-4 and CD18/HPAF cells were 
maintained in 1000 µg/mL and 600 µg/mL neomycin sulfate, respectively. 
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Similarly, shSEMA5A and control T3M-4 cells were transiently transfected with a 
FLAG-tagged cDNA containing full-length mouse Sema5A cDNA in the BKCMV 
vector (generous gift from Dr. Andreas W. Püschel, Westfälische Wilhelms-
Universität Münster, Germany) or with the extracellular fraction of mouse Sema5A 
conjugated to human IgG Fc expressed in the pcDNA3.1 vector (generous gift from 
Dr. David Stretavan, University of California, San Fransisco, CA).  
IV. Animal Models and Details of In vivo Studies: 
Study Approval:  
 Mice were maintained under specific pathogen-free conditions. All 
procedures performed were by institutional guidelines and approved by the 
University of Nebraska Medical Center Institutional Animal Care and Use 
Committee (IACUC). 
Xenogenic Mouse Models:  
 Female athymic BALB/c nude mice (NCI-nu, 6-8 weeks old) were 
purchased from the National Cancer Institute. For in vivo injection, cells were 
harvested following trypsinization using a brief exposure with 0.25% trypsin in 
0.02%EDTA (Invitrogen). Trypsinization was stopped with medium containing 
serum, and then cells were washed twice with Hank’s balanced salt solution 
(HBSS). Single cell suspensions of >95% viability (tested by trypan blue exclusion 
assay) were used for injection.  
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 For the tumorigenic assay, mice were injected subcutaneously with 106 
cells/0.05 mL of HBSS per animal into the lateral flank. Tumor growth was 
monitored, and animals were euthanized when they were 10-weeks old. Tumors 
were measured with calipers twice a week. Tumor volume was calculated by the 
following formula: volume = W2 x L / 2, where W = short diameter and L = long 
diameter. Tumor tissues were harvested and processed for further analysis.  
 For tumor growth and metastasis, tumor cells were injected orthotopically 
into the pancreas. Mice were anesthetized, a small incision was created, and 
pancreatic tumor cells (5 X 105 cells/0.05 mL HBSS) were injected into the anterior 
lobe of the pancreas using a 1/2-cc U-100 insulin disposable syringe (EXEL 
International Inc., Los Angeles, CA). A subcapsular intrapancreatic injection was 
identified as successful by the appearance of a fluid bleb without leakage. To 
prevent leakage, a cotton swab was held over the site of injection for 1 min. The 
lesion was closed with two separate layers. The abdominal muscular layer was 
closed using 4-0 or 5-0 vicryl or polydioxanone (PDS), and the outer skin layer was 
closed with stainless steel wound clips. The animals tolerated the surgical 
procedure well, and no anesthesia-related deaths occurred. Wound clips were 
removed at approximately 10-14 days post-surgical procedure. Mice were 
monitored for tumor growth. Details of the experimental model used for the 
SEMA5A knockdown study and Plexin B3 knockdown study are described in the 
schematics shown in Figure 2.1 and Figure 2.2, respectively. Animals 
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weresacrificed when moribund. Primary tumors and metastases were resected 
and processed for further analysis. 
V. Gene Expression Analysis: 
RNA Isolation:  
 Total cellular RNA was isolated from cells using TRIzol® reagent 
(Invitrogen, Carlsbad, CA). Cells were washed three times with Phosphate Buffer 
Saline (PBS) made in DEPC-treated water. Cells were scraped using a scraper 
and pelleted at 7500 rpm for 5 min at 4°C. One mL of Trizol was used per well of 
a 6-well plate. Cells lysed in Trizol were incubated at room temperature for 2-3 
min. Chloroform (200 l) per 1 mL of TRIzol® reagent was added to the tube 
containing the lysed cells, and the tube was shaken vigorously for 15 sec by hand. 
The cells were centrifuged for 15 min at 12000 rpm at 4°C. After centrifugation; the 
mixture separated into three phases. The lower phase was red in color, containing 
phenol- chloroform followed by a thin interphase and an upper colorless aqueous 
phase. RNA remained exclusively in the aqueous phase (approximately half of the 
total volume). Following careful removal of the aqueous phase of the sample and 
transferal of it to the fresh tube, 500 L of 100% isopropanol was addede to the 
aqueous phase and the tube was incubated at room temperature for 10 min, then 
centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was removed from 
the tube, leaving only the invisible RNA pellet. The obtained pellet was washed 
with 1 mL of 75% ethanol. The sample was vortexed briefly and then centrifuged 
at 7500 rpm for 5 min at 4°C. The wash was discarded, and the RNA pellet was 
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air dried for 5–10 min. Obtained RNA was resuspended in 20 L DEPC containing 
water. RNA was quantified using absorbance at 260 nm, and the quality of the 
RNA obtained was checked with a spectrophotometer using the 260/280 ratio. 
Reverse Transcription: 
 The cDNA was synthesized using 2 µg of the obtained RNA for a 20 µL 
reaction using iScript™ Reverse Transcription Supermix for RT-qPCR (BIO-RAD, 
Hercules, CA, USA). 
Quantitative Real-Time PCR (qRT-PCR):  
 qRT-PCR reactions were prepared using FastStart SYBR Green Master Mix 
(Roche; Indianapolis IN, USA) and performed using BIO-RAD Connect machine. 
BIO-RAD RFX Manager 3.1 software was used to run the analysis. Primer sets 
used for the study are listed in Table 2.1. For real-time PCR, mean Ct values of 
the target genes were normalized to mean Ct values of the endogenous control, 
ribosomal protein large 13 A (RPL13A) or Hypoxanthine-guanine 
phosphoribosyltransferase(HPRT); [-∆Ct = Ct (RPL13A/HPRT) – Ct (target gene)]. 
The ratio of mRNA expression of target genes versus RPL13A was defined as 2(-
∆Ct). Melting curve analysis was performed to check the specificity of the amplified 
product. Amplified cDNA was resolved on EtBr containing 1% or 1.5% agarose 
gels. 
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VI. Protein analysis: 
Protein Isolation, Quantification, and Immunoblotting:  
 Cells were washed three times using PBS and lysed using Membrane Lysis 
Buffer (M-PER®, Pierce, Rockford, IL) containing protease inhibitors (complete 
Mini, Roche Diagnostics, Mannheim, Germany). The cell lysate was incubated on 
ice for 30 min followed by centrifugation at 10,000 rpm for 10 min at 4°C. The 
supernatant was transferred into a fresh Eppendorf tube, and the protein 
quantitation was performed using a BCA kit (Pierce™ BCA Protein Assay Kit 
(Thermo Scientific, Rockford, IL, USA). Quantified protein (25 g) was denatured 
using SDS Laemmli buffer (Laemmli, 1970). The denatured proteins were 
separated on 10% SDS-PAGE at a constant voltage of 100V until the dye reached 
at the end of the gel. The separated proteins were transferred to 0.45 m PVDF 
membrane (Millipore, Billerica, MA) at constant voltage 100 V for 90 min. Next, the 
membrane was blocked with 3% BSA in 0.1 % Tween containing Tris Buffer Saline 
(TBST) for overnight at 4°C. The following day, the membrane was incubated with 
a respective primary antibody (details in Table 2.2) for 2 hours at room 
temperature or at 4°C overnight. The membrane was washed with TBST for 10 
min for three times. After washing, the blots were incubated with secondary 
horseradish peroxidase antibody (mouse (Sigma), 1:5000; rabbit (Thermo 
Scientific), 1:5000) for an hour at room temperature. The membrane was washed 
as described above. Finally, the blots were developed using the LuminataTM Forte 
(Millipore) on Molecular Imager® Gel Doc™ XR System (BIO-RAD) using Image 
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Lab version 5.2.1. The intensity of the bands obtained from immunoblotting was 
measured using Image J software. Peaks were quantified for a protein of interest 
and their respective loading control. Bands were normalized to the control cells 
used in the study. 
Enzyme-linked Immunosorbent Assay (ELISA): 
 Equal numbers (0.3 x 106) of T3M-4-control and T3M-4-shSEMA5Acells 
were plated in 35 mm dishes in complete medium. After attachment of cells to the 
plate, the medium was changed to serum-free DMEM. Supernatants of cultured 
cells were collected at 48 hours. ELISA assay for TGF2 was performed using a 
Duoset kit (R & D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s protocol. All the experiments were performed in duplicates. 
Immunofluorescence: 
 Cells (1x105) were allowed to adhere overnight on 22x22 mm sized 
coverslips (Fisherbrand ®, Pittsburgh, PA) in 6 well plates and cultured. After 
washing twice with PBS, the cells were fixed using 4% paraformaldehyde in PBS 
for 10 min. Next, cells were treated with 0.1% Triton-X for 10 min for 
permeabilization, followed by incubation with the respective primary antibodies in 
immunofluorescence solution (PBS with 5% BSA and 0.2% Saponin) for two hours 
at room temperature. Secondary antibodies conjugated with either FITC (Jackson 
Immunoresearch, West Grove, PA) or Cy3 (Jackson Immunoresearch) were 
added for one hour at room temperature. Nuclei were counterstained with DAPI 
(4, six diamidino-2-phenylindole) for 5 min at room temperature. Finally, slides 
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were mounted with Vectashield® mounting medium (Vector Laboratories, 
Burlingame, CA, USA). Immunofluorescence was detected using a Nikon 
fluorescent or LSM 710 Zeiss confocal microscope. 
Immunohistochemistry (IHC): 
 Fixed paraffin-embedded tissue samples on slides were deparaffinized in a 
series of xylene and alcohol treatments (two times xylene, one time each in 100%, 
95%, 80% and 70% alcohol) for 5 min each. Antigen retrieval was performed using 
10 mM sodium citrate buffer (pH = 6.0). The slides were washed with PBS three 
times for 5 min each and quenched for endogenous peroxidase activity by 
incubating with 0.3% H2O2 in PBS for 30 min. Slides were again washed thoroughly 
with PBS and blocked with antigen diluent reagent (BD Biosciences, Franklin 
Lakes, NJ) for 30 min. Without further washing, the samples were incubated with 
primary antibody (Table 2.2) in PBS overnight at 4°C. Biotinylated secondary 
antibody (Vector Laboratories, Burlingame, CA) was applied for 30 min to 1 hour 
after washing with PBS. The samples were then incubated with ABC reagent 
(Vector Laboratories) for 30 min. Finally, DAB substrate (Vector Laboratories) was 
added until a brown color developed and the slides were counterstained with 
hematoxylin. Quantitation of cell number for a particular stain was determined by 
counting at least five different random fields in the same section at 200x resolution 
using a Nikon microscope. 
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VII. In vitro Cell Based Assays: 
In vitro Cell Proliferation Assay: 
 Cells (2x103 or 4X103) were seeded in 96-well plates and were allowed to 
adhere. Cells were washed with HBSS and were incubated with medium alone or 
medium containing different serum concentrations (1.25%, 2.5% or 5%) or medium 
containing specified concentrations of the SEMA5A protein for 48 hours. Cell 
viability was determined by MTT assay (3- (4, 5, dimethylthiazol-2-yl)-2, 5- 
diphenylate-tetrazolium bromide, tetrazole) as previously describe (Li et al., 2001).  
Cell Migration-Wound Healing Assay: 
 Cells (0.2x106) were plated per well in 12 well plate. The following day, the 
cells had reached 90-95% confluency. A wound was generated using a 1 mL 
pipette tip. Cells were washed with HBSS and incubated with either serum-free 
medium or with serum-free medium with different concentrations of SEMA5A for 
24 hours. Cells were photographed under an inverted microscope at a 40x 
magnification at time T = 0 hours and T = 24 hours. The width of the wound was 
measured using Image J software. Distance migrated was calculated by the 
formula: Initial wound width (T = 0 hours) – Final wound width (T = 24 hours).  
Chemotaxis Assay: 
 Chemotaxis assay was performed using Transwell chambers (Corning 
Costar Corp., Cambridge, MA) with polycarbonate membrane containing 8.0 µm 
pores. Cells (1 x 105) were plated onto Transwell chambers with serum-free media. 
Media (serum-free) alone or media containing SEMA5A protein were kept in the 
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bottom of 6-well plate, and the chambers were incubated at 37°C in 5% CO2 for 
24 hours. After 24 hours, cells from the top of the Transwell chambers were 
removed using a cotton swab (residual cells). The membrane was stained using 
Hema 3 kit (Fisher Scientific Company L.L.C., Kalamazoo, MI) as per the 
manufacturer’s instructions and cells were counted in five independent high-power 
fields (200x), using a Nikon Eclipse E800 microscope.  
Invasion Assay: 
 Invasion assay was performed using Transwell Corning® BioCoat™ 
Matrigel® Invasion Chambers with 8.0 μm PET Membrane in 6-well Plates. Cells 
(1 x 105) were plated onto Transwell chambers with serum-free media and 
incubated at 37°C in 5% CO2 for 24 hours. After 24 hours, cells from the top of the 
Transwell chambers were removed using a cotton swab (residual cells). The 
membrane was stained using a Hema 3 kit (Fisher Scientific Company L.L.C., 
Kalamazoo, MI) as per the manufacturer’s instructions and cells were counted in 
five independent high-power fields (200x), using a Nikon Eclipse E800 Nikon 
microscope.  
Cell Scatter Assay:  
 Cells were seeded at a density of 2 x 102 cells per well in a 6-well plate in 3 
mL of DMEM supplemented with 5% FBS and allowed them to grow as discrete 
colonies at 37°C in a humidified atmosphere of 5% CO2 for 72 hours. When the 
majority of colonies contained 20-30 cells, the medium was replaced by the DMEM 
containing 5% FBS only or different concentrations of recombinant SEMA5A 
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protein. After 16 hours of SEMA5A treatment, the medium was removed, and the 
cells were washed with PBS. The cells were fixed with methanol at room 
temperature for 10 min. After removal of methanol, the dish was allowed to air dry 
and stained with Giemsa stain at room temperature for 15 min. The stain was 
removed, and the dish was washed several times with distilled H2O and allowed to 
air dry. The percentage of scattered colony was measured from the total number 
of colonies counted. When half of the cells in the given colony had lost contact with 
their neighbors and exhibited a fibroblast-like phenotype, it was judged as a 
“scattered” colony. 
Three-dimensional Colony Formation Assay: 
 Growth factor-reduced Matrigel was thawed on ice. Cells suspension with a 
density of 1x104 cells per mL in serum-free media was used to dilute Matrigel in 
1:1 ratio. Cell culture 96-well plate was kept on the ice.150 L of cells containing 
Matrigel were plated per well and incubated at 37°C in a humidified atmosphere of 
5% CO2 for half an hour. Culture media was added, and colonies were visualized 
after 72 hours.  
TOP-FLASH Assay:  
 Cells were plated into 12-well dishes. The following day, the cells were 
transiently transfected with the TOP-flash or FOP-flash vector (0.5 µg/well) and a 
Renilla Vector as a transfection control (0.1 µg/well), n=6 per cell line and vector. 
Vectors were obtained from Promega (Madison, WI). Two days later, the cells were 
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assayed for firefly/Renilla luciferase using the Dual-Glo reagent (Promega, 
Madison, WI) as per the manufacturer’s instruction. 
VIII. Quantification and Analysis 
IHC Scoring and Analysis:  
 The scoring of IHC was performed in accordance with following criteria: 
percentage of positive cells on the slides was numbered as follows: 0 (negative), 
0.1 (1%–10% of cells positive), 0.2 (11%–20% of cells positive), and 0.3 (20%-
30% of cells positive) and more. Furthermore, the intensity was designated as 
weak (1 point), moderate (2 points), strong (3 points) or very strong (4). The IHC 
composite score was calculated by multiplying the extent of positive cells with 
intensity. Two independent observers examined each slide, and their observations 
were positively correlated with each other. Average scores were used for analysis 
and if the two observers significantly differed in their scoring, a third observer 
examined the slide. 
Quantification of Lamellipodium and Filopodium:  
 For quantification of lamellipodium and filopodium, the actin cytoskeleton 
was stained as described in the section of immunofluorescence using Texas Red 
Phalloidin (Molecular Probes) for 20 min. We quantified the number of cells, 
lamellipodia, and filopodia with a free edge in 5 different random fields in the same 
coverslip at 630x resolution using a LSM 710 Zeiss Confocal Microscope. We 
counted the number of Lamellipodia and Filopodia per cell. 
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Statistical Analysis:  
 Statistical analysis was conducted using GraphPad Prism software 
(GraphPad Software, Inc., La Jolla, CA). The significance was determined by 
Student’s t-test or nonparametric Mann-Whitney U-test. Comparisons between 
different groups were evaluated using parametric or Kruskal-Wallis nonparametric 
Analysis of Variance or followed by Bonferroni adjustment for multiple 
comparisons. For all statistical tests, a p-value of ≤ 0.05 was considered 
significant.  
66 
 
 
Table 2.1 List of Human Primers Used for the Study: 
 
 
Gene 
Temper
ature Size 
Orientation Primer Sequence 
1 E-cadherin 58°C 314 
Forward 
Reverse 
AGTGCCAACTGGACCATTCA 
TCTTTGACCACCGCTCTCCT 
2 
N-Cadherin 
 
58°C 217 
Forward 
Reverse 
TCAGGCTGTGGACATAGAAACC 
GCTGTAAACGACTCTGGCACT 
3 
TWIST 
 
58°C 159 
Forward 
Reverse 
GTCCGCAGTCTTACGAGGAG 
CCAGCTTGAGGGTCTGAATC 
4 SNAIL 58°C 207 
Forward 
Reverse 
TTTACCTTCCAGCAGCCCTA 
CCCACTGTCCTCATCTGACA 
5 RPL13A 58°C 126 
Forward 
Reverse 
CCTGGAGGAGAAGAGGAAAGAGA 
TTGAGGACCTCTGTGTATTTGTCAA 
6 HPRT 58°C 144 
Forward 
Reverse 
AGGGTGTTTATTCCTCATGGAC 
GTAATCCAGCAGGTCAGCAAAG 
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Table 2.1 List of Antibodies Used for the Study: 
 
 
Antibody with Species 
Reactivity 
Supplier and 
Catalogue 
Number 
Host 
Species 
WB 
(dilution) 
IF 
(Dilution) 
IHC 
(Dilution) 
1 
SEMA5A 
(Human, Mouse) 
Invitrogen 
(PA5-12278) 
Rabbit 1:1000   
2 
E-cadherin 
(Human, Mouse) 
Gift from Dr. 
Keith Johnson 
(Hybridoma 
Supernatant) 
Mouse 1:100 1:5  
3 
N-cadherin 
(Human, Mouse) 
Gift from Dr. 
Keith Johnson 
(Hybridoma 
Supernatant) 
Mouse 1:100 1:5  
4 
-catenin 
(Human, Mouse) 
Gift from Dr. 
Keith Johnson 
(Hybridoma 
Supernatant) 
Mouse 1:200 1:10  
5 
PCRP-SNAI3 
(Human) 
Developmental 
Studies 
Hybridoma 
Bank 
Mouse 1:100   
6 
TWIST 
(Human, Mouse) 
Santa Cruz 
Biotechnology 
15393 
Rabbit 1:200   
7 
PCNA 
(Human, Mouse) 
 
Santa Cruz 
Biotechnology 
sc-56 
Mouse   1:100 
8 
SEMA5A 
(Human, Mouse) 
Singh-lab-
purified 
(1mg/mL) 
Rabbit  1:25 1:50 
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9 Texas Red Phalloidin 
Molecular 
Probes   
1:50  
10 CD31 
Abcam 
(28364) 
Rabbit   1:50 
11 
Plexin B3 
(Human, Mouse, Rat) 
 
Santa Cruz 
Biotechnology 
(sc-67144) 
Rabbit 1:200  1:50 
12 
Met 
(Human, Mouse, Rat) 
 
Santa Cruz 
Biotechnology 
(sc-8307) 
Rabbit 1:200   
13 
GAPDH 
(Human, Mouse) 
Santa Cruz 
Biotechnology 
(sc-59541) 
Mouse 1:2000   
14 
-Actin 
(Human, Mouse) 
Sigma 
(A2066) 
Rabbit 1:5000   
15 
p-MET 
(Tyr1234/1235) 
(Human, Mouse, Rat) 
 
Cell Signaling 
#3077 
Rabbit 1:1000   
16 
PI3K 
(Human, Mouse) 
Abcam 
86714 
Mouse 1:1000   
17 
p-PI3K 
(p85(Tyr458/p55(Tyr199) 
(Human, Mouse) 
Cell Signaling 
#4228 
Rabbit 1:1000   
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18 
AKT 
(Human, Mouse) 
BD 
Transduction 
Laboratories TM 
610861 
Mouse 1:1000   
19 
p-AKT 
(Ser473) 
(Human, Mouse) 
Cell Signaling 
#9271 
Rabbit 1:1000   
20 
GSK3
(Human, Mouse, Rat) 
 
Cell Signaling 
#12456 
Rabbit 1:1000   
21 
p-GSK3
(Ser 9) 
(Human, Mouse) 
Cell Signaling 
#9336 
Rabbit 1:1000   
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Figure 2.1: The experimental model used for evaluation of the metastatic 
potential of T3M-4 Control and T3M-4-shSEMA5A cells. 
This schematic diagram is representing the experimental strategy used for 
tumor implantation and end-point analysis of the growth of T3M-4 Control and 
T3M-4-shSEMA5A cells in athymic nude mice.  
. 
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 Figure 2.2: The experimental model used for evaluation of the metastatic 
potential of CD18/HPAF-Control and CD18/HPAF-shPlexin B3 cells. 
This schematic diagram is representing experimental strategy used for tumor 
implantation and end-point analysis of CD18/HPAF-Control and CD18/HPAF-
shPlexin B3 cells in athymic nude mice.  
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Chapter 3 
Differential Expression of SEMA5A in PC Progression and Metastasis 
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I. Abstract: 
 Identified as a cell adhesion molecule involved in organ-specific metastasis, 
SEMA5A has differential cell surface expression between normal and cancer cells 
and represents an attractive target for therapeutic intervention in PC. In this study, 
we delineated the pathological expression of SEMA5A during PC progression and 
metastasis. We utilized human Tissue Microarray (TMA) and took advantage of 
three different mouse models of PC disease progression, including exocrine as 
well as neuroendocrine tumors. KC and KPC mice were used for studying 
SEMA5A expression in PDAC, and the RIP1-Tag2 (RT2) model of islet-cell 
carcinoma was used for PanNET. Using IHC, SEMA5A expression was analyzed 
on human and mouse tissue sections qualitatively. Our results demonstrate 
highest SEMA5A expression in liver metastases in human, followed by primary 
pancreatic tumor with least/no SEMA5A expression in the normal pancreas. 
SEMA5A expression was localized on the membrane of tumor cells with no 
staining for surrounding stroma. Likewise, in the KC mouse model, SEMA5A 
expression was low in the normal pancreas but increased with disease progression 
in tumor tissues. We also observed positive SEMA5A expression at different 
metastatic sites in the KPC mouse model. Similar to PDAC, in endocrine tumors, 
we observed higher SEMA5A expression in liver metastases in comparison with 
normal and primary tumors in the RT2 PanNET mouse model and human PanNET 
patient samples. Overall, we conclude that SEMA5A expression is upregulated 
during PC initiation and this expression is furthermore elevated at metastatic sites, 
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especially liver, in both exocrine and endocrine tumors. Therefore, SEMA5A 
represents a potential molecule for targeting metastasis and has stage-specific 
expression in the primary tumor.  
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II. Introduction: 
 Semaphorins are well known for their role as guidance and migration cues 
for a cell to reach the target site during the embryonic development of nervous 
system and cardiovascular patterning (Eichmann et al., 2005; Epstein et al., 2015; 
Tamagnone and Comoglio, 2000). Recent literature suggests aberrant expression 
of axonal guidance cue molecules in cancer, and their dysregulated signaling plays 
a significant role in cancer angiogenesis and metastasis (Gu and Giraudo, 2013; 
Muratori and Tamagnone, 2012; Neufeld and Kessler, 2008; Neufeld et al., 2016; 
Neufeld et al., 2012; Rizzolio and Tamagnone, 2007). Our lab identified one such 
molecule (SEMA5A) to be involved in organ-specific homing during PC 
(Sadanandam et al., 2007; Sadanandam et al., 2010b). Understanding the pattern 
of expression of SEMA5A in primary tumors and metastasis with relevance to PC 
disease progression and stages can increase the candidacy of this molecule for 
the development of novel diagnostic and targeted therapies in future.  
 One of the parameters to be effective in the clinic is the evaluation of a 
target in different models of PC malignancy (Olive and Tuveson, 2006). In the past 
few years, many mouse models of PC have been developed that provide 
information about the development and genetic causes of PC (Hruban et al., 2006). 
The popular models are based on murine Kras gene mutation in pancreatic 
progenitor cells, such as conditional activated Kras in KC (Hingorani et al., 2003; 
Tuveson et al., 2004) and KPC (Hingorani et al., 2005; Olive et al., 2004). These 
bear a striking similarity to the human PDAC condition (Olive and Tuveson, 2006) 
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and recapitulate the histopathologic condition of metastasis to relevant sites. Both 
KC and KPC models enable the evaluation of cellular pattern and identification of 
the time point of expression of a molecule of interest during PDAC disease 
development. 
 Mouse models different from the one described above are utilized to study 
the endocrine type of PC. The RT2 model is the most popular one for studying 
PanNET (Tuveson and Hanahan, 2011). In this model,-cell-specific expression 
of the SV40 T-antigen leads to islet-cell carcinomas (Hanahan, 1985). The SV40 
T-antigen under the regulation of the rat insulin promoter induces tumorigenesis in 
pancreatic islet cells by inactivation of the p53 and retinoblastoma tumor 
suppressor pathways (Hunter et al., 2013). 
 Currently, SEMA5A expression has not been evaluated during PC disease 
progression and in metastasis. Thus, to understand the probable pathological roles 
of SEMA5A in PC, we first evaluated the expression pattern of SEMA5A in human 
PC primary tumor and metastasis tissue specimens. Furthermore, using 
pancreatic tissues derived from the KC and KPC mouse models, we analyzed the 
pattern of SEMA5A expression during the development and progression of PDAC. 
Additionally, we identified the SEMA5A expression pattern in PanNET 
progression, by utilizing the RT2 mouse model. Understanding the pattern of 
expression of SEMA5A in primary tumors and metastasis with relevance to PC 
disease progression and stages will furthermore elucidate whether there is a 
possibility of utilization of this molecule as a target for the development of 
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biomarkers or targeted therapies in future. Our data demonstrate that SEMA5A 
expression is increased during PC initiation and is dependent on the stage of the 
disease. Furthermore, SEMA5A expression is also observed at different metastatic 
sites and represent a potential molecular target.  
III. Results: 
SEMA5A Expression Depends on the Differentiation Status of PC: 
 We performed SEMA5A IHC analysis on a TMA containing 33 cases of 
human patients with PC and four unmatched normal pancreatic tissues in 
duplicate. SEMA5A expression was mainly observed in PC tumors whereas 
normal tissue either showed low or no expression, and the expression was 
localized on the membrane of tumor cells with no staining for surrounding stroma 
(Fig. 3.1A). We also analyzed the correlation of SEMA5A expression with 
differentiation status of the tumor. SEMA5A expression was significantly higher (p 
< 0.05) for well differentiated (n = 4) and moderately differentiated (n = 15) tumors 
in comparison with poorly/undifferentiated (n = 8) tumors as well as normal 
pancreatic tumors (n = 4) (Fig. 3.1A, 1B). Furthermore, analysis of SEMA5A 
expression within different stages of PC revealed a significant difference (p < 0.05) 
in SEMA5A expression between normal pancreatic tissues and different stages of 
PC (Fig. 3.1C). We also observed lower SEMA5A expression for advanced stages 
like Stage IIB (n = 10) and Stage IV (n = 12) than initial stages like Stage IB (n = 
2) and IIA (n = 6), but this difference in SEMA5A expression was not significant 
among stages (Fig. 3.1C).  
80 
 
 
SEMA5A Gene Amplification Occurs in PC Cases: 
 Using The Cancer Genome Atlas (TCGA) Database, we analyzed copy 
number variation of SEMA5A in pancreatic adenocarcinoma cases. We found the 
gain of SEMA5A gene in 35 out of 49 pancreatic adenocarcinomas (Fig. 3.1D). 
The gain of SEMA5A gene ranged between the value of 2 to 3 of copy number in 
a diploid cell.  
SEMA5A Expression is Higher at Metastatic Sites in Comparison with the Primary 
Tumor: 
 With an interest to evaluate SEMA5A expression between primary cancer 
and different metastatic sites, we utilized a TMA with 21 cases of PC patients with 
primary tumor and either one, two or three metastatic sites like liver, diaphragm, 
and bowel. IHC scoring of SEMA5A was highest for a liver metastatic site (n =16) 
with a significant difference between normal (n = 3) (p < 0.001) /primary cancer (n 
= 17) (p < 0.05) and liver metastasis (Fig. 3.2A, 2B). There was no significant 
difference in SEMA5A expression at diaphragm metastatic site (n = 14) and the 
primary tumor of human PC metastasis specimens. We also observed non-specific 
background staining of SEMA5A for normal liver cells.  
 We also analyzed SEMA5A expression in metastatic variants derived from 
fast-growing (FG) COLO 357 cells, as described by Burns et. al in their in vivo 
selection study using orthotopic implantation in nude mice (Bruns et al., 1999). We 
observed higher SEMA5A expression in highly metastatic L3.6pl cells than the low 
metastatic potential L3.3 cells (Fig. 3.2C). 
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Sema5A Expression is Higher in the Cancerous Lesions of KC Mice than in the 
Normal Pancreas: 
 To evaluate Sema5A expression during PC disease progression, KC mice 
pancreatic tissues derived from mice sacrificed at different time points (10, 20, 30 
and 50 weeks) were used to generate a progression model. We observed no 
expression of Sema5A in the normal pancreas, derived from the control PDX-cre 
mice. However, tumors in KC mice beginning at 10 weeks of age were positive for 
Sema5A expression (Fig. 3.3). This expression was further intensified in the 
tumors of mice at 20, 30 and 50 weeks age. The pancreas of a 50-week aged 
mouse represents fully developed PDAC. Similarly to SEMA5A expression in 
human pancreatic tissues, localization of Sema5A expression in mice was on the 
membrane of tumor cells with no staining for surrounding stroma. We observed 
non-specific background staining in acinar ducts of the pancreas. 
Metastatic Sites of KPC Mice are Positive for Sema5A Expression: 
 With an objective to evaluate Sema5A expression at metastatic sites, we 
utilized the KPC mice model to derive metastatic site tissues from the liver, lymph 
node, peritoneum, and diaphragm.of mice sacrificed at 50-week time point. We 
observed that Sema5A expression is positive for all the cancer cells established at 
the metastatic site except lymph nodes (Fig. 3.4).  
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Sema5A Expression is High in Angiogenic Islets and Metastasis-like-Primary 
(MLP) Tumors in PanNET: 
 We investigated the Sema5A mRNA expression profiles from the 
progressive stages of the disease in RT2 mice. Sadanandam et. al. in their study 
of cross-species analysis of PanNET provides a description of parameters for 
hierarchical clustering and resulting stage-classified groups (Sadanandam et al., 
2015). The stages of disease progression described in this paper are normal, 
hyperplastic, and angiogenic islets. Furthermore, classification of primary tumor 
samples by their similarities with the metastases resulted in the formation of two 
distinct groups called metastasis-like primary (MLP) and well-differentiated 
islet/insulinoma tumors (ITs). As the name suggests, gene expression of MLP was 
similar to the gene expression at metastatic sites in the RT2 model. This dataset 
included pools of normal (n = 3), hyperplastic/dysplastic (n = 3), and angiogenic (n 
= 3) islets, as well as individual tumors (n = 10) and liver macrometastases (Mets; 
n = 3). In this mRNA evaluation, we found upregulation of SEMA5A expression in 
liver metastasis in comparison with normal islets (Fig. 3.5A), followed by MLP and 
angiogenic islets. On the other hand, hyperplastic/dysplastic islets and well 
differentiated IT showed downregulation of SEMA5A expression in comparison 
with normal islets. 
Next, SEMA5A expression was evaluated in human mRNA transcriptomes 
of PanNET patients using NMF consensus clustering analysis as described by 
Sadanandam et al in a cross-species analysis of PanNET (Sadanandam et al., 
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2015). This mRNA transcriptome had core clinical gene expression information for 
86 patients classified as nonfunctional PanNETs, insulinomas, and normal 
pancreatic islet samples (Missiaglia et al., 2010). This dataset included four normal 
islets, 75 primary tumors positive or negative for metastasis, and seven samples 
of either liver or lymph node metastases. Highest SEMA5A mRNA expression was 
found in liver metastasis in comparison with normal islets (Fig. 3.5B, 5C) followed 
by primary tumors positive for metastasis. In contrary, SEMA5A mRNA expression 
was down-regulated in lymph node metastasis, and we observed no change of 
SEMA5A expression in patients negative for metastasis.  
IV. Discussion: 
 There is an urgent need to identify new targets in PC that can bring down 
the rate of metastasis-driven mortality. An ideal target for such a case will be a 
molecule that can restrict the escape of a cancer cell by targeting metastatic 
cascade. Guidance cue molecules represent an attractive class for such a 
scenario. In the family of guidance cue ligands, Semaphorins represent the largest 
and the most well-studied member and are well-known players in angiogenesis 
and cellular migration processes in cancer. Our group became interested in the 
SEMA5A molecule, which belongs to the class 5 of Semaphorin family, due to the 
organ-specific homing property of the seven amino acid peptide NAFTPDY of this 
molecule (Sadanandam et al., 2007). In this earlier study (Sadanandam et al., 
2007) performed for the identification of cell adhesion molecules critical for 
metastasis, SEMA5A emerged as an important candidate for targeting PC 
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metastasis. In this present study, we furthermore tested the prospects of SEMA5A 
as a target by analyzing the pattern of SEMA5A expression in both human and 
murine primary pancreatic tumor tissues as well as metastases, and normal 
pancreas (Fig. 3.6).  
 With this objective, we utilized human PC TMA of primary cancer and 
metastasis as well as the human PanNET patient database. We also took 
advantage of KC and KPC mouse models for studying SEMA5A expression in 
PDAC and the RT2 model of islet-cell carcinoma for PanNET. The KC and KPC 
models are generated by crossing mice with a conditional activated Kras allele 
(LSL-KrasG12D) to either of Pdx-Cre or p48Cre recombinase in pancreatic lineages 
(Hingorani et al., 2003; Tuveson et al., 2004). KC mice successfully develop PanIN 
but develop PDAC tumors only at an advanced age. This condition suggests Kras 
alone cannot drive tumor formation and additional events are necessary before 
tumor formation could proceed. To overcome this problem, animals expressing 
Pdx-Cre with multiple conditional mutations were generated such as both Kras and 
Trp53 (Hingorani et al., 2005; Olive et al., 2004). Thus, KPC mice with Kras and 
Trp53 mutation develop PanIN lesions at an early age, which leads to the 
occurrence of metastasis to relevant sites. Likewise, the RT2 mouse model of islet 
cell carcinoma has been instrumental in studying PanNET progression and has 
been utilized for prediction of clinical efficacy of new therapeutics.  
 Our results demonstrate an increased expression of SEMA5A in the 
metastasis and primary tumor burden of human and mice PC tissue. The normal 
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pancreas was either negative or showed low expression of SEMA5A. The 
localization of SEMA5A was on the membrane of tumor cells with no staining for 
surrounding stroma. The increase of SEMA5A expression in primary tumor also 
goes by our observation of gain of copy number in SEMA5A in pancreatic 
adenocarcinoma patients. Likewise, a study of samples from gastric carcinoma 
patients illustrated elevated expression levels of both SEMA5A and its receptor 
plexin-B3 in primary gastric carcinoma and lymph node metastasis in comparison 
to the non-neoplastic tissue (Pan et al., 2009). On the other hand, although not 
significant, we found a decrease of SEMA5A expression in an advanced stage of 
PC progression  
 Next, we for the first time have identified the expression of Sema5A in the 
disease progression model of KC mice with tumor sections obtained at different 
week/time points (10-50 week). We identified the qualitative increase of Sema5A 
expression in the pre-cancerous lesions of20-week old KC mice which became 
further elevated with increasing time points. This observation does not go in hand 
with what we have seen for human PC patients. The possible reasons for these 
contrary results could be limited sample size of early staged PC patients, as most 
of the diagnosis occurs at an advanced stage for these patients. Another reason 
could be that our observations in the KC mouse progression model are at a 
qualitative level. Lastly, in these mouse models, we are examining Sema5A 
expression in the presence of Kras as a driver mutation, which may not reflect the 
entire representation of patient samples present in the TMA.  
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 We also compared Sema5A expression at different metastatic sites like 
liver, mesenchymal lymph node, peritoneum, and diaphragm in KPC mice, and we 
observed positive Sema5A expression for different metastases except lymph 
nodes. In endocrine tumors as well, we observed the similar pattern of highest 
SEMA5A expression at liver metastasis followed by primary tumor burden with no 
expression in normal pancreas. In contrary to SEMA5A analysis in human patient 
TMA, which revealed higher SEMA5A expression in differentiated tumors than 
poorly/undifferentiated tumors, in the RT2 model we observed downregulation of 
SEMA5A expression in well-differentiated IT tumors, and higher SEMA5A 
expression in poorly differentiated MLP. Li et al. in 2010 have published similar 
findings on SEMA5A in glioblastoma in regards with differentiation in human 
patient samples, demonstrating that the treatment of glioblastoma cell lines with 
SEMA5A impaired cellular motility and promoted differentiation (Li et al., 2012b; Li 
and Lee, 2010). Interestingly, lymph node metastases of human PanNET patients 
showed downregulation of SEMA5A expression. Similarly, in KPC mice 
metastasis, we did not observe any variation in Sema5A expression in different 
metastatic sites except lymph nodes. Lymph node metastasis may represent 
cancer cells in transition that do not upregulate cell adhesion molecules such as 
SEMA5A. Lastly, though PDAC and PanNET represent malignancy of pancreas, 
they each have different pathophysiology.  
 In summary, our data demonstrate that expression of SEMA5A in PC may 
be of predictive value for the occurrence and progression of PC. Thus, SEMA5A 
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may represent a potential target for the diagnosis and treatment of pancreatic 
tumors in the future. 
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Figure 3.1: Increased SEMA5A expression is observed in human PC 
primary tumor in comparison with the normal pancreas.  
(A) Representative images showing SEMA5A expression in normal pancreas, 
primary well differentiated and poorly differentiated PC in human patients. 
Images are taken at 200x using a Nikon Eclipse E800 microscope. (B, C) Bar 
graph showing SEMA5A immunohistochemistry (IHC) score between tumors at 
different cellular differentiation status and normal tissues and different stages 
of tumors and normal tissues. Shown with symbol “a” (a) are the significant 
statistical differences (p ≤ 0.05) between various tumors and the normal 
controls. Similarly, the symbol “b” (b) represent significant statistical differences 
(p ≤ 0.05) between various tumors and poorly/undifferentiated tumors. 
SEMA5A expression is higher in different stages in comparison with the normal 
tissues and the higher SEMA5A expression is seen in well-differentiated tumors 
in comparison with normal and poorly/undifferentiated tumors. SEMA5A 
expression in tumor tissue (n = 33 in duplicates) and normal pancreas (n = 4 in 
duplicates) in TMA was examined using IHC. The values are mean IHC 
composite score ± Standard Error of Mean (SEM). The significance of the data 
was determined by the non parametric Mann-Whitney U-test (two-tailed). A 
value of p < 0.05 was deemed significant. (D) Pancreatic Adenocarcinoma 
cases show the gain of SEMA5A gene copy number as observed using The 
Cancer Genome Atlas (TCGA) Database. The X-axis represents log 2 value of 
copy number, and the Y-axis represents individual pancreatic adenocarcinoma 
(n = 49) cases. The gain of SEMA5A gene ranged between the value of 2 to 3 
in copy number calculated by the formula 2*(log20-log20.5) in a diploid cell. 
However, aberrant gene expressions have a gain of copy number greater than 
3. 
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Figure 3.2: Increased SEMA5A expression is observed in human PC 
metastatic sites in comparison with the normal pancreas and primary 
pancreatic tumor.  
(A) Representative images are showing SEMA5A expression in normal 
pancreas, primary PC and metastatic sites like liver and diaphragm in human 
patients. Images were taken at 200x using a Nikon Eclipse E800 microscope. 
(B) The graph shows higher SEMA5A IHC Score at metastatic sites in 
comparison with the primary tumor, evaluated using TMA with 21 cases of PC 
patients. The values are mean IHC composite score ± SEM. We found the 
highest IHC scoring of SEMA5A for liver metastatic site (n = 16) with a 
significant (p ≤ 0.001) difference between normal (n = 3)/primary cancer (n = 
17). The significance of the data was determined using one-way ANOVA with 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns p > 0.05). Black bars represent a 
comparison between groups with respect to normal, blue bars represent a 
comparison between different groups with respect to primary pancreatic tumor 
and red bars represent comparison between groups with respect to the liver. 
(C) Western blot analysis is showing higher SEMA5A expression in L3.6pl (high 
metastatic potential) in comparison with L3.3 (low metastatic potential) cell lines 
using GAPDH as a loading control. Quantification of the SEMA5A by their 
intensity of the bands with respect to their loading control GAPDH was 
performed by Image J software. Bands were normalized on the L3.3 cells. 
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Figure 3.3: Sema5A expression progressively increases in the developing 
cancerous lesions of KC mice. 
Representative images of Sema5A immunohistochemistry performed on the 
progression model derived from tumors of KC mice (n = 5) at different ages (10 
weeks, 20 weeks, 30 weeks and 50 weeks) demonstrating progressively 
increasing qualitative Sema5A expression. The normal pancreas of 50-week 
Pdx1-cre mice is negative for Sema5A expression. The images were taken at 
200x magnification using a Nikon Eclipse E800 microscope.  
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Figure 3.4: Metastatic sites of KPC mice are positive for the Sema5A 
expression. 
 Representative images of Sema5A immunohistochemistry performed on 
metastatic sites (mesenchymal lymph node (n = 1), liver (n = 5), diaphragm (n 
= 1), and peritoneum (n = 2)) of KPC mice, demonstrating that metastatic sites 
are positive for the expression of Sema5A except lymph node. The images 
were taken at 200x magnification using a Nikon Eclipse E800 microscope. “N” 
represents normal tissue while “M” represents metastasis. 
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Figure 3.5: SEMA5A expression is higher at metastasis in comparison 
with normal islets in PanNET cases.  
(A) Expression of Sema5A as median-centered fold change with respect to 
normal islets (N; n = 3) in different stages (hyperplastic/dysplastic (H; n = 3) 
islets and angiogenic (A; n = 3) islets), tumor subtypes (n = 10; classified into 
Insulinoma/Islet Tumors (IT) and Metastasis Like Primary (MLP) Tumors) and 
liver metastases (Mets; n = 3) of RT2 mouse model of PanNET. Angiogenic 
islets, MLP tumors, and liver metastases show upregulation of Sema5A with 
respect to normal islets. (B) Expression of SEMA5A as median-centered fold 
change with respect to normal islets in primary tumor with (Yes) or without (No) 
metastasis and liver (Liver) and lymph node (Lymph Node) metastases from 
human PanNETs. This dataset included four normal islets, 75 primary tumors 
positive or negative for metastasis and seven samples of either liver or lymph 
node metastases. The significance of the data is determined using Student t-
test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05). (C) Representative images 
of SEMA5A immunohistochemistry performed on pancreas and liver of a 
patient suffering from PanNET. The images were taken at 200x magnification 
using a Nikon Eclipse E800 microscope.  
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Figure 3.6: Expression levels of SEMA5A in PC. 
Schematic showing representation of SEMA5A expression in normal pancreas, 
primary tumor, and metastatic sites, analyzed utilizing different PC mouse 
models and human patient samples in TMA. Schematic representation 
suggests an increase in SEMA5A expression in PC with low or no expression 
in normal pancreas. Furthermore, SEMA5A expression is also present in PC 
metastatic sites like liver, spleen, and others. Especially, for pancreatic 
neuroendocrine cases, metastatic sites show furthermore upregulation of 
SEMA5A expression in comparison with the primary tumor.  
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Chapter 4  
SEMA5A Regulates Cellular Motility in PC Through the Plexin B3 Receptor 
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I. Abstract: 
 Previous reports from our laboratory provide evidence that SEMA5A 
enhances PC metastasis. Based on the results obtained from our previous studies, 
we hypothesized that SEMA5A induces cellular migration and thereby enhances 
PC metastasis through its interaction with receptor Plexin B3 in malignant cells. To 
test this hypothesis, we stably down-regulated the expression of Plexin B3 in cell 
lines T3M-4 and CD18/HPAF and evaluated migratory response using wound 
scratch assay, scattering assay, chemotaxis, and staining the actin cytoskeleton. 
Activation of Met receptor in the presence of SEMA5A was examined using 
Western blots. Treatment of Control- and Plexin B3- knockdown T3M-4/ 
CD18/HPAF cells with SEMA5A resulted in the higher migration in the Control cells 
in comparison with shPlexin B3 cells. Another piece of supporting evidence 
indicating increased migratory response came from the treatment of Control cells 
seeded at low density with SEMA5A that demonstrated an increased formation of 
membrane ruffles, showing dismantling of stress fibers in cells treated with 
SEMA5A compared with the untreated cells. Similarly, Control colonies showed an 
increased scattering response under the treatment of SEMA5A, but the similar 
effect of SEMA5A treatment was absent in the shPlexin B3 colonies. We observed 
lower chemotaxis towards SEMA5A in Plexin B3 knockdown cells. Lastly, 
SEMA5A treatment also led to phosphorylation of Met at tyrosine 1234/1235 in 
control cells, which represent activation of this receptor. In summary, our data 
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demonstrate that SEMA5A can elicit migratory response and activation of Met 
through the Plexin B3 receptor. 
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II. Introduction: 
 A growing body of evidence now supports the roles of various semaphorins 
in oncogenesis via their involvement in pathological processes such as 
angiogenesis and cellular migration during metastasis (Neufeld and Kessler, 2008; 
Neufeld et al., 2016; Neufeld et al., 2012; Rehman and Tamagnone, 2013; Rizzolio 
and Tamagnone, 2007; Sakurai et al., 2012; Tamagnone and Comoglio, 2004; 
Trusolino and Comoglio, 2002). Semaphorins are well recognized as major 
regulators of cellular migration and guidance to reach their respective targets. The 
gain of migration ability with the loss of cellular adhesion is a key event in the 
process of metastasis. Metastasis represents the reason for 90% of cancer-related 
death (Das and Batra, 2015; Rahib et al., 2014; Siegel et al., 2017). Metastatic 
nature of PC is majorly responsible for the significantly worse prognosis of PC 
patients (Oberstein and Olive, 2013). For decreasing mortality rate in PC, further 
exploration of the molecular mechanism(s) that lead to metastatic dissemination is 
warranted (Fidler and Kripke, 2015; Steeg, 2016). 
 The importance of these axonal guidance cue ligands gains supports from 
a recent study demonstrating aberration in axonal guidance cue pathways in the 
PC genome (Biankin et al., 2012). Semaphorins and their receptor Plexins 
represent the largest and the well-characterized class of the axon guidance cue 
family (Tamagnone and Comoglio, 2000). Semaphorins are either secreted or 
membrane-bound and have a conserved “Sema” domain towards their N-terminus. 
Subclass 5 of this family comprises transmembrane semaphorins, and in addition 
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to the Sema domain, they contain a unique extracellular domain containing seven 
thrombospondin type 1 repeats. Several studies have demonstrated the 
expression and role of subclass 5 member SEMA5A in various malignancies 
including glioma, lung, prostate, melanoma and gastric (Balakrishnan et al., 2009; 
Li et al., 2012a; Li and Lee, 2010; Lu et al., 2010; Pan et al., 2010; Pan et al., 2013; 
Pan et al., 2009). Previous reports from our laboratory provide evidence that 
SEMA5A enhances PC metastasis (Sadanandam et al., 2012; Sadanandam et al., 
2007; Sadanandam et al., 2010b). Our group identified SEMA5A as a putative cell 
adhesion molecule involved in organ-specific homing of PC cells (Sadanandam et 
al., 2007). We also demonstrated that SEMA5A overexpression in a PC cell line 
endowed enhanced metastatic potential when the cells were implanted in an 
orthotopic nude mouse model (Sadanandam et al., 2010b). Interestingly, 
overexpression of the secreted form of SEMA5A showed further enhanced micro 
metastases to the liver, with a lower primary tumor burden, when orthotopically 
implanted in the nude mice (Sadanandam et al., 2012).  
 Furthermore, previous studies report Plexin B3 as a SEMA5A interacting 
partner in non-pancreatic tissue (Artigiani et al., 2004; Sadanandam et al., 2008). 
A study of samples from gastric carcinoma patients demonstrated the pathological 
relevance of this interaction, showing the elevated expression of both SEMA5A 
and Plexin B3 in primary gastric carcinoma and lymph node metastasis in 
comparison to the non-neoplastic tissue (Pan et al., 2010; Pan et al., 2009). 
Various PC cell lines also document the co-expression of SEMA5A and Plexin B3 
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(Sadanandam et al., 2008). Like SEMA5A, Plexin B3 and Met also shares the 
structural sema domain, and Met has been implied to form receptor complexes 
with Plexin B3 (Artigiani et al., 1999). Met is a well-known key contributor to 
migratory cellular behavior in various cancers, including PC (Gentile et al., 2008). 
These data suggest potential cross talk between SEMA5A, Plexin B3, and Met. 
 We used the above-mentioned accumulated knowledge to build the 
rationale for our working hypothesis that interaction of SEMA5A with Plexin B3 is 
necessary for downstream signaling events and regulation of cellular phenotypes 
associated with cellular migration and metastasis in PC. Our data demonstrate that 
SEMA5A induces increases cellular migration in PC cells and this effect is 
mediated through Plexin B3 receptor. Furthermore, activation of Met receptor is 
responsible for the SEMA5A-induced migration. 
III. Results: 
SEMA5A Treatment Induced Cellular Migration of PC Cells: 
 To evaluate the effect of SEMA5A on PC cells, we treated PC cell lines 
AsPC-1 and T3M-4 with two different concentrations (50 ng and 100 ng) of 
recombinant human SEMA5A. We utilized a scratch wound-healing and transwell 
migration assay for evaluation of cellular migration and chemotaxis, respectively. 
We observed a higher percentage of wound closure/migration in both AsPC-1 (Fig. 
4.1A) and T3M-4 (Fig. 4.1B) cells on treatment with recombinant human SEMA5A 
in comparison with their respective untreated control cells. We found a significant 
difference in the wound closure ability of T3M-4 cells treated with 100 ng of 
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SEMA5A in comparison with untreated cells (p = 0.0234). Similarly, we observed 
chemotaxis of both AsPC-1 (Fig. 4.1C) and T3M-4 (Fig. 4.1D) towards SEMA5A. 
A higher number of AsPC-1 cells migrated towards 50 ng and 100 ng in 
comparison with the untreated control cells. Also, there was a significant difference 
in the number of T3M-4 cells that had migrated towards 100 ng (p < 0.001) in 
comparison with the untreated control cells. We also observed an increase (p = 
0.0438) in cellular protrusion or cellular spreading of T3M-4 cells when treated with 
50 ng of SEMA5A for 30 min (Fig. 4.1E).  
SEMA5A Treatment Showed no Effect on Proliferation of PC cells: 
 Next, we evaluated the effect of SEMA5A on PC cells’ proliferation by using 
the MTT assay. For this, we seeded PC cell lines AsPC-1, T3M-4 and CD18/HPAF 
at two different cell densities and treated them with three different concentrations 
(25 ng, 50ng, and 100ng) of recombinant human SEMA5A. We observed no 
differences in cellular proliferation of AsPC-1(Fig. 4.2A), T3M-4 (Fig. 4.2B), and 
CD18/HPAF (Fig. 4.2C) under treatment with different concentrations of SEMA5A 
evaluated after 24 hours. Likewise, we observed no differences in the proliferation 
of AsPC-1 seeded at 6000 cells per well (Fig. 4.2D) and at 2000 cells per well (Fig. 
4.2E) evaluated at different time points for different concentrations of SEMA5A.  
SEMA5A Mediates Cellular Migration in PC cells Through Plexin B3 Receptor: 
 Next, we generated stable Plexin B3 knockdown in T3M-4, and CD18/HPAF 
cell lines (Fig. 4.3A). We evaluated migration (Fig. 4.3B), chemotaxis towards 
SEMA5A (Fig. 4.3C) and scattering potential (Fig. 4.3D, E, F) of T3M-4-Control 
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and T3M-4-shPlexin B3 cells by treating with recombinant SEMA5A protein. We 
observed reduced effects of SEMA5A-induced migration and chemotaxis towards 
SEMA5A on T3M-4-shPlexin B3 knockdown cells in comparison with the T3M-4 
Control cells. Scattering of colonies (Fig. 4.3D) in both CD18/HPAF (Fig. 4.3E) 
and T3M-4 (Fig. 4.3F) cells were higher in SEMA5A-treated cells in comparison 
with their respective untreated Control cells. On the other hand, both CD18/HPAF- 
and T3M-4-Plexin B3 knockdown cells showed a lower response to SEMA5A-
induced scattering of colonies.  
SEMA5A Acts in a Plexin B3 Manner to Activate Met Signaling and Results in 
Increased Migration: 
 Lastly, for evaluation of Met activation on treatment with SEMA5A, we 
treated CD18/HPAF Plexin B3 knockdown and CD18/HPAF Control cells with 50 
ng of SEMA5A protein. We probed cell lysates of untreated- and SEMA5A treated-
CD18/HPAF-shPlexin B3 and CD18/HPAF-Control cells for phospho-Met 
(Tyr1234/1235) and observed activation of Met in CD18/HPAF-Control cells on 
treatment with 50 ng SEMA5A protein (Fig. 4.4A). However, the similar activation 
of Met receptor was absent in SEMA5A-treated CD18/HPAF-shPlexin B3 cells 
(Fig. 4.4A). Total cellular Met receptor levels remain unchanged with knock down 
of Plexin B3 (Fig. 4.4B). We also evaluated chemotaxis towards SEMA5A of T3M-
4-Control and T3M-4-shPlexin B3 cells in presence and absence of 5 g Met 
neutralization. We observed that Met neutralization leads to a decrease of 60% in 
the T3M-4-Control cells chemotaxis towards SEMA5A (Fig. 4.4C). Furthermore, 
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knockdown of Plexin B3 leads to a 30% decrease in chemotaxis towards SEMA5A 
(Fig. 4.4C). However, knockdown of Plexin B3 along with Met neutralization leads 
to a decrease of 90% chemotaxis towards SEMA5A (Fig. 4.4C). 
IV: Discussion: 
 Previous reports on various cancer types have suggested both tumor 
suppressive and oncogenic roles of SEMA5A (Purohit et al., 2014). In this study, 
we have investigated the effect of SEMA5A on PC cells and whether the PC cells 
respond to SEMA5A in a Plexin B3-dependent manner. We report that the 
treatment of PC cells with SEMA5A acting as a ligand leads to an increase in 
cellular motility and induction of scattering as well as having a chemotactic action 
on different PC cells. Under this scenario, SEMA5A is acting in a forward signaling 
manner. Our present results furthermore explain our previous findings that 
SEMA5A enhances PC metastasis. Previously, we reported that overexpression 
of SEMA5A in Panc-1 cell line resulted in enhanced in vivo migration or metastasis. 
Likewise, Pan et al. reported that gastric cancer cells expressing SEMA5A could 
promote invasion and metastasis by involving the PI3K/Akt/uPA signal 
transduction pathway (Pan et al., 2009). This study does not define whether 
SEMA5A increases invasion and metastasis in a forward or reverse manner. 
However, in contrast to our findings, SEMA5A acting as a ligand in a forward 
signaling manner by Plexin B3 receptor impedes cellular motility in glioblastoma 
patients (Li et al., 2012a; Li and Lee, 2010). 
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 With the gain of knowledge that forward signaling of SEMA5A acting as a 
ligand induces a migratory phenotype in PC cells, we went ahead to explore 
whether ligand SEMA5A acts on PC cells using Plexin B3 as the interacting 
receptor. Our in vitro studies suggest that SEMA5A induces migration and another 
similar phenotype in PC cells in a Plexin B3-dependent manner. Various reports 
based upon bioinformatics tools (Sadanandam et al., 2008) as well as functional 
assays carried out using different cancer cells like glioblastoma and others also 
suggest Plexin B3 as the interaction partner of SEMA5A (Artigiani et al., 2004; Li 
et al., 2012b; Li and Lee, 2010; Pan et al., 2009). However, there are other known 
receptors for SEMA5A as well. Using both in vivo and in vitro studies, Sema5A 
and Sema5B have been shown to inhibit retinal neurite outgrowth through 
PlexinA1 and PlexinA3 (Matsuoka et al., 2011). Thus, there is a need for future 
experiments to gain a vision whether SEMA5A acts only through Plexin B3 in PC 
cells or there are other receptors, that can mediate the effects of SEMA5A as well. 
 To furthermore explore signaling downstream of SEMA5A and Plexin B3, 
we went ahead to neutralize the Met receptor. Plexins share high similarity with 
Met and Recepteur d'Origine Nantais kinase (RON) members of the Scattered 
Factor Receptor Family (Artigiani et al., 1999), and recently Conrotto et. al. showed 
association of Met in receptor complexes formed by Plexin B2 and Plexin B3 but 
not with other family members (Conrotto et al., 2004). In our experiments, we 
observed activation of Met-mediated in a Plexin B3 manner (Fig. 4E). The 
chemotaxis of PC towards SEMA5A was inhibited by more than 50% by 
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neutralization of Met, suggesting Met activation as a necessary downstream event 
in the SEMA5A-mediated migratory response. Since we were able to inhibit only 
around 50% of the SEMA5A response, we cannot rule out the possibility of 
SEMA5A engaging other kinase receptors for chemotaxis activity. Another 
possibility is that Plexin B3 can elicit two different signaling pathways, one 
dependent on the cytoplasmic domain of Plexins and other type is dependent on 
engaging tyrosine kinase receptors such as Met for mediating cellular migration. 
Moreover, other Semaphorins like Semaphorin 4D can also engage the Met 
receptor using Plexin B1 as a receptor and can initiate invasive growth program 
(Giordano et al., 2002) and angiogenesis (Conrotto et al., 2005). 
 In conclusion, our results provide novel insights into the role of SEMA5A 
acting as a ligand in a forward manner on PC cells through Plexin B3 receptor. 
Moreover, our results suggest a possible role involvement of SEMA5A/Plexin B3 
with Met receptor thereby inducing a migratory response in PC cells.                                                                                                                                                                         
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Figure 4.1: Treatment with SEMA5A induces migration of PC cell lines. 
(A, B) Bar graph showing a higher percentage of distance migration in AsPC-1 
(A) and T3M-4 (B) cell lines treated with 50 ng/mL and 100 ng/mL 
concentrations of SEMA5A in comparison with untreated cells. Wound scratch 
assay was used to evaluate migration. After placing a scratch followed by 
SEMA5A treatment,  20 hours represent the endpoint of scratch evaluation. 
Significant migration difference was seen between T3M-4 untreated and T3M-
4-100ng treated group (p = 0.0234). The values are a mean percentage of 
migration ± SEM. The significance of the data was determined using one-way 
ANOVA. (C, D) Box plot graphs are showing chemotaxis of AsPC-1 (C) and 
T3M-4 (D) towards SEMA5A. Using transwell migration assay chemotaxis was 
evaluated for different SEMA5A concentration (50 ng and 100 ng of SEMA5A 
concentration and no serum medium as a control). The migrated cells were 
counted in five independent fields (100x), using a Nikon Eclipse E800 
microscope. The values are a mean number of migrated cells ± SEM. The 
significant migrational difference was seen among AsPC-1 untreated, and both 
50 ng and 100 ng SEMA5A-treated cells. Similarly, significant migration 
differences were seen between T3M-4 untreated and T3M-4-100ng treated 
group. The significance of the data was determined using the Kruskal-Wallis 
test by ranks (*p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, nsp > 0.05). (E) Representative 
images of cellular spread in presence and absence of SEMA5A (50ng). Images 
were taken at 400x magnification using a Nikon Eclipse E800 microscope.Bar 
graph showing an increase (p = 0.0438) in the ratio of the area of cellular 
spreading with respect to the area of the nucleus of T3M-4 cells treated with 50 
ng of SEMA5A for 30 min. Area of cellular spread and area of their respective 
nucleus was calculated for 15 different SEMA5A-treated and -untreated cells 
using Image J Software. The values are mean of the ratio of cellular area and 
area of nucleus ± SEM. The significance of the data was determined using the 
Mann-Whitney U Test.  
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Figure 4.2: Treatment with SEMA5A has no effect on cellular proliferation 
in PC cells. 
(A, B, C) Line graph demonstrating no effect of SEMA5A treatment at three 
different concentrations (25 ng, 50ng, and 100ng) on cellular proliferation of 
AsPC-1 (A) T3M-4 (B) and CD18/HPAF (C) cells seeded at two different 
concentrations. Cellular proliferation was evaluated after 24 hours of SEMA5A 
treatment using the MTT assay. (D, E) Line graph demonstrating no effect of 
SEMA5A treatment at three different concentrations (25 ng, 50 ng, and 100 ng) 
on proliferation of AsPC-1 seeded at 6000 cells per well (D) and at 2000 (E) 
cells per well and evaluated at different time points. The MTT assay was read 
using BIO-TEX ELx-800 plate reader at 570 nm wavelength. The values are 
mean of absorbance at 570 nm ± SEM. The significance of the data was 
calculated using Two-way ANOVA test. Cell lines treated at different densities 
were taken as Column Factor, and different SEMA5A concentration was taken 
as Row Factor. No statistical differences were seen between Row Factor. 
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Figure 4.3: Acting through Plexin B3 receptor, SEMA5A mediates cellular 
migration. 
(A) Western blot analysis of whole cell lysates of T3M-4 and CD18/HPAF 
Control and Plexin B3 knockdown cells. Plexin B3 expression is downregulated 
in Plexin B3 knockdown cells of T3M-4 and CD18/HPAF in comparison with 
their respective Control cells. Quantification of the Plexin B3 protein by their 
intensity of the bands with respect to their loading control GAPDH was 
performed by Image J software. Bands were normalized on the T3M-4 or 
CD18/HPAF Control cells. (B) Bar graph showing the percentage of migration 
of T3M-4 Control and Plexin B3 knockdown cells with and without the treatment 
with SEMA5A (50 ng). Control T3M-4 cells show a higher percentage of 
migration (p ≤ 0.05) in response to the treatment of SEMA5A. T3M-4 Plexin B3 
knockdown cells show no difference in the percentage of migration with the 
treatment of SEMA5A. Wound healing assay is used for evaluation of migration 
of the T3M-4 Control and knockdown cells. The values are a mean percentage 
of migration ± SEM.The significance of the data was calculated using Two-way 
ANOVA test. The PC Cell line in the presence and absence of SEMA5A were 
taken as Row Factor and Control and Plexin B3 were taken as Column Factor. 
(C) Box plot graph showing the chemotactic ability of the Control and Plexin B3 
knockdown cells towards SEMA5A. The graph shows the higher chemotactic 
ability of the T3M-4-Control cells towards the 50 ng (p ≤ 0.05) and 100 ng (p ≤ 
0.001) concentrations of SEMA5A. There is no significant difference in 
migration of Plexin B3 cells treated with different SEMA5A concentration and 
control. The migrated cells were counted in five independent fields (100x), 
using a Nikon Eclipse E800 microscope The values are a mean number of 
migrated cells ± SEM. The significance of the data was determined using 
Kruskal-Wallis test by ranks (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05). (D) 
Representative images of nonscattered and scattered colonies. Images are 
taken at 200x magnification using a Nikon Eclipse TS100 microscope. (E, F) 
Bar graph of scattering potential of Control and Plexin B3 knockdown cells 
towards SEMA5A. The graph shows a higher scattering of colonies in both 
T3M-4 (F), and CD18/HPAF (G) Control cells with SEMA5A treatment in 
comparison with their respective untreated control cells. T3M-4- and 
CD18/HPAF-Plexin B3 knockdown cells showed a significantly lower response 
to SEMA5A-induced scattering of colonies. The percentage of scattered 
colonies were counted in five independent fields (40x), using a Nikon Eclipse 
E800 microscope. The values are a mean number of percentage of scattered 
colonies ± SEM. The significance of the data was determined using Kruskal-
Wallis test by ranks (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05). 
 
118 
 
 
 
  
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.4: SEMA5A activate Met signaling and results in increased 
migration in a Plexin B3 dependent manner. 
(A) Western blot analysis of whole cell lysates of Control and Plexin B3 
knockdown CD18/ HPAF cells. The analysis shows Met activation on treatment 
with SEMA5A in CD18/HPAF control cells. No increase in phospho-Met 
(Tyr1234/1235) levels was observed in CD18/HPAF Plexin B3 knockdown with 
50 ng of SEMA5A  protein. Quantification of the phospho-MET(Tyr1234/1235) 
protein by their intensity of the bands with respect to their loading control 
GAPDH was performed by Image J software. Bands were normalized on the 
T3M-4 Control or shPlexin B3 cells. (B) Western blot analysis showing no 
change in total cellular Met receptor levels with knock down of Plexin B3. 
Quantification of the Met protein by their intensity of the bands with respect to 
their loading control GAPDH was performed by Image J software. Bands were 
normalized on the T3M-4 Control cells. (C) Bar Graph showing inhibition of 
chemotaxis towards SEMA5A of T3M-4 cells with cMET inhibition. Transwell 
migration assay was utilized to evaluate chemotaxis of T3M-4- Control and 
Plexin B3 knockdown cells towards SEMA5A in the presence and absence of 
5 g Met neutralization. Considering the number of migrated T3M-4 cells 
towards SEMA5A as 100%, Met neutralization led to 40% migration of T3M-4-
Control cells towards SEMA5A. Knockdown of Plexin B3 led to a 70% migration 
of T3M-4 towards SEMA5A, and the combined effect of Plexin B3 knockdown 
along with Met neutralization led to 10% of T3M-4 cells migrating towards 
SEMA5A. The values are a mean number of percentage of migration ± SEM. 
The significance of the data was determined using Kruskal-Wallis test by ranks 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, nsp > 0.05. 
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Figure 4.5: Schematic showing forward signaling of SEMA5A. 
The representative schematic shows that SEMA5A as a ligand can act through 
Plexin B3 receptor and activates MET tyrosine kinase receptor to trigger PC 
cellular migration. 
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Chapter 5  
SEMA5A Maintains Epithelial Phenotype in Malignant PC Cells 
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I. Abstract: 
 SEMA5A has been shown to be involved in organ-specific homing during 
PC metastasis. We have also demonstrated that SEMA5A expression was higher 
in well-differentiated tumors in comparison with poorly differentiated and normal 
pancreas. In this report, we hypothesized that SEMA5A expression in malignant 
PC cells regulates phenotypes associated with metastasis. We generated 
SEMA5A knockdown T3M-4- and CD18/HPAF cells and assessed morphology, 
motility, and expression of epithelial and mesenchymal markers. Control and 
shSEMA5A cells were injected into the pancreas of nude mice to study primary 
tumor growth and metastasis. Knockdown of SEMA5A leads to a transition from 
epithelial to a mesenchymal phenotype, downregulation of E-Cad, an increased 
expression of N-cad, and activation of the Wnt-signaling pathway. Moreover, 
orthotopic injection of SEMA5A knockdown cells into nude mice resulted in a 
significant increase in tumor burden and the liver metastases in comparison with 
the Control cells. Furthermore, re-establishing SEMA5A expression with a 
knockdown resistant mouse Sema5A in SEMA5A knockdown cells resulted in a 
reversion to the epithelial state, as indicated by the rescue of E-Cad and N-Cad 
expression. Collectively, our data demonstrate that SEMA5A expression 
modulates cancer cell motility and aggressiveness by maintaining epithelial 
phenotype in PC.  
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II. Introduction: 
 Metastasis is responsible for 90% of cancer-associated deaths (Kitamura 
et al., 2015). PC is the fourth leading cause of cancer-related deaths and is 
projected to be the second leading cause by 2030 (Das and Batra, 2015; Rahib et 
al., 2014). Due to the lack of any reliable early diagnostic markers and a higher 
incidence of metastasis at the time of diagnosis, it has a dismal five-year survival 
rate of only 6% (Das and Batra, 2015; Hingorani et al., 2003; Rahib et al., 2014; 
Siegel et al., 2014). The National Cancer Institute reports nearly equal numbers of 
estimated new cases and expected deaths in the United States from PC every 
year, statistics that have not changed in almost 50 years (Rahib et al., 2014; Siegel 
et al., 2014). Such epidemiological facts highlight the gravity of the situation, 
making it necessary to explore further and understand the molecule(s) and 
mechanisms(s) that lead to metastatic dissemination in PC. 
 A growing body of evidence now supports the role of various axon guidance 
cue molecules, such as the semaphorins, in metastasis (Battistini and Tamagnone, 
2016; Capparuccia and Tamagnone, 2009; Casazza et al., 2007; Kruger et al., 
2005; Muratori and Tamagnone, 2012; Neufeld et al., 2012; Rehman and 
Tamagnone, 2013; Sakurai et al., 2012; Tamagnone and Comoglio, 2004; 
Worzfeld and Offermanns, 2014). Semaphorins represent the largest family of 
axon guidance cue molecule, which helps lay down the precise network of 
neuronal circuits and blood vessels. These molecules play important roles in 
pathological functions such as cellular migration (Casazza et al., 2007; Kruger et 
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al., 2005; Tamagnone and Comoglio, 2004), angiogenesis (Neufeld et al., 2012; 
Sakurai et al., 2012), and organ-specific homing of cancer cells (Sadanandam et 
al., 2007). SEMA5A is a novel member of this family that is unique in having seven 
thrombospondin repeats in its extracellular region, in addition to its characteristic 
‘sema’ domain (Adams et al., 1996). SEMA5A can act as either a repulsive or an 
attractive cue during cellular migration (Kantor et al., 2004). In the past decade, 
SEMA5A has emerged as a promising molecule in cancer biology (Purohit et al., 
2014). Studies on various cancer types have suggested both tumor suppressive 
and oncogenic roles for SEMA5A. 
 We have previously reported that SEMA5A expression was higher in well-
differentiated tumors in comparison with undifferentiated pancreatic tumors and 
normal pancreas (Sadanandam et al., 2010b). Overexpression of SEMA5A in 
Panc1 cells was sufficient to enhance metastasis (Sadanandam et al., 2012; 
Sadanandam et al., 2010b). However, the functional significance of SEMA5A in 
PC cells expressing higher endogenous levels of SEMA5A remained unexplored. 
In the present study, we tested the hypothesis that knockdown of SEMA5A will 
modulate phenotypes associated with tumor growth and metastasis in PC. To test 
this hypothesis, we performed in vitro and in vivo assays to understand the effect 
of SEMA5A deletion on PC metastasis. In contrary to our expectation, loss of 
SEMA5A promoted tumorigenesis and enhanced metastatic potential of the PC 
cell by regulating EMT. 
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III. Results: 
SEMA5A Knockdown Induces Mesenchymal Phenotype: 
 To understand the role of SEMA5A in PC, we knocked down SEMA5A 
expression in T3M-4 and CD18/HPAF cells with short hairpin (sh)RNA-mediated 
gene silencing. Liver metastasis-derived T3M-4 cells exhibit high SEMA5A 
expression (Sadanandam et al., 2010b). Cells treated with shRNA of SEMA5A 
(T3M-4-shSEMA5A) showed significant reduction of SEMA5A expression in 
comparison with the non-targeting shRNA-treated T3M-4 control cells (Control) at 
both the RNA, shown by RT-PCR (Fig. 5.1A), and the protein levels, as shown by 
western blot analysis (Fig. 5.1B). Another evidence for the SEMA5A knockdown 
came from immunofluorescence staining, which shows less SEMA5A staining at 
the membrane in the T3M-4-shSEMA5A cells in comparison with the Control (Fig. 
5.1C).  
 We observed a marked difference in morphology between SEMA5A 
knockdown and vector control cells. Though heterogeneous, the T3M-4 and 
CD18/HPAF Vector control cells demonstrated epithelial morphology with a 
cobblestone-like appearance and closely apposed cell-cell junctions when plated 
on plastic (Fig. 5.1D, 5.1E). In contrast, T3M-4-shSEMA5A and CD18/HPAF-
shSEMA5A cells had a mesenchymal morphology with spindle-like fibroblastoid 
cells (Fig. 5.1D, 5.1E).  
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Loss of SEMA5A Enhances Migration Ability: 
  The gain of mesenchymal phenotype leads to enhanced migration and 
invasion ability of cells (Polyak and Weinberg, 2009; Thiery, 2002). We evaluated 
motility of the vector controls and SEMA5A knockdown cells by scratch-wound 
assay (Fig. 5.2A). We observed that SEMA5A knockdown cells had increased 
motility in comparison with the Control in T3M-4 (p = 0.004), (Fig. 5.2B), and 
CD18/HPAF cells (p = 0.001), (Fig. 5.2C). We also quantified lamellipodia and 
filopodia-like protrusions in the Control and SEMA5A knockdown cells (Fig. 5.2D). 
We found a significantly higher number of lamellipodia (p = 0.0079), (Fig. 5.2E) 
and an increase in the number of filopodia in T3M-4-shSEMA5A cells (Fig. 5.2F). 
The above data showing differences in morphology and motility ability of Controls 
and T3M-4-shSEMA5A, CD18/HPAF-shSEMA5A cells suggest that loss of 
SEMA5A in PC cells leads to loss of epithelial phenotype and a gain of 
mesenchymal characteristics.  
Loss of SEMA5A Induces EMT Markers and Activation of Wnt Signaling:  
 To characterize the observed morphological changes associated with the 
knockdown of SEMA5A at the molecular level, we first evaluated the expression 
of E-cad, a marker for epithelial characteristics. We performed Western blot 
analysis and immunofluorescence to study the amount of E-cad expression and 
its cellular localization respectively. Western blot analysis revealed decreased E-
Cad expression in SEMA5A knockdown cells, in comparison with the Control cells 
(Fig. 5.3A). Immunofluorescence analysis showed similar results with prominent 
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plasma membrane staining of E-Cad in control cells, on the other hand, there was 
less staining found for E-cad in T3M-4-shSEMA5A cells (Fig 5.3B). 
 Second, we went ahead to evaluate the expression of mesenchymal 
markers in our Control and SEMA5A knockdown cells. We started with N-cad and 
observed increased N-cad expression in the T3M-4-shSEMA5A cells by 
immunofluorescence (Fig. 5.3C) as well as Western blot analysis (Fig. 5.3D) in 
comparison with the Control cells. We observed more plasma membrane as well 
as cytosolic staining for N-cad in the knockdown cells. Next, we evaluated the 
mRNA expression levels of transcription factors Snail and Twist, which are known 
suppressors of epithelial phenotype (Rosivatz et al., 2002). We observed that T3M-
4-shSEMA5A cells demonstrate higher levels of transcripts of SNAIL (p = 0.035) 
(Fig. 5.3E) and TWIST (p = 0.034), (Fig. 5.3F) compared with the Control cells. 
Furthermore, we observed a similar increase for the Snail (Fig. 5.3G) and Twist 
(Fig. 5.3H) protein expression in the whole cell lysates of T3M-4-Control/-
shSEMA5A cells.  
 Using immunofluorescence, we observed increased intensity and a shift of 
β-catenin localization from the plasma membrane to the cytoplasm (Fig. 5.4A) as 
well as increased stabilization of β-catenin by Western blot (Fig. 5.4B) upon 
SEMA5A knockdown. Furthermore, to confirm the presence of -catenin in the 
nucleus, we went ahead and performed TOP-FLASH Wnt reporter assay. We 
observed a significant increase in Wnt activity (p < 0.05) in T3M-4-shSEMA5A cells 
in comparison with Control cells (Fig. 5.4C). Collectively, these data indicate that 
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epithelial PC cells expressing SEMA5A undergo EMT upon SEMA5A depletion 
and this transition to the mesenchymal state results in activation of the Wnt 
signaling pathway.  
SEMA5A Knockdown Enhances Metastasis and Invasion: 
 In previous studies from our laboratory, we observed that ectopic over-
expression of SEMA5A in poorly differentiated cells (with low expression of 
SEMA5A) enhanced their metastatic potential upon orthotopic injection 
(Sadanandam et al., 2010b). Thus, it was our expectation that SEMA5A 
knockdown (in cells that endogenously express SEMA5A) would reduce their 
tumorigenic and metastatic potential. However, given our in vitro observation that 
SEMA5A knockdown promotes EMT, mesenchymal tumor cells are known to be 
more mobile and hence more metastatic (Mani et al., 2008), thereby may promote 
metastasis. To address in which direction this balance will tip, we injected SEMA5A 
knockdown and Control T3M-4 cells (105) subcutaneously into the neck and flank 
regions of athymic nude, female mice (n = 6). Tumor growth was monitored twice 
weekly for three weeks. To our surprise, we did not observe a difference in tumor 
incidence (Fig. 5.5A), growth (Fig. 5.5B) or morphology (Fig. 5.5C) between 
SEMA5A knockdown and Control cells. 
 Furthermore, we injected 1X105 T3M-4-shSEMA5A or Control cells 
orthotopically into athymic nude, female mice. Twenty-one days later, we sacrificed 
the mice and examined for tumor growth and metastasis. We observed a 
statistically significant difference in both organism weight (p = 0.034), (Fig. 5.5D) 
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and tumor weight (p = 0.00159) (Fig. 5.5E) between T3M-4-shSEMA5A and 
Control cells. Also, there was also a statistically significant difference in the number 
and location of liver micrometastases (p = 0.0079), (Fig. 5.5F). Specifically, 
SEMA5A knockdown cells metastasized to the liver and peritoneum with high 
incidence (Fig. 5.G). It is important to understand that differences in metastasis 
could also be a result of higher tumor burden in mice injected with T3M-4-
shSEMA5A cells. Before investigating further, we confirmed the maintenance of 
SEMA5A knockdown in the tumors by performing immuno-histochemical staining 
of SEMA5A in tumor sections (Fig. 5.5H). 
 Lastly, we investigated whether the difference in primary tumor burden is 
due to proliferation differences between Control and SEMA5A knockdown cells. 
Both the intensity of PCNA staining and the fraction of tumor cells positive for 
PCNA were significantly higher in tumors in mice injected with T3M-4-sh-SEMA5A 
cells than injected Control cells (Fig. 5.5F, 5.5G). H&E staining showed higher 
cellular density in tumors of mice injected with SEMA5A knockdown cells than 
Control cells (Fig. 5.5H). These data demonstrate that SEMA5A knockdown in 
T3M-4 cells promotes tumorigenesis and metastatic potential in the pancreatic 
microenvironment. 
Knock-in of shRNA-Resistant SEMA5A Rescues Epithelial Phenotype:  
 To characterize the specificity of SEMA5A-induced mesenchymal 
characteristics, we performed experiments to re-establish SEMA5A expression in 
T3M-4-shSEMA5A cells and observed a reversal of the gain of mesenchymal 
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characteristics. Hence, we transiently over-expressed knockdown resistant either 
full-length murine Sema5A construct in T3M-4-shSEMA5A cells. Convincingly, 
SEMA5A over-expression (Fig. 5.6A) reversed the morphological changes 
observed upon knockdown of SEMA5A in T3M-4- cells (Fig. 5.6B). Furthermore, 
the decrease in E-Cad expression was rescued (Fig. 5.6C) with the re-
establishment of SEMA5A. Similarly the increase in expression of N-Cad (Fig. 
5.6D) and enhanced stability of -catenin (Fig. 5.6E) seen in T3M-4-shSEMA5A 
cells was lowered upon re-establishment of SEMA5A.  
IV. Discussions: 
  In this study, we examined whether SEMA5A knockdown in PC cell lines 
modulates tumor progression and metastasis. Unexpectedly, we observed 
pronounced morphological changes associated with EMT upon SEMA5A 
knockdown. Orthotopic pancreatic injection of SEMA5A knockdown cells resulted 
in a significant increase in tumor weight and the number of distant metastases as 
compared to Control cells. Furthermore, re-establishing SEMA5A expression in 
SEMA5A knockdown cells resulted in a reversion of the mesenchymal to the 
epithelial state (MET), suggesting a novel role for SEMA5A in the establishment 
and maintenance of PC cells in the metastatic microenvironment through 
maintenance of epithelial phenotype.  
 Metastatic progression requires a loss of contact with neighboring cells and 
the gain of both extracellular matrix invasion and migration properties; this process 
of morphogenetic reprogramming is termed "epithelial-mesenchymal transition" or 
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EMT (Zavadil et al., 2008). EMT begins with the loss of the epithelial-like 
characteristics, including loss of cell adherent junctional complexes, particularly 
the adherent junction protein E-cad, epithelial intermediate filament cytokeratin as 
well as cell polarization (Das and Batra, 2015; Yilmaz and Christofori, 2009; 
Zavadil et al., 2008). These changes follow the acquisition of mesenchymal-like 
characteristics, including a gain of the adherent junction protein N-cad, the 
cytoskeletal element vimentin, and upregulation of transcriptional factors such as 
zinc finger E-box binding homeobox 1, SNAlL, SLUG and TWIST (Rosivatz et al., 
2002; Zavadil et al., 2008). The increase in migration ability is also associated with 
changes in polarized assembly of the actin cytoskeleton resulting in the formation 
of protrusive and invasive structures (lamellipodia and filopodia) that help the cell 
to navigate through the extracellular matrix (ECM) and through/into the vasculature 
(Yilmaz and Christofori, 2009). Metastasis initiates when less aggressive epithelial 
tumor cells within the primary organ acquire invasive and migratory abilities by 
transitioning into mesenchymal cells (Chaffer et al., 2006; Polyak and Weinberg, 
2009; Thiery, 2002). In doing so, such cells acquire the ability to pass into the 
circulation and reach secondary organs. When tumor cells of mesenchymal 
morphology reach a secondary site, they can revert to an epithelial state through 
the reverse process of mesenchymal-epithelial transition (MET). Though the 
classical view of metastasis was a late event during the progression of the disease, 
recent studies with the use of mathematical modeling and genetically labeled 
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mouse models of PC suggest early dissemination of cancer cells before the 
formation of a primary tumor, as reviewed by Das and Batra (Das and Batra, 2015).  
 An important evidence for the role of SEMA5A in PC came from our 
previous report demonstrating differential expression of SEMA5A in normal 
tissues, well-differentiated tumors, and poorly differentiated tumors. Moreover, 
exogenous expression of SEMA5A in the Panc1 cell line resulted in enhanced 
migratory potential and metastasis of these cells without showing a significant 
increase in the process of tumorigenesis, suggesting a tumor-promoting role of 
SEMA5A in PC.  Likewise, a study of samples from gastric carcinoma patients 
illustrated elated expression levels of both SEMA5A and its receptor plexin-B3 in 
primary gastric carcinoma and lymph node metastasis in comparison to the non-
neoplastic tissue (Pan et al., 2009). 
 Surprisingly, our present observations are in contrast to our previously 
reported data, since we observed increased in vitro motility, enhanced tumorigenic 
and metastatic potential of T3M-4-shSEMA5A cells when implanted orthotopically 
in nude mice in comparison with the Control cells. Furthermore, we observed a 
marked difference in morphology between SEMA5A knock-down cells as 
compared to their Control cells. Also, numerous studies have demonstrated that 
E-Cad forms a complex at the plasma membrane with β-caten,in which is important 
for maintaining the normal phenotype of epithelial cells (Fodde and Brabletz, 2007; 
Heuberger and Birchmeier, 2010; Moon et al., 2004). Upon loss of E-Cad 
expression, β-catenin translocates from the plasma membrane to the cytoplasm 
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where it can either be phosphorylated by GSK-3β, and ultimately degraded, or 
translocated into the nucleus. The relocalization of plasma membrane-bound β-
catenin into the nucleus is both an indicator that epithelial cells are transitioning to 
the mesenchymal state and a central component in Wnt-responsive gene 
activation (Moon et al., 2004). These changes in morphology suggested the 
induction of mesenchymal phenotype in T3M-4-shSEMA5A cells. Furthermore, in 
vitro and in vivo behavior of T3M-4-shSEMA5A cells were in accordance, as 
mesenchymal cells are known to demonstrate an enhanced potential for migration 
and results in the formation of aggressive tumors. Other semaphorins, like 
Semaphorin 7A in breast cancer cells (Allegra et al., 2012) and Semaphorin 3E 
through the PlexinD1 axis (Tseng et al., 2011) in ovarian cancer cells are known 
to mediate EMT. Li et al. have published similar findings on SEMA5A in 
glioblastoma demonstrating, that the treatment of glioblastoma cell lines with 
SEMA5A impaired cellular motility and promoted differentiation (Li et al., 2012b; Li 
and Lee, 2010). 
 Our result suggests a functional role for SEMA5A in early dissemination of 
cancer cells as well as the late stage dissemination of metastasis. Ectopic 
expression in the poorly differentiated PC cell lines promotes migration and 
metastasis without affecting the primary tumor burden, indicating parallel migration 
of cancer cells at the distant site along with primary tumor formation. However, 
loss of SEMA5A progresses a well-differentiated cancer cell to a poorly 
differentiated state, representing metastasis as a consequence of the late stage of 
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tumor progression (Fig. 5.7). Another possible explanation for the discrepancy that 
both gains of SEMA5A in primary tumor cells or loss of SEMA5A in metastatic PC 
cells result in higher metastasis may come from the involvement of two different 
pathways. To describe, in short, Type 1 TSP repeats, a unique structural feature 
of class 5 semaphorins, is known to activate the latent form of TGFβ, known player 
of EMT induction. A Drosophila homolog of SEMA5A has been shown to increase 
metastasis by activating the Dpp (TGFβ-like) pathway (Woodhouse et al., 2003), 
suggesting increased SEMA5A will induce EMT. On the other hand in 
glioblastoma, loss of SEMA5A leads to Rac1 activation results in increased 
invasiveness, indicating that SEMA5A suppresses motility of cell (Li et al., 2012b; 
Li and Lee, 2010).  Thus, to completely understand the complex role of functional 
SEMA5A in PC and metastasis, further experimentation and better model systems 
are needed. Together with our previous data, these results suggest a context-
specific bi-functional role for SEMA5A: ectopic expression in the primary tumor 
setting promotes cancer cell proliferation, migration, and metastasis, whereas 
subsequent repression and re-expression in metastatic setting facilitates EMT and 
MET, respectively, thereby endowing cancer cells with metastatic capacity. 
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Figure 5.1: Confirmation of SEMA5A knockdown in PC cells and resulting 
mesenchymal morphology. 
(A) Bar graph showing fold change decrease in mRNA expression of SEMA5A. 
HPRT is used as a control by RT-PCR analysis. The values are mean fold 
changes ± SEM (bars) change calculated using T3M-4 transfected with a 
pSUPER vector as a control. (B) Western blot analysis of cell lysates of Control 
and T3M-4-shSEMA5A cells confirming decreased SEMA5A protein 
expression with β-actin as a loading control. Quantification of the protein of 
interest by the intensity of the bands with respect to their loading control was 
performed by Image J software. Bands were normalized on the T3M-4-Control 
cells. (C) Immunofluorescence of SEMA5A shows less staining of SEMA5A 
(red) at the plasma membrane in T3M-4-shSEMA5A cells. Nucleus (blue) is 
stained with DAPI and images were taken at 1000x magnification using a Nikon 
Eclipse E800 microscope. (D, E) Morphological changes upon SEMA5A 
knockdown. Cobblestone-like T3M-4-Control cells change to spindle shapes in 
T3M-4-shSEMA5A cells. Images were taken at 200x magnification. 
CD18/HPAF-Control cells change to spindle shapes in CD18/HPAF-
shSEMA5A cells. Images were taken at 100x magnification using a Nikon 
Eclipse TS100 microscope. 
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Figure 5.2: Loss of SEMA5A increases migration ability in PC cells. 
(A) Images showing scratch assay of Control and T3M-4-shSEMA5A at 0 hours 
and 24 hours (100x magnification). (B) Quantitation of scratch assay using 
ImageJ software showing a significant (p = 0.004) enhancement of migration in 
T3M-4 SEMA5A knock-down cells. (C) Quantitation of scratch assay showing 
a significant (p = 0.001) enhancement of migration in CD18/HPAF-1 SEMA5A 
knock-down cells. The bars in the graphs represent mean percentage of the 
distance of migration  SEM and the significance of the data is calculated using 
using Student’s t-test. (D) Image showing staining of the actin cytoskeleton in 
T3M-4-Control and T3M-4-shSEMA5A cells with increased number of 
lamellipodium- and filopodium- like structures in SEMA5A knockdown cells. 
Images were taken at 630× magnification using a LSM 710 Zeiss Confocal 
Microscope. (E) Bar graph representing quantitation of lamellipodia in control 
and knockdown cells showing an increase in the number of lamellipodia formed 
(p = 0.0079) in knock-down cells. (F) Bar graph depicting quantitation of 
filopodia, showing an increase in the number of filopodia in knock-down cells. 
Five independent fields were used for quantification. The values in the graph 
represent a number of Lamellipodia formation/ or filopodia per cell and the error 
bars  SEM. The significance of the data is calculated using non-parametric 
Mann-Whitney U test. 
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Figure 5.3: Loss of SEMA5A induces EMT in PC cells. 
(A) Immunofluorescence analysis shows lower E-cadherin expression on the 
plasma membrane in T3M-4-shSEMA5A cells in comparison with Control cells. 
Images were taken at 630× magnification using a LSM 710 Zeiss Confocal 
Microscope. (B) Western blot analysis of whole cell lysates of T3M-4 Control 
and SEMA5A knockdown cells shows a decrease in E-cadherin protein levels 
with β-actin as a loading control in T3M-4-shSEMA5A in comparison with the 
Control cells. (C) IF analysis of T3M-4 Control and SEMA5A knockdown cells 
shows an increase in N-cadherin expression on the plasma membrane as well 
as cytoplasm in T3M-4-shSEMA5A cells. Images were taken at 630× 
magnification using a LSM 710 Zeiss Confocal Microscope (D) Western blot 
analysis showing an increase in N-cadherin protein levels with -actin as a 
loading control in T3M-4-shSEMA5A. E-cadherin and N-cadherin are stained 
in red, and the nucleus is stained with DAPI (blue). (E, F) Bar graph showing 
an increase in fold expression of transcription factors-SNAIL (p = 0.035) and -
TWIST (p = 0.036) in T3M-4-shSEMA5A in comparison with Control cells 
evaluated using RT-PCR. The Ct values in RT-PCR were normalized to HPRT. 
Values are mean Fold changes ± SEM (bars) of two experiments.  (G, H) 
Western blot analysis showing a similar increase in Snail and Twist protein 
level. -Actin was used as loading control.  The intensity of the bands in 
Western blot analysis was quantified by Image J and was normalized with 
respect to the T3M-4 Control cells.  
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Figure 5.4: SEMA5A knockdown activates Wnt signaling in PC cells. 
(A) Images showing immunofluorescence analysis of β-catenin localization in 
Control and T3M-4-shSEMA5A cells. Images are taken at 200× magnification 
using a Nikon Eclipse E800 fluorescent microscope. β-catenin staining is 
depicted in red, and the nucleus is stained with DAPI in blue. (B) Western blot 
analysis showing an increase in β-catenin protein levels in T3M-4-shSEMA5A 
compared with Control cells.-actin is used as a loading control. The intensity 
of the bands in Western blot analysis was quantified by Image J software and 
was normalized with respect to the Control cells. (C) Bar graph showing an 
increase in Wnt activity T3M-4-shSEMA5A than Control cells. TOP-FLASH was 
utilized, and this assay was normalized to both FOP and Renilla vector 
illustrating increased Wnt activity upon SEMA5A knockdown. The bars in the 
graphs represent fold changes  SEM. *p < 0.05 using Student’s t-test. 
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Figure 5.5: SEMA5A knockdown enhances tumor size and metastatic 
potential. 
(A) Incidence of the tumor, (B) presentation (as measured by H&E staining; 
200× magnification; Nikon Eclipse E800 microscope) and (C) growth kinetics 
of Control and T3M-4-shSEMA5A cells injected subcutaneously into nude mice. 
Tumor volume was determined twice a week for three weeks. (D, E, F) Graph 
showing increase in the average weight of the mice (p = 0.034), (D)  the primary 
tumor (p = 0.0159) (E) and number of liver metastases (p = 0.0079). (F) in mice 
orthotopically injected with T3M-4 shSEMA5A cells in comparison with mice 
injected with T3M-4-Control cells. (G) The chart shows the incidence of tumor 
formation and metastasis. (H) SEMA5A expression (as measured by IHC 
staining using 200× magnificationon a Nikon Eclipse E800 microscope) of 
orthotopic pancreatic tumors from T3M-4 shSEMA5A and Control cells. (I) The 
relative proliferation of tumor cells stained with PCNA (p = 0.023) in athymic 
mice orthotopically injected with T3M-4-shSEMA5A cells in comparison with 
those injected with Control cells. The error bars in the graphs presented in this 
section represent  SEM. *p < 0.05 using Student’s t-test. (J) Representative 
images showing PCNA staining of tumor cells in athymic mice orthotopically 
injected with T3M-4-shSEMA5A cells in comparison with those injected with 
Control cells. Images are taken at 200× magnification using a Nikon Eclipse 
E800 microscope. 
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Figure 5.6: Overexpression of shRNA-resistant SEMA5A rescues 
epithelial phenotype. 
 (A) Western blot analysis showing SEMA5A in T3M-4-shSEMA5A and T3M-4-
shSEMA5A transfected with full-length mouse SEMA5A. GAPDH was used as 
loading control. (B) Morphology of T3M-4-shSEMA5A and T3M-4-shSEMA5A 
transfected with full-length mouse SEMA5A. Images are taken on 100x 
magnification using Nikon Eclipse TS100 microscope. (C) E-Cadherin, N-
cadherin and (D) -catenin protein expression with respect to loading control. 
GAPDH was used as a loading control for -catenin, similarly -actin was used 
as a loading control for E-cadherin and N-cadherin in T3M-4-shSEMA5A cells 
and T3M-4-shSEMA5A cells transfected with full-length mouse SEMA5A.  The 
intensity of the bands in Western blot analysis was quantified using Image J 
software and was normalized with respect to the T3M-4-shSEMA5A cells.  
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Figure 5.7: The suggestive dual role of SEMA5A in PC. 
 This schematic representation depicts the potential role and expression of 
SEMA5A in PC under the following conditions: (A) Pancreas and Liver under 
normal homeostasis condition: no or low SEMA5A expression in Pancreas. (B) 
Early stages of PC: a higher expression of SEMA5A in comparison with the 
normal. Previous reports (Sadanandam et al., 2010a; Sadanandam et al., 
2012) suggest that ectopic expression of SEMA5A facilitates early 
dissemination of PC cells, thereby establishing metastasis with no significant 
difference in tumor burden between the Control and SEMA5A overexpressing 
cells. The increase in angiogenesis can be attributed as one of the reasons for 
the enhanced metastasis. (C) Late stages of PC: a decrease of SEMA5A 
expression in comparison with early stages but the higher SEMA5A expression 
in comparison with the normal. In the current chapter, knockdown of SEMA5A 
expression leads to EMT, as which results in the formation of aggressive tumors 
with higher tumor burden thereby resulting in higher metastasis. 
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Chapter 6  
SEMA5A preserves epithelial phenotype in PC cells by regulating cross-
talk between Wnt and TGF signaling 
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I. Abstract: 
In the previous chapter of this dissertation, we observed that with the loss 
of SEMA5A expression, cells exhibited a transition from an epithelial to 
mesenchymal phenotype with a concomitant increase in cellular motility. 
Furthermore, we observed a decrease in E-cad expression, nuclear translocation 
of -catenin, and higher WNT activity. The aim of this section is to delineate the 
mechanism associated with loss of SEMA5A-induced EMT. A Thrombospondin 
repeat domain that is known to bind latent TGFmolecules is the characteristic 
feature of a SEMA5A molecule. With this rationale, we first went ahead to evaluate 
the changes in secretion of TGF2 ligands, since TGF is also one of the major 
drivers of the process of EMT. We observed that loss of SEMA5A increased 
TGF2 production. Higher Wnt signaling along with increased TGF2 production 
delineates the loss of differentiation and epithelial markers. Moreover, we 
observed that non-canonical TGF2/ PI3K/AKT-mediated inhibition of Glycogen 
Synthase Kinase-3β (GSK3- is responsible for increased stability of-catenin 
and SNAIL, thereby activating Wnt signaling in SEMA5A knockdown cells. Our 
observations demonstrate that SEMA5A might have a potential role in maintaining 
epithelial phenotype in PC cells by keeping cross-talk between Wnt and TGF 
signaling under check. 
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II. Introduction: 
 A plethora of current literature now extends our understanding of the 
functions of semaphorins far beyond their initial characterisation as axon guidance 
cues, such as in vascular and cardiac development, the immune system, cancer 
progression, and in the pathology of various diseases and injury states 
(Capparuccia and Tamagnone, 2009; Gu and Giraudo, 2013; Kolodkin et al., 1993; 
Muratori and Tamagnone, 2012). Both during development as well as pathological 
processes, Semaphorins and their receptors are well-recognized and major 
regulators of cellular morphology and migration (Casazza et al., 2007; Tamagnone 
and Comoglio, 2000; Tran et al., 2007). Despite the growing wealth of information 
regarding varying biological functions of Semaphorins, many aspects of the 
regulation of these functions remain unknown.  
 Semaphorin-induced cellular responses are variable, involving a complex 
signaling network mediated through a multitude of possible receptors and signaling 
molecules (Jackson and Eickholt, 2009; Zhou et al., 2008). The diverse range of 
outcomes generated though semaphorin ligand and receptor complexes are often 
cell type-dependent. Even within a given cell type, diverse outcomes are possible 
in response to a particular semaphorin signal. The most important receptors for 
semaphorins are members of the plexin family. The reverse signaling or 
participation of semaphorin as a receptor in certain specific settings is also coming 
into the light. Furthermore, current investigations also suggest that a cellular 
response to semaphorin depends on the extracellular matrix composition in which 
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production and presentation of semaphorins are occurring (Jackson and Eickholt, 
2009; Kantor et al., 2004). Till date, our current understanding of semaphorin 
signaling is largely dependent on studying several common molecular features of 
semaphorin family through which this family mediates their responses.  
 Since Semaphorin-induced cellular responses are variable and work in a 
context-dependent fashion, they have pleiotropic roles in cancer and can either 
promote or inhibit tumor progression. Recent studies investigating different 
semaphorin-initiated intracellular molecular mechanisms suggest crosstalk among 
multiple signaling pathways including small GTPases, integrin, Mitogen-Activated 
Protein Kinase (MAPK) and PI3K/AKT/GSK-3β axes (Kruger et al., 2005; Tran et 
al., 2007; Zhou et al., 2008). All of the signaling axes mentioned above can lead 
to rearrangements in cytoskeleton affecting cellular motility and migration.  
 In this part of the study, we wanted to delineate the molecular signaling 
behind the loss of SEMA5A-induced mesenchymal phenotype and resulting 
increase in motility. Our results demonstrate that SEMA5A might have a potential 
role in keeping cross-talk between Wnt and TGF signaling under check for 
maintaining an epithelial phenotype in the PC cancer cell. 
III. Results: 
Knock down of SEMA5A Upregulates TGF2 Liigands: 
 SEMA5A is a member of the Thrombospondin Repeat Superfamily (Fig. 
6.1A) and can bind to TGF through “GGWPTW” motif but lacks the “KRFK” motif 
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known to activate TGF(Fig. 6.1B)The “GGWPTW” motif is present in the 
thrombospondin domain of SEMA5A-(Fig. 6.1C). With this rationale, we 
evaluated the protein levels of the TGFβ2 ligands by using ELISA. The T3M-4-
shSEMA5A cells showed a marked increase in the expression of the TGFβ2 ligand 
(Fig. 6.2A). Next, we evaluated nuclear localization of proteins homologous to 
Drosophila protein, mothers against decapentaplegic (MAD) and the 
Caenorhabditis elegans protein SMA (derived from gene sma for small body size) 
known as SMAD (SMA+MAD) in humans. Immunofluorescence was used for 
nuclear localization of pSMAD2 levels. Our results demonstrate that the T3M-4-
shSEMA5A cells show no change in the percentage of cells having nuclear 
localization of SMAD2 (Fig. 6.2B). Furthermore, Western blot analysis 
demonstrated no change in p-SMAD2 and p-SMAD3 levels in the T3M-4-
shSEMA5A cell line (Fig. 6.2C).  
Loss of SEMA5A Activates PI3K/Akt Signaling Pathway: 
 We next examined the activation of PI3K/Akt signaling pathway as a 
possible mechanism of mesenchymal transition induced by knockdown of 
SEMA5A. We observed no changes in the protein levels of PI3-K and Akt levels 
between the Control and SEMA5A knockdown cells. However, p-PI3-K(Tyr458) 
and p-AKT (Ser473) levels in SEMA5A knock down cells were found to be higher 
than their respective control. We also went ahead to evaluate the levels of total 
and p-GSK-3β (Ser9) in SEMA5A knockdown and the Control cells and observed 
higher p-GSK-3in the SEMA5A knockdown cells (Fig. 6.3).
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IV. Discussions: 
 We observed that loss of SEMA5A leads to a marked difference in 
morphology between SEMA5A knockdown cells and the respective Control cells, 
demonstrating a transformation from epithelial to mesenchymal morphology with 
increased cellular migration and resulting metastasis. For evaluation whether there 
is an association between this transformation and EMT, we went ahead to analyze 
EMT markers. We observed downregulation of epithelial marker E-cad that is a 
key event in the induction of EMT. We also found upregulation of expression levels 
of mesenchymal marker N-cad and transcription factor Snail, a known suppressor 
of the epithelial phenotype. We also observed a shift in β-catenin localization from 
the plasma membrane to the nucleus and higher expression of the β-catenin 
protein resulting from SEMA5A knockdown by Western blotting, suggesting its 
decreased degradation. Increased β-catenin in the nucleus can lead to the 
activation of Wnt signaling pathway. By performing TOP-FLASH Wnt reporter 
assay, we found the activation of Wnt signaling in our SEMA5A knockdown cells.  
Thus, this chapter of the dissertation delineates our findings on the mechanism 
associated with loss of SEMA5A-induced EMT. 
 Towards this aim, we first examined the role of TGF, one of the major 
regulators of EMT (Katsuno et al., 2013; Wendt et al., 2009; Xu et al., 2009). For 
instance, TGFβ strongly inhibits the growth of epithelial cells and hence is a potent 
anti-tumor agent. However, TGFβ can also induce changes in transcriptional 
activities (Derynck and Akhurst, 2007) and re-program epithelial cells into 
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mesenchymal cells, leading to tumor metastasis and invasion. TGF, apart from 
being major EMT regulator, also binds to thrombospondin repeat; a unique domain 
of SEMA5A molecule (Adams and Tucker, 2000; Hayashi and Sakai, 2012; 
Tucker, 2004; Woodhouse et al., 2003). The SEMA5A amino acid sequence 
contains “GGWPTW”, the potential peptide through which SEMA5A can bind latent 
TGF molecule. However, SEMA5A amino acid sequence lacks KRFK the peptide 
known to activate TGF which implies that SEMA5A can bind to TGF molecule 
but cannot activate it. We observed that loss of SEMA5A increased TGF2 
production. Furthermore, to investigate the downstream pathways, the next 
rational step was to study the SMAD pathway as through genetic studies in 
Caenorhabditis elegans, and Drosophila revealed that Smads, are crucial players 
in mediating the intracellular responses to TGFβ and its related factors (Derynck 
and Zhang, 1996). Smads are transcription factors that constantly shuttle between 
the cytoplasm and the nucleus. TGFβ receptors activation leads to 
phosphorylation of Smads that further get accumulated in the nucleus to regulate 
target gene transcription. However, we observed no differences in nuclear 
localization of p-Smad2 nor did the total cellular levels of p-Smad2 and p-Smad3 
change.  
 Apart from Smad signaling, there is emerging evidence that suggests the 
ability of TGFβ receptors to activate non-Smad pathways through either 
phosphorylation or direct interaction. These non-Smad pathways include various 
branches of Rho-like GTPase signaling, MAPK, and PI3K/ AKT pathways (Zhang, 
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2009). Before going ahead to decide with which non-Smad signaling we should 
start our exploration, we went back and re-analyzed our results described in the 
last chapter. We observed stabilization of -catenin and Snail protein in our 
knockdown cells. In the cytoplasm, phosphorylation of β-catenin and Snail occurs 
by GSK-3β, which target these molecules for degradation (Patel and Woodgett, 
2008; Sutherland, 2011). Thus, one possible mechanism in our SEMA5A 
knockdown cells could be inhibition of GSK-3β,  leading to stabilization of β-catenin 
and Snail protein. With this rationale, we evaluated the inhibitory phosphorylation 
of GSK-3β at Ser9, and observed increased phosphorylation of  GSK-3β at Ser9 
in SEMA5A knockdown cells in comparison with the Control cells with no changes 
in the total protein level of GSK-3β. 
 Out of non-Smad pathways discussed at the beginning of this discussion, 
PI3K/AKT signaling is known to mediate inhibitory phosphorylation on GSK-3β 
(Cross et al., 1995). With this knowledge, we made the choice of exploring the 
PI3K/AKT pathway first and observed increased phosphorylation of AKT at Ser473 
and PI3K at Ser458, indicating activation of these proteins in SEMA5A knockdown 
cells in comparison with the Control cells. There were no significant differences in 
the total protein levels of PI3K and AKT proteins in the Control and knockdown 
cells.  
 Our obtained results suggest one possible mechanism associated with the 
loss of SEMA5A-induced EMT that is through a noncanonical TGF pathway 
mediated EMT. According to this mechanism, the thrombospondin repeat domain 
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of SEMA5A molecule keeps latent activation of TGF2under inhibition. With the 
loss of SEMA5A, TGF2 gets secreted and activates noncanonical PI3K/AKT 
pathway. The activation of the PI3K/AKT pathway leads to inhibition of GSK-3β, 
which in turn results in stabilization of β-catenin and Snail protein. Stabilization of 
β-catenin leads to active translocation of β-catenin from the cytoplasm into the 
nucleus, furthermore leading to activation of WNT signaling. On the other hand, 
stabilization of Snail protein leads to the repression of mRNA transcription of E-
cad. This repression of E-cad mRNA transcription leads to a decrease in the E-
cad protein levels as well leading to induction of EMT (Fig. 6.4). However, our 
suggested mechanism needs further validation by utilizing neutralization antibody 
against TGF2 and inhibitors against PI3K and AKT.  
 Finally, our data demonstrate that loss of SEMA5A initiates crosstalk 
between TGF and WNT signaling. These observations also demonstrate the link 
between SEMA5A and both TGF and WNT pathways that cooperate towards 
epithelial de-differentiation leading to EMT. Our data leads to better understanding 
of the Semaphorin-mediated signaling pathway that leads to different in vitro 
processes like migration, dispersion, invasion and in vivo progression of 
metastasis. 
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Figure 6.1: SEMA5A is a member of the Thrombospondin Repeat 1 
Superfamily and has motif “GGWPTW” known to bind TGF but does not 
have “KRFK” motif known to activate TGF
 (A) Domain structure of representative members of the Thrombospondin 
Repeat 1 Superfamily. SEMA5A is a member of this Superfamily. Represented 
in yellow diamonds, are Thrombospondin Repeats. (B) Different peptide 
signatures through which Type 1 (represented in yellow), Type 2 (represented 
in oval green) and Type 3 (represented in blue striped box) Thrombospondin 
repeats bind to different molecules like Heparan sulfate proteoglycans (HSPG), 
TGF and, CD36 and many other molecules through the extracellular region.   
(C) Represented amino acid sequence is of human SEMA5A. Highlighted 
amino acid sequence in blue represents the sequence of thrombospondin 
domain-containing seven Type 1 repeats. The amino acid sequence 
“GGWPTW” shown in red represents the potential peptide through which 
SEMA5A binds latent TGF molecule. However, SEMA5A does not contain the 
KRFK peptide known to activate TGF molecule that implies that SEMA5A can 
bind to TGF- molecule but cannot activate it.  
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Figure 6.2: Loss of SEMA5A activates TGF  
(A) Bar graph showing higher TGF2 secretions in T3M-4 SEMA5A knockdown 
cells in comparison with T3M-4-Control cells, evaluated using ELISA for TGF2. 
(B) Immunofluorescence showing no differences in pSMAD2 nucleus 
localization in T3M-4 Control and shSEMA5A knockdown cells. Phospho 
SMAD2 (Ser465/467) is depicted in red and nuclei are depicted in blue. Images 
were taken at 200x magnification using a Nikon Eclipse E800 Microscope.(C) 
Western blots show no changes in levels of p-SMAD2(Ser465/467) and p-
SMAD3(Ser423/425)  in T3M-4-shSEMA5A and T3M-4 Control cells. The 
intensity of the bands in Western blot analysis was quantified by ImageJ using 
-actin as an internal control and was normalized with respect to the T3M-4 
Control cells. 

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Figure 6.3: Loss of SEMA5A activates the non-canonical PI3K/AKT 
pathway. 
Western blots on whole cell lysates showing an increase in levels of p-PI3K 
(Ser 458), p-AKT(Ser 473) and GSK3Ser9 in T3M-4-shSEMA5A in 
comparison with T3M-4 Control cells, suggesting activation of non-canonical 
PI3K/AKT activation. GAPDH serves as a loading control. Western blots show 
no change in the total protein levels of PI3K, AKT, and GSK3 The intensity of 
the bands in Western blot analysis was quantified by Image J using GAPDH as 
an internal control and was normalized with respect to the T3M-4 Control cells. 
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Figure 6.4: Suggested mechanism demonstrating how the loss of 
SEMA5A can trigger TGF activation, resulting in EMT and initiation of 
Wnt signaling. 
Representative schematic demonstrates the proposed mechanism of 
regulation of TGF by SEMA5A. The thrombospondin repeat domain of 
SEMA5A molecule keeps latent activation of TGF2under inhibition. With the 
loss of SEMA5A, TGF2 gets secreted and activates non-canonical PI3K/AKT 
pathway. The activation of PI3K/AKT pathway leads to inhibition of GSK-3β, 
which in turn results in stabilization of β-catenin and Snail protein. Stabilization 
of β-catenin leads to active translocation of β-catenin from the cytoplasm into 
the nucleus, further leading to activation of WNT signaling. On the other hand, 
stabilization of Snail protein leads to the repression of mRNA transcription of E-
cadherin.  This repression of E-cadherin mRNA transcription leads to a 
decrease in the E-cadherin protein levels, as well as leading to induction of 
EMT. 
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Chapter 7  
Loss of Plexin B3 Increases Cellular Motility and Metastasis in PC 
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I. Abstract: 
 Plexins are the primary receptors for semaphorins, guidance cue ligands, 
which regulate cellular adhesion and the motility of different cell types in response 
to their ligand. A growing body of evidence now supports the roles of various 
semaphorins and plexins in cancer progression by their involvement in 
pathological processes such as angiogenesis, cellular migration, and metastasis. 
The significantly worse prognosis of PC is largely attributable to the metastatic 
nature of the disease. Recent studies associate expression of SEMA5A with higher 
metastasis in PC. SEMA5A was identified as a cell adhesion molecule critical for 
organ-specific homing of cancer cells in PC. However, the expression and role of 
the SEMA5A receptor, Plexin B3, is yet to be investigated in PC. In the present 
study, we investigated the role of Plexin B3 receptor by knocking down Plexin B3 
expression in PC cell lines T3M-4 and CD18/HPAF. Knockdown of Plexin B3 cells 
resulted in a change of epithelial phenotype to mesenchymal state with enhanced 
in vitro cellular migration. Plexin B3 knockdown cells also showed impaired colony 
formation on a three-dimensional growth factor-reduced Matrigel Matrix. We 
observed similar in vivo results with higher metastasis and lower tumor burden in 
Plexin B3 knockdown cells injected orthotopically into nude mice in comparison 
with the Control cells. We also went ahead to investigate the expression of Plexin 
B3 in the disease progression model of PDX-Cre-Kras(G12D) mice and observed 
low expression of Plexin B3 in normal mice with higher Plexin B3 expression in 
initial time points (20 weeks) in comparison with later time points. Our observations 
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indicate that Plexin B3 inhibits cellular motility and maintains epithelial phenotype 
of PC cells. The mechanism behind this phenotype needs further investigation.  
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II. Introduction: 
 PC is often diagnosed at an advanced stage that makes surgical resection 
of tumor unfeasible, and thus PC is the fourth leading cause of cancer death in the 
United States (Siegel et al., 2017). Also, most cases present themselves with 
regional lymph nodes and liver secondary tumor growth, indicating the spread of 
cancer to nearby and distant places by the process called metastasis (Das and 
Batra, 2015). One of the important events for the process of metastasis is the gain 
of migration ability. Both physiological and pathological cell migration is regulated 
by guidance clue molecules, which can be membrane bound or secreted. The 
semaphorin and their receptor plexin families of proteins are neuronal guidance 
molecules characterized by the presence of a conserved ‘sema’ domain of ~ 500 
amino acids in the N-terminal region (Yazdani and Terman, 2006). Recent 
literature reports aberrant expression as well as dysregulated signaling of these 
molecules in cancer progression (Biankin et al., 2012; Neufeld et al., 2005). 
 Previous reports from our laboratory provide evidence for a realizable role 
of SEMA5A, a novel member of this family of proteins, in the pathogenesis of PC 
metastasis (Sadanandam et al., 2012; Sadanandam et al., 2007; Sadanandam et 
al., 2008). Using an in vivo phage display library and integrated computational 
analysis, we identified SEMA5A as a putative cell adhesion molecule involved in 
organ-specific homing during PC metastasis (Sadanandam et al., 2007). We have 
demonstrated that the Panc1 cell line with overexpression of SEMA5A acquired 
enhanced metastatic potential when implanted orthotopically in a nude mouse 
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(Sadanandam et al., 2010b). These data point towards a possible involvement of 
SEMA5A in PC metastasis. For better understanding the downstream signaling 
events and regulation of cellular phenotypes associated with SEMA5A in PC 
metastasis, it is necessary to characterize the role of its receptor Plexin B3 in PC.  
 The Plexins family is comprised of four subfamilies named Plexin A, B, C, 
and D and were initially identified as molecules that mediate cell adhesion (Gu and 
Giraudo, 2013; Janssen et al., 2010). Both membrane-bound and secreted form 
of Plexins are known, and they can mediate autocrine or paracrine signaling by 
binding to their respective semaphorin (Negishi et al., 2005). Interestingly, Plexins 
can act as ligands as well as receptors for semaphorins. Plexins are known to 
mediate an auto-inhibitory effect in the absence of the ligand by their extracellular 
“sema” domain. Their intracellular region contains two highly conserved GTPase 
activating proteins (GAP like domains) and a linker region with no intrinsic GAP 
activity. Additional to the above domains, Class B plexins, also have a C-terminal 
consensus sequence that interacts with PDZ domains. Thus, our primary objective 
for the current study was to characterize the role of SEMA5A receptor Plexin B3 in 
PC cell lines. Knocking down of Plexin B3 in T3M-4 and CD18/HPAF cells resulted 
in increased in vitro and in vivo migratory potential. These effects were found to be 
associated with the induction of mesenchymal phenotype.  
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III. Results: 
Loss of Plexin B3 Enhances In vitro Cell Migration: 
 We stably downregulated the expression of Plexin B3 in T3M-4 and 
CD18/HPAF cells, as described previously in Chapter 5. We observed a marked 
difference in morphology between CD18/HPAF-shPlexin B3 cells (Fig. 7.1A) 
compared to their Control cells. The CD18/HPAF- Control cells demonstrated 
clump-like structures with closely placed cells when plated on plastic. In contrast, 
CD18/HPAF-shPlexin B3 cells had a mesenchymal morphology with spread and 
spindle-like fibroblastoid cells. Next, we evaluated the effect of Plexin B3 
knockdown on cellular migration and invasion. In vitro cellular migration was 
evaluated by performing wound healing and transwell migration assay. Consistent 
with our morphological data, in vitro cell migration was higher in both Plexin B3 
knockdown cells in comparison to the Control cells (Fig. 7.1B, 1C, 1D).  
We also evaluated invasion properties of these cells by using the Transwell 
invasion assay. In this assay, the well was coated with Matrigel and both 
CD18/HPAF- and T3M-4 Control cells and their respective Plexin B3 knockdowns 
were evaluated. We found an increase in the invasion with Plexin B3 knockdown 
in CD18/HPAF cells (Fig. 7.1E), however, in T3M-4 cells there was less invasion 
of Plexin B3 knockdown cells in comparison with the Control (Fig.7 1F), but this 
difference was not statistically significant. 
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Plexin B3 Knockdown Results in Lower Tumor Burden: 
 CD18/HPAF-shPlexin B3 or CD18/HPAF-Control cells were injected 
orthotopically into athymic female nude mice. Mice were sacrificed at 34 days after 
injection. We observed a lower tumor weight (p = 0.0159) (Fig. 7.2A, 7.2B, 7.2C) 
in mice injected with CD18/HPAF-shPlexin B3 cells in comparison with mice 
bearing CD18/HPAF-Control cells. We did not see any difference in the average 
weight of mice from these groups (Fig.7 2D). Furthermore, H and E evaluation 
revealed lower necrosis, and higher infiltration of tumor microenvironment cells in 
tumor burden of CD18/HPAF-shPlexin B3-injected mice in comparison with tumors 
of mice injected with CD18/HPAF-Control cells (Fig.7 2E). We also observed the 
lack of colony formation of Plexin B3 knockdown cells on three-dimensional matrix 
compared with their respective Control cells (Fig. 7.2F). However, in vitro analysis 
of proliferation of CD18/HPAF- and T3M-4 Control cells and their respective Plexin 
B3 knockdowns showed no proliferation differences (Fig.7 2G). 
Loss of Plexin B3 Enhances Metastasis: 
 Evaluation of metastases in mice injected with CD18/HPAF-shPlexin B3 
showed a higher incidence of liver, peritoneal cavity and lymph node metastasis 
and incidence of ascites (Fig. 7.3A). There was a significantly higher number of 
micrometastases (p = 0.0259) in the liver of mice injected with CD18/HPAF-
shPlexin B3 cells compared with mice bearing the CD18/HPAF-Control cells (Fig. 
7.3B, C, D). 
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Differential Plexin B3 Expression in PC Tumor Progression KC model:  
 To evaluate Plexin B3 expression during PC disease progression, 
pancreatic tissues derived from KC mice sacrificed at different time points (10, 20, 
30 and 50 weeks) were used to generate a progression model. We observed low 
expression of Plexin B3 in the normal pancreas, derived from the control PDX-cre 
mice. However, in KC mice there was an increase in Plexin B3 expression 
beginning at 10 and 20 weeks of age (Fig. 7.4). This expression decreased in the 
tumors of mice at 30 and 50 weeks age, which represents fully developed PDAC.  
No Change in EMT Markers Occurs With Loss of Plexin B3: 
 We evaluated EMT markers in Control and Plexin B3 knockdown cells. We 
observed no change in the expression of E-cad, N-cad, -catenin, and Snail at 
protein levels in T3M-4-(Fig. 7.5A,) or CD18/HPAF- (Fig. 7.5B) shPlexin B3 cells 
and their respective Control cells.  
IV. Discussion: 
 In this study, we have investigated the role of SEMA5A receptor Plexin B3 
in PC progression and metastasis. An important piece of evidence for the role of 
SEMA5A in PC metastasis came from our previous report demonstrating the 
functional role of SEMA5A (Sadanandam et al., 2010a; Sadanandam et al., 2007; 
Sadanandam et al., 2008; Sadanandam et al., 2010b). However, the role and 
function of the SEMA5A receptor Plexin B3 are yet to be explored in PC. To 
investigate the role of Plexin B3 in PC, we went ahead to evaluate the in vitro and 
in vivo effect of downregulating Plexin B3 on the biological behavior of T3M-4 and 
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CD18/HPAF PC cell line. We observed enhanced in vitro migration with the loss 
of Plexin B3. Supporting our in vitro assay results, the knock-down of Plexin B3 
resulted in enhanced metastatic potential of CD18/HPAF cells when implanted 
orthotopically in nude mice.  
 Furthermore, we observed a marked difference in morphology between 
CD18/HPAF-shPlexin B3 cells compared to their Control cells. We also observed 
the lack of three-dimensional colony formation in Plexin B3 knockdown cells. 
However, we did not observe any significant difference in in vitro proliferation of 
Plexin B3 knockdown cells and their Control counterparts. Our in vitro functional 
assays explain our in vivo observation of lower tumor burden in mice injected with 
Plexin B3 knockdown cells. Loss of colony formation rather than defective 
proliferation appears to be the cause of this lower tumor burden. Our observations 
are supported by the recently published unrecognized function of the Semaphorin-
Plexin B2/B1 system as a crucial regulator of mitotic spindle orientation that is 
important in the establishment and maintenance of epithelial architecture during 
morphogenesis and repair (Xia et al., 2015). 
 We also observed an initial increase in Plexin B3 expression in tumor 
progression model of KC mice, however, in advanced stages of the tumor, loss of 
Plexin B3 expression was observed. Similar results were reported by Balakrishnan 
et al. showing somatic mutations in Plexin B3 in PDAC cases (Balakrishnan et al., 
2009). Through functional assays in cellular models, the group demonstrated that 
c.1613G, R538H mutation in the extracellular domain of Plexin B3 prevented 
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binding of the ligand Sema5A, These missense mutations result in loss of Plexin 
B3 function. Likewise, the mRNA and protein expression levels of Plexin B3 were 
found to be downregulated in hepatocellular carcinoma samples in comparison 
with the corresponding adjacent non-cancerous tissue (Liu et al., 2015). This group 
further elucidated the correlation between Plexin B3 expression and 
clinicopathological data by performing IHC on 84 hepatocellular carcinoma 
archived specimens and reported lower expression level of Plexin B3 in tumor 
tissues in comparison with the corresponding adjacent non-cancerous tissue.  
 We also evaluated motility and invasiveness of our Plexin-B3 knockdown 
and their respective Control cells using different in vitro functional assays. We 
observed higher in vitro cellular motility for both CD18/HPAF-shPlexin-B3 and 
T3M-4-shPlexin-B3 cells in comparison with their respective Control cells. We 
observed a similar increase in the number of T3M-4-shPlexin-B3 migrated cells 
than T3M-4-Control cells using Transwell migration assay and also an increase in 
the invasiveness of CD18/HPAF-Plexin-B3 knockdown cells in comparison with 
the CD18/HPAF-Control. Our in vitro functional assays explains our in vivo 
observation of higher incidence of metastasis in different organs of mice injected 
with CD18/HPAF-Plexin-B3 knockdown cells in comparison with the group of mice 
injected with CD18/HPAF-Control cells. Similarly, we observed a higher number of 
macro, and micro metastases in the liver of CD18/HPAF Plexin-B3 injected mice 
than in CD18/HPAF-Control injected mice. This increase in incidence and number 
of metastasis is not a consequence of the difference in primary tumor burden but 
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increase invasiveness and migration properties of Plexin-B3 knockdown cells. Our 
results suggest that loss of Plexin-B3 enhances escape of a tumor cell from the 
main tumor by increasing motility and invasiveness of the cancer cell, thereby 
resulting in low tumor burden with high metastasis. 
However, to delve further into the molecular mechanism regarding the change of 
morphology in Plexin B3 knockdown cells, we examined these cell lines for the 
expression of markers of epithelial and mesenchymal phenotypes. Our data 
demonstrated no changes in epithelial and mesenchymal markers with the loss of 
Plexin B3. In conclusion, for the first time in our knowledge, our work provide novel 
insights into the role of SEMA5A receptor Plexin-B3 in PC tumor growth and 
metastasis. Loss of Plexin-B3 accelerates the process of metastasis in PC by 
enhancing the migration and invasion ability of these cells. 
  
  
181 
 
 
 
 
 
 
 
  
182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7.1: Knock down of Plexin B3 enhances in vitro migration of 
Pancreatic Cancer (PC) cells. 
 (A) Representative images of the morphology of CD18/HPAF Control and 
Plexin B3 knockdown cells. Images show morphological differences in 
CD18/HPAF Control cells with clustered cells changing to flat and spindle 
shaped with knockdown of Plexin B3. Images were taken at 100x using a Nikon 
Eclipse TS100 microscope. (B, C) Bar graphs are showing higher in vitro 
migration of Plexin B3 knockdown cells in CD18/HPAF (p < 0.0001) (B) and 
T3M-4 (p = 0.0162) (C) in comparison with their respective Control cells using 
wound scratch assay. The values in the graph represent the percentage of 
distance migration, and the error bars represent SEM. Statistical p-value was 
calculated using Student’s t-test. (D) Box plot analysis shows higher in vitro 
migration of Plexin B3 knockdown cells in T3M-4 (p = 0.0078) in comparison 
with the Control cells using Transwell migration assay. The values represent 
number of migrated cells and error bars in the box plot represent SEM. 
Statistical p-value was calculated using non-parametric Mann-Whitney U-Test. 
(E, F) Bar graph shows the number of invaded cells in the Control and Plexin 
B3 knockdown in CD18/HPAF cells and T3M-4 cells. Bar graphs show a higher 
number of cells invading through the matrix in CD18/HPAF-Plexin B3 (p = 
0.057). Knockdown cells in comparison with the respective control cells. T3M-
4 Plexin B3 knockdown cells show a lower number of invaded cells in 
comparison with the Control cells (p = 0.067). The values in the graph represent 
the number of invaded cells, and the error bars represent SEM. Statistical p-
value was calculated using non-parametric Mann-Whitney U-Test. 
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Figure 7.2: Knockdown of Plexin B3 results in low tumor burden. 
 (A) Representative image of tumors formed from the injection of CD18/HPAF-
Control and CD18/HPAF-shPlexin B3 cells in athymic nude mice. The image 
shows the higher tumor size of CD18/HPAF-Control cells’ derived tumors in 
comparison with CD18/HPAF-shPlexin B3 derived tumors. (B) The chart is 
showing tumor incidence, average tumor weight and average mice weight of 
mice injected with CD18/HPAF-Control and CD18/HPAF-shPlexin B3. (C) 
Graph showing tumor weight of five different mice in each CD18/HPAF-Control 
and CD18/HPAF-shPlexin B3 group and their average. The graph shows lower 
tumor burden of CD18/HPAF-shPlexin B3 group in comparison with 
CD18/HPAF-Control cells (p = 0.0162). (C) Graph showing weights of five mice 
in each CD18/HPAF-Control and CD18/HPAF-shPlexin B3 group and the 
average mouse weight. The graph shows no differences in mouse weight of 
CD18/HPAF-shPlexin B3 group and CD18/HPAF-Control cells (p = 0.562). The 
values in the graph represent tumor weight or mice weight, and error bars in 
the graphs represent SEM. Statistical p-value was calculated using non-
parametric Mann-Whitney U-test. (E) Representative images of H and E 
staining of primary tumor burden formed by the CD18/HPAF-shPlexin B3 and 
CD18/HPAF-Control cells. Images show lower necrosis and higher infiltration 
of tumor microenvironment cells in tumor burden of CD18/HPAF-shPlexin B3 
in comparison with CD18/HPAF-Control tumors. Images were taken at 100x 
magnification using a Nikon Eclipse E800 microscope. (F) Representative 
images of colonies formed by CD18/HPAF-Control and CD18/HPAF-shPlexin 
B3 cells in three-dimensional Matrigel matrix. Images show stained nucleus 
(DAPI) of the cells in a colony demonstrating a lack of ability of CD18/HPAF 
Plexin B3 cells to form compact colonies in comparison with their respective 
Control cells. Images are taken at 100x magnification using a Life EVOS FL 
fluorescence microscope. (G, H). Line graphs are demonstrating no difference 
in the cellular proliferation of the Plexin B3 knockdown and Control cells of 
CD18/HPAF (G) and T3M-4 (H). The MTT assay was read using BIO-TEX ELx-
800 plate reader at 570 nm wavelength. The values are mean of absorbance 
at 570 nm ± SEM. The significance of the data was calculated using Two-way 
ANOVA test. Cell lines treated at different densities were taken as Column 
Factor, and different Control and Plexin B3 knockdown cells were taken as Row 
Factor. No statistical differences were seen between Row Factor. 
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Figure 7.3: Knockdown of Plexin B3 enhances metastasis. 
(A) Chart of the percentage of metastasis incidence at different sites like liver, 
lymph, peritoneum, and percentage of ascites formation in mice injected with 
CD18/HPAF-Control and CD18/HPAF-shPlexin B3 cells.  The chart shows 
higher metastases incidence in mice injected with CD18/HPAF-shPlexin B3 in 
comparison with the mice injected withCD18/HPAF-Control cells. (B) 
Representative images of H and E staining of the liver showing a higher number 
of micrometastases in the liver. Images were taken at 100x using a Nikon 
Eclipse E800. (C, D) Graph showing number of micro (C) and macro (D) 
metastases in five different in each CD18/HPAF-Control and CD18/HPAF-
shPlexin B3 group and the average number of metastases. The graphs shows 
higher no micro (p = 0.029) and macro (p = 0.089) metastases formation in 
group of mice injected with CD18/HPAF-shPlexin B3 cells in comparison with 
the group injected with CD18/HPAF-Control cells (p = 0.0162). The values in 
the graph represent the number of macrometastasis or micrometastasis in liver 
per mice. The error bars in the graphs represent SEM. Statistical p-value was 
calculated using non-parametric Mann-Whitney U-Test.  
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Figure 7.4: Plexin B3 Expression progressively increases in the 
developing cancerous lesions of KC mice and decreases in the cancerous 
lesions at a later time point. 
Representative images of Plexin B3 immunohistochemistry performed on 
progression model derived from tumors of KC mice (n = 5) at different ages (20 
weeks, 30 weeks and 50 weeks). The pictorial graph demonstrates first a 
progressive increase in qualitative Plexin B3 expression followed by a decrease 
in Plexin B3 expression at 30- and 50- weeks age mice that represent fully 
developed PDAC. The normal pancreas of 50- week Pdx1-cre mice shows low 
Plexin B3 expression. The images were taken at 100x magnification using a 
Nikon Eclipse E800 microscope.  
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Figure 7.5: Knockdown of Plexin B3 shows no difference in expression of 
epithelial and mesenchymal markers. 
(A, B) Western blot analysis of whole cell lysates of T3M-4 and CD18/HPAF 
Control and Plexin B3 knockdown cell lysates. Western blot analysis shows no 
change in the expression of E-cadherin, N-cadherin, -catenin, and Snail at 
protein levels in T3M-4- (A) CD18/HPAF-shPlexin B3 cells (B) and their 
respective Control cells. The intensity of the bands in Western blot analysis was 
quantified by Software ImageJ using -actin as an internal control and was 
normalized with respect to the T3M-4 or CD18/HPAF Control cells. 
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Chapter 8  
Major Conclusions and Future Directions 
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SEMA5A in PC: a perspective: 
 Like other cancers, PC is also a complex disease with loss of control in the 
regulation of normal physiological processes, ranging from cell proliferation to 
restricted cell migration. The growth and spread of the cancer cells rely not only 
on the genetic and epigenetic alterations in the tumor cells but also take active 
advantage of the dysregulation in the microenvironment resulting as a 
consequence of the tumor. 
 However, unlike other cancers, there are limited advances made in the 
treatment of PC with its incidence almost equivalent to mortality. As described 
previously in Chapter 1, targeting metastasis is the real challenge for improving 
the mortality rate in PC. Since the process of metastasis is a cascade of several 
steps, efforts are being made to identify targets that are mediating different steps 
of this process. Out of all the steps of metastatic cascade, the last step of 
metastatic colonization represents an important step in PC. The reason being 
already mentioned earlier that mostly at the time of diagnosis, cancer has already 
metastasized to distant organs. Hence it is believed that cancer cells have already 
undergone through all the steps of the metastatic cascade. Thus, any target that 
can inhibit establishment of metastasis furthermore will improve the survival time 
of the patient. These are unconventional targets that do not a prime rapid division 
of tumor cells to inhibit tumor growth but limit their escape from the primary tumor 
to distant organs. Their drawback could be that they cannot be used alone but in 
combination therapy only. 
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 One such emerging unconventional target belongs to the family of guidance 
cue ligands, such as Semaphorins and their receptors Plexins, Semaphorins and 
their receptor signaling are known to play an important role during the development 
of different organ systems such as nervous, immune, cardiovascular, and others. 
However, their expression is found to decrease in the adult. Considering their wide 
expression pattern and role in development, it is distinctly possible that their 
dysregulated signaling will impact different aspects of cancer biology.  
 Recent reports reveal defective axon guidance signaling in the pancreatic 
genome (Biankin et al., 2012). However, expression of semaphorins in PC cannot 
be treated as the driver mutation and their aberrant signaling is a consequence of 
the accumulation of other multiple gene mutations. Several previously published 
reports from our laboratory have suggested the potential of SEMA5A as a 
“molecular target” for PC therapies. In general, SEMA5A has higher cell surface 
expression in the cancer cells in comparison with the normal pancreas. To 
understand the functional aspect, we overexpressed two forms of SEMA5A- 
membrane-bound and secretory and observed higher metastasis with both forms 
of SEMA5A overexpression. However, the resulting primary tumor burden from the 
orthotopic injection of control and SEMA5A overexpressing cells in the nude mice 
showed no difference with membrane-bound SEMA5A and lower primary tumor 
with a secretory form of SEMA5A.  
 The purpose of the research presented in this dissertation was to 
furthermore investigate our previous findings and delineate the function and 
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pathological expression of SEMA5A in the malignant PC tumor cells and 
metastatic establishments. In this chapter, I will summarize the major findings and 
conclusions of all the chapters compiled in this dissertation. Also, in the later 
section, I will discuss the questions that are still unanswered and possible 
experiments to investigate these questions in future. 
Major Findings: 
When and where is SEMA5A expressed in PC? 
i) In human as well as in mice, the normal pancreas either shows low or no 
SEMA5A expression; however, in PC tissues, their expression is located 
mostly on malignant ducts. 
ii) Surrounding tumor stroma is not positive for SEMA5A expression. Analysis 
of SEMA5A expression between different stages of PC revealed no 
significant difference.  
iii) SEMA5A expression was significantly higher in well-differentiated and 
moderately differentiated tumors in comparison with poorly/undifferentiated 
tumors.   
iv) Upregulation of the SEMA5A expression in primary tumor can be seen from 
20-weeks old KC mice, and there is a gradual increase in later time points. 
v) SEMA5A expression was positive in different metastatic sites of humans as 
well as KPC mice. Metastatic sites such as liver showed higher SEMA5A 
expression in comparison with the primary tumor. 
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vi) SEMA5A expression is seen in PDAC (exocrine) as well as PanNET 
(endocrine tumors) and their respective metastasis. 
vii) The gain of copy number variation of SEMA5A is seen for pancreatic 
adenocarcinoma and PDAC cases. 
viii) SEMA5A expression, whether low or high, correlates with poor survival of 
PC cases. However, high SEMA5A shows better survival for PC patients 
than a low expression of SEMA5A. 
What is the function of SEMA5A as a ligand on PC tumor cells? 
i) SEMA5A induces cellular migration, chemotaxis, and scattering in PC cells. 
ii) SEMA5A mediates its effect through the Plexin B3 receptor. 
iii) SEMA5A through Plexin B3 leads to catalytic activation of MET receptor.  
What is the function of endogenous SEMA5A expression on tumor cells? 
i) Downregulation of endogenous SEMA5A in differentiated cells leads to a 
mesenchymal phenotype. 
ii) Downregulation of SEMA5A upregulates EMT markers. 
iii) Downregulation of SEMA5A increases migratory and invasive phenotype 
both in vivo and in vitro. 
iv) Overexpression of SEMA5A in SEMA5A knockdown cell rescues the 
epithelial phenotype, suggesting a possible role of SEMA5A in metastatic 
colonization and establishment at the metastatic site. 
What can be possible pathways affected by the endogenous SEMA5A molecule in 
PC? 
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i) Increase in Wnt activation. 
ii) Increased TGF2 levels with no changes seen in SMAD pathway. 
iii) Activation of PI3K/AKT pathway and inhibition of GSK3 
What is the function of endogenous SEMA5A receptor-Plexin B3 on PC tumor 
cells? 
i) Loss of Plexin B3 leads to the acquisition of mesenchymal morphology with 
increased invasiveness and migration.with impaired colony formation on 3-
dimensional matrix. 
ii) No change in EMT markers.  
iii) Loss of Plexin B3 shows an increase in metastasis even with lower primary 
tumor burden. 
iv) Upregulation of the Plexin B3 expression in primary tumor can be seen in a 
20-weeks old KC mice, but there is a gradual decrease in expression at 
later time points. 
Summary and Major Conclusion: 
 Based on several observations made by downregulating the expression of 
SEMA5A and its putative binding partner Plexin B3 in PC cell lines and studying 
the effect of this downregulation by different in vitro or in vivo assays, we 
summarize the role of SEMA5A in PC progression in the following paragraphs: 
 Healthy pancreas shows no expression of SEMA5A, but during initiation of 
PC due to factors unknown, the SEMA5A expression is upregulated on the surface 
of oncogenic cells. The upregulation of SEMA5A molecule is also suported by a 
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gain of copy number of SEMA5A in Pancreatic adenocarcinoma cases. The 
upregulated SEMA5A molecule is cleaved by some metal metalloproteases, and 
the secreted SEMA5A can attract endothelial cells, leading to angiogenesis as well 
as causing the migration or escape of cancer cells from the primary tumor by acting 
through Plexin B3 receptor. The proliferating tumor cells loses SEMA5A and Plexin 
B3 expression and thereby proceeds from differentiated to undifferentiated status. 
Loss of SEMA5A expression with disease progression is also supported by 
analysis of SEMA5A expression in human patients, TMA by IHC. Furthermore, 
loss of both SEMA5A and Plexin B3 increases the invasive and migratory 
phenotype of cancer cells, which leads to an increase in metastasis formation. 
 On the other hand, tumor cells reaching different metastatic sites 
furthermore upregulates the expression of SEMA5A molecule to regain epithelial 
state and undergoes establishment. In accordance, we have observed an increase 
in SEMA5A expression at metastatic sites in comparison with the primary tumor in 
human patients as well as in the KPC mouse model.  
 Thus, in the general scenario of PC cases where primary tumors have 
already metastasized to nearby and distant organs, SEMA5A expression should 
be positive in the metastatic establishments, whereas the advanced primary tumor 
should have low SEMA5A expression. In conclusion, based on the results 
generated in this study we conclude that SEMA5A play multifaceted roles during 
PC progression and establishment of metastasis. SEMA5A represents a potential 
candidate for targeting metastatic establishments, but whether the same holds true 
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for primary tumors still needs further investigation. The summary and major 
conclusions of this dissertation are presented in a pictorial form in Figure 8.1 and 
Figure 8.2, respectively. 
Future Directions: 
What are the factors that regulate the expression of SEMA5A and Plexin B3?  
 Currently, we do not have any knowledge regarding regulatory controls of 
SEMA5A. However, there is evidence that links SEMA5A with inflammation such 
as the report of neutrophil infiltration in mastitis resistance (Sugimoto et al., 2006), 
induction and secretion of Th1/Th17 cytokines with SEMA5A treatment and 
increased SEMA5A expression in serum of rheumatoid arthritis patients (Gras et 
al., 2014). Likewise, we have also seen upregulation of Interleukin-8 with 
overexpression of secretory SEMA5A in PC cells (Sadanandam et al., 2012). The 
link between inflammation and cancer is well known but whether inflammation or 
cancer is the causative agent and the other of the two is the effector is yet to be 
established (Coussens and Werb, 2002). Taken together these findings suggest 
that inflammation and SEMA5A may connect through a feedback response, and 
possibility needs to be investigated in future. In the future, regulation of SEMA5A 
can be investigated using in silico analysis of promoter and initiation area, 5′rapid 
amplification of cDNA ends, reporter-gene assays, gel shift and co-expression 
experiments. 
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 Plexin B3 transcriptional regulation was analyzed, and a 234 base pair 
region upstream of Plexin B3 exhibited promoter activity (Tiismus et al., 2008) 
using the above mentioned techniques. Further analysis of this region showed 
binding sites for myeloid zinc finger protein 1 and neurogenin 3. Out of the two, 
Neurogenin-3 is expressed in endocrine progenitor cells and is required for its 
development in the pancreas and intestine (Wang  et al., 2006). In normal adult 
human, Neurogenin 3 (NGN3) is expressed by 2-10% of acinar and duct cells. 
Further investigations are needed to understand the regulation of Plexin B3 by 
Neurogenin 3 in PC.  
Which metalloproteinase can cleave transmembrane SEMA5A and make it 
secretory? 
 The mechanism by which SEMA5A is cleaved from the PC cell surface is 
still unknown. However, A disintegrin and metalloproteinase 17 (ADAM-17) has 
been shown to be involved in the release of secreted SEMA5A in rheumatoid 
arthritis patients (Gras et al., 2014). A recent report provides evidence of aberrant 
expression of the proteolytically active ADAM17 in advanced precursor lesions 
(PanIN-3) (Ringel et al., 2006). Hence, it will be interesting to investigate whether 
active ADAM 17 is involved in cleaving SEMA5A from the PC cell surface and their 
combined activity on PC metastasis.  
 Elucidation of reverse signaling for the molecule of SEMA5A. 
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 In chapter1 we have discussed different types of possible signaling between 
SEMA5A and Plexin B3 molecule. In this dissertation, we were only able to 
delineate forward signaling of SEMA5A as a ligand and Plexin B3 as a putative 
receptor. Since secretion of Plexin B3 is also known in nature, it will be interesting 
to understand signaling through cytoplasmic domain of SEMA5A. 
Binding Partners for SEMA5A  
We have yet to define the domains of SEMA5A that are critical for binding 
to Plexin B3 receptor. Also, our current results do not rule out the potential of NRP2 
as a binding partner of secretory SEMA5A and need investigation in future. 
Similarly, known neuronal SEMA5A receptors Plexin A1 and A3 also needs 
evaluation in the context of PC. 
Defining the Role of Stage-Specific SEMA5A Expression in PC:  
To define the stage-specific role of SEMA5A, we need to generate a 
knockout model of SEMA5A in the pancreas of genetically engineered PC 
progression mouse model such as Pdx1-cre; KrasG12D under an inducible control 
system. Future directions are also represented in a pictorial form in Figure 8.3. 
 There is an urgent requirement for new molecular targets for improving 
therapeutics and biomarkers in PC. In this dissertation, we evaluated the 
expression and function of SEMA5A in PC pathology. The results presented here 
clearly suggest a dual role of SEMA5A in PC. Overexpression of SEMA5A 
increases metastasis by enhancing the angiogenesis step of metastatic cascade 
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while downregulating the expression of SEMA5A leads to tumor promotion by 
mediating mesenchymal transition. We believe that these results will serve as a 
guiding light for future research, but to reach an unequivocal conclusion, further 
research efforts in the field of semaphorins in cancer are essential.  
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Figure 8.1: Summary of the project “The role of SEMA5A in PC 
progression and metastasis”. 
Schematic representation summarizing the role of SEMA5A in PC. (A) 
SEMA5A expression analysis in different PC mouse models and human patient 
samples in a TMA suggests an increase in SEMA5A expression with the 
progression of PC with low or no expression in normal pancreas.  (B) SEMA5A 
is also present in different PC metastatic sites like liver, spleen, and others. In 
pancreatic neuroendocrine cases, metastatic sites show furthermore 
upregulation of SEMA5A expression in comparison with the primary tumor. (C) 
The increase in SEMA5A during PC progression facilitates migration of PC 
cells. SEMA5A acts as a ligand and acts through Plexin B3 receptor and 
activates MET tyrosine kinase receptor for triggering PC cellular migration. (D) 
However, endogenous expression both SEMA5A and Plexin B3 maintains the 
epithelial phenotype of a cancer cell that can aid the establishment of 
macrometastasis at metastatic sites.  
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Figure 8.2: Major conclusions of the project “The role of SEMA5A in PC 
progression and metastasis”. 
 Schematic diagram summarizing pro- and anti- tumor effects of SEMA5A in 
PC. (A) Loss of expression of both SEMA5A and its receptor Plexin B3 leads 
to an invasive phenotype in PC cells and results in higher metastasis 
suggesting that SEMA5A and receptor Plexin B3 maintains epithelial 
phenotype of the PC cell and keeps metastasis under check. (B) However, 
expression of SEMA5A, especially the secreted form, also results in higher 
metastasis, suggesting a dual effect of SEMA5A on PC. (C) Lastly, SEMA5A 
as a ligand induces angiogenesis, as well as increases cancer cell migration, 
thereby resulting in higher metastasis and demonstrating pro-tumor effects of 
SEMA5A in PC. 
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Figure 8.3: Future directions of the project “The role of SEMA5A in PC 
progression and metastasis”: 
 Schematic diagram presenting questions which we have yet to answer. (A) 
The factors which can regulate the expression of SEMA5A and are these 
factors differentially present in primary tumor and metastatic sites. (B) Which 
proteases can cleave transmembrane SEMA5A and make it secretory in PC 
environment. (C) Apart from Plexin B3, Plexin A1 and Plexin A3 are also known 
to mediate the effects of SEMA5A in non-pancreatic tissues. Neuropilin 2 
(NRP2) can act as a co-receptor for secretory Semaphorins. Thus, receptor 
Plexin A1 and Plexin A3 as well as possibly Neuropilin as co-receptor for 
SEMA5A in PC needs further evaluation. (D) Reverse signaling of SEMA5A 
acting as a receptor also needs an evaluation. (E) Lastly, stage-specific 
expression of SEMA5A needs evaluation to determine whether we can use 
SEMA5A at prevention or intervention or a regression stage.  
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